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ABSTRACT 
Hypoxic-ischaemic encephalopathy (HIE) is one of the leading causes of mortality and 
morbidity in infants, globally. This disorder eventuates following a reduction in 
oxygenated cerebral blood flow to the foetus in utero, leading to excitotoxic-mediated 
brain cell (e.g. neuron, glia and glial progenitor cell) death. Currently, there is no 
clinically appropriate neuroprotective treatment to reduce acute brain injury following 
HIE. Recent studies have demonstrated that poly-arginine and cationic arginine-rich 
peptides (CARPs; e.g. R18: R = arginine residues) exhibit potent neuroprotective 
properties in both in vitro and adult animal models of ischaemia, and therefore have 
the potential to be developed into a neuroprotective treatment to reduce brain injury 
following HIE. Therefore, the aim of this thesis was to assess the neuroprotective 
efficacy of CARPs in a model of perinatal HIE in the rat.  
 
To elucidate the neuroprotective efficacy of CARPs, a novel surgical modification to 
the original in vivo Rice-Vannucci model of perinatal HIE was developed. Using 7-
day old Sprague-Dawley rats, brain injury was induced following the permanent 
ligation of the common and external carotid arteries, followed by a period of transient 
hypoxia (8% O2/92% N2). Results from this experiment demonstrated that the 
occlusion of common and external carotid arteries reduced cerebral communicational 
and/or anastomotic blood flow, reducing variability and improving the reliability in 
the presence of a cerebral infarct. The demonstration and termination of cerebral 
communicational and/or anastomotic blood flow improved the pre-clinical assessment 
of neuroprotective therapies to treat HIE.  
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The CARPs, R18, R18D (D-enantiomer) and JNKI-1-TATD, were assessed in the 
modified Rice-Vannucci model of HIE when administered intraperitoneally, 
immediately after the cessation of hypoxia-ischaemia (HI; 8% O2/92% N2 for 2.5 h). 
Treatment with R18 and R18D significantly reduced infarct volume and improved 
behavioural assessments in this model. Surprisingly, the well-characterised 
neuroprotective peptide JNKI-1-1TATD, used as a positive control and benchmark, 
did not exhibit any significant neuroprotection. Succeeding positive results obtained 
following R18D administration immediately after HI, its therapeutic window was 
further assessed. R18D significantly decreased infarct volume and improved 
behavioural assessments when administered intraperitoneally up to 1 hour after the 
cessation of HI; correlating to 3.5 hours since HI onset. To confirm the neuroprotective 
mechanism of action of CARPs in HIE, an established in vitro primary cortical 
neuronal excitotoxic injury model was used. Results from this experiment demonstrate 
that CARPs reduce excitotoxic intracellular calcium influx in a dose-dependent 
fashion, providing evidence for a role in the reduction of several calcium-dependent 
pro-cell death cascades. The demonstration of significant neuroprotection following 
R18 peptide administration provides evidence for a novel therapeutic, which has the 
potential to reduce brain injury in infants who suffer HIE.   
 
In summary, this thesis has identified a novel surgical modification to improve the 
reliability and reproducibility of the original Rice-Vannucci model of HIE. In addition, 
the administration of the R18 and R18D peptides following perinatal HIE, significantly 
reduces brain injury and improves behavioural assessments when administered up to 
3.5 hours after the onset of HI. These findings demonstrate that CARPs provide an 
exciting and novel approach to reduce brain injury following HIE.  
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Chapter 1 
General Introduction 
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1.1 INTRODUCTION 
Perinatal hypoxic-ischaemic encephalopathy (HIE; also referred to as perinatal 
asphyxia) is a devastating condition, which affects the brain of term (> 36 weeks 
gestation) and pre-term (≤ 36 weeks gestation) infants. Brain injury associated with 
HIE is a leading cause of mortality among infants, while survivors are often left with 
lifelong disabilities such as cerebral palsy, epilepsy, intellectual disability and autism 
spectrum disorders (Kolevzon, Gross, & Reichenberg, 2007; O’Shea, 2008; Perlman, 
1997; Pisani et al., 2009). There are currently no clinically available pharmacological 
neuroprotective treatments to reduce brain injury following HIE. For this reason, there 
is an urgent need for the development of a safe and widely applicable neuroprotective 
agent for infants who suffer HIE. Current clinical interventions to minimise HIE are 
limited to the use of hypothermia in term infants. However, the availability of a 
neuroprotective agent that can be administered soon after hypoxia-ischaemia (HI), to 
both pre-term and term infants, either in combination with hypothermia or alone (e.g. 
when hypothermia therapy is not an available treatment option), would provide the 
best opportunity to preserve brain tissue and thereby reduce mortality, improve patient 
quality of life and lessen the social and economic impact of this devastating condition. 
 
Recent studies in A/Prof Meloni’s laboratory have demonstrated that cationic arginine-
rich peptides and poly-arginine peptides (hereafter referred to as CARPs, unless 
otherwise stated) have potent neuroprotective properties in in vitro and animal injury 
models that mimic the effects of brain ischaemia (Meloni, Brookes, et al., 2015; 
Meloni et al., 2014, 2017; Meloni, Milani, et al., 2015; Milani et al., 2018, 2017; 
Milani, Clark, et al., 2016; Milani, Knuckey, Anderton, Cross, & Meloni, 2016). To 
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determine the neuroprotective potential of CARPs as a neuroprotective therapy for 
HIE, initial pre-clinical studies using in vitro and a small animal model of HIE are 
required. Consequently, the focus of this thesis was to examine the efficacy of the 
poly-arginine peptide R18 in HIE by using an in vitro neuronal cell excitotoxicity 
model and in an in vivo model of HIE in the P7 rat. 
 
1.2 PERINATAL HYPOXIC-ISCHAEMIC ENCEPHALOPATHY 
(HIE) 
1.2.1 Epidemiology 
Perinatal HIE remains a leading cause of infant mortality and morbidity, accounting 
for 23% of infant mortality worldwide (Lawn, Shibuya, & Stein, 2005), with an 
incidence in developed countries of 2 – 6 per 1,000 live term births and 7 per 1,000 
live pre-term births (Chalak et al., 2012; de Haan et al., 2006; Hankins & Speer, 2003; 
Wall et al., 2010). In developing countries, the incidence drastically increases to 30 – 
100 per 1,000 live births overall (Simiyu, Mchaile, Katsongeri, Philemon, & Msuya, 
2017). Of infants surviving HIE, 10% demonstrate persistent motor abnormalities and 
50% demonstrate sensory and/or cognitive abnormalities (Hack et al., 1992; Lee et al., 
2013). The frequency of motor and cognitive disorders associated with HIE has 
remained stable since the 1990s (Vincer et al., 2006; Wilson-Costello et al., 2007). 
 
1.2.2 Aetiology 
The aetiology associated with HIE represents the complexity of this neurological 
condition. Risk factors associated with HIE are summarised in Table 1.1 and include 
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intrapartum insults (e.g. nuchal cord, umbilical cord knotting, umbilical haemorrhage, 
placental abruption, pre-eclampsia and shoulder dystocia) and demographic factors 
(e.g. nulliparity and gestational age of foetus). 
 
Table 1.1 Risk factors associated with HIE  
Risk factor  Evidence References 
Nuchal cord  Nuchal cord increases the risk of HIE due to the 
reduction of cerebral blood flow through the 
compression of arterial and venous flow in the 
fetal neck 
Peesay, 
2017 
Umbilical cord 
knotting 
Umbilical cord knotting increases the risk of HIE 
due to the reduction in perfusion of blood to the 
foetus via the impairment of arterial and venous 
flow in the umbilical cord.  
Peesay, 
2017 
Umbilical 
haemorrhage 
Umbilical haemorrhage increases the risk of HIE 
due to the reduction in perfusion of blood through 
the foetus 
Scutiero et 
al., 2018 
Placental 
abruption  
Detachment of the placenta from the uterus 
increases the risk of HIE due to the reduction in 
the perfusion of blood to the placenta and foetus 
Downes, 
Grantz, & 
Shenassa, 
2017 
Pre-eclampsia Disorders of maternal hypertension increase the 
risk of HIE due to the development of placental 
lesions, leading to a reduction in the perfusion of 
blood to the foetus 
Martinello, 
Hart, Yap, 
Mitra, & 
Robertson, 
2017 
Shoulder 
dystocia  
Shoulder dystocia is known to increase the risk of 
HIE 
Politi, 
DʼEmidio, 
Cignini, 
Giorlandino, 
& 
Giorlandino, 
2010 
Maternal 
infection 
Maternal infections are known to increase the risk 
of HIE 
Jenster et al., 
2014 
Nulliparity  An increased risk of HIE is associated with first 
time pregnancies 
Liljestrom, 
Wikstrom, 
Agren, & 
Jonsson, 
2018 
Gestational age An increased risk of HIE is associated with lower 
gestational age 
(Ong et al., 
2015) 
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1.2.3 Clinical aspects  
The clinical presentation of symptoms following HIE is complex, with no early 
definitive diagnostic modality available to the clinician. Every infant born at 1 and 5 
minutes of age is subjected to an Apgar assessment (inclusion criteria for therapeutic 
hypothermia, which is discussed below), which includes the assignment of a numerical 
score from 0 - 2 following examination of each of an infant’s appearance, pulse, 
grimace, activity and respiration; with a low score indicating potential infant demise. 
If HIE is suspected within the first hours of birth, a neurological examination of the 
infant is performed and scored using the Sarnat grading scale; 1 = mild HIE, 2 = 
moderate HIE and 3 = severe HIE (see Table 1.2). A diagnosis of HIE occurs through 
the combination of Apgar and Sarnat scores, and when possible magnetic resonance 
imaging and amplitude integrated/conventional electroencephalography. Generally, 
between the age of 18 – 24 months, confirmatory diagnostic tests are performed for 
infants who have suffered HIE. The Bayley Scales of Infant and Toddler Development 
assessment is a common confirmatory diagnostic test examining a child’s cognitive 
score, language score, motor score, cognitive delay, language delay and motor delay. 
Often it is not until later in life can an individual be definitively diagnosed with 
neurological sequelae associated with HIE (e.g. cerebral palsy, epilepsy, intellectual 
disability and autism spectrum disorders) (Driscoll, Felice, Kenny, Boylan, & 
O’Keeffe, 2018; Glass et al., 2009; Perlman, 1997; Robertson & Finer, 1993).  
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Table 1.2 Sarnat staging for diagnosis of HIE severity 
Severity Stage 1 (Mild) Stage 2 (Moderate) Stage 3 (Severe) 
Level of 
consciousness  
Hyperalert Lethargic or 
obtuned 
Stupor or coma 
Activity Normal Decreased Absent 
Muscle tone  Normal Mild hypertonia Flaccid 
Posture Mild distal flexion Strong distal flexion Intermittent 
decerebration 
Stretch reflexes Overactive Overactive Decreased or 
absent 
Suck Weak Weak or absent Absent 
Moro (startle) Strong Weak Absent 
Tonic neck Slight Strong Absent 
Pupils Mydriasis Miosis Variable 
Heart rate Tachycardia Bradycardia Variable 
Seizures None Common Uncommon 
 
1.3 PATHOPHYSIOLOGY 
HIE occurs following an impediment of oxygenated cerebral blood flow (CBF), 
resulting in a pathophysiological cascade eventuating in programmed cell death. The 
fetal brain is particularly sensitive to a HI environment, due to the requirement of a 
constant supply of energy in the form of adenosine triphosphate (ATP). When this 
energy supply is interrupted, excitotoxicity occurs through the uncontrolled release of 
excitatory neurotransmitters such as glutamic acid; marking the beginning of the 
ischaemic cascade (Johnston, 1995). An in-depth assessment of pathophysiological 
cascades following HI is presented below and in Chapter 2.  
 
1.3.1 Necrosis 
Cellular necrosis is the primary cell death pathway initiated following severe HI 
(Northington, Chavez-Valdez, & Martin, 2011) and is defined by cellular swelling, 
karyolysis and lysis. Necrosis occurs following the failure of homeostasis due to an 
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excitotoxic influx of calcium and sodium, resulting in mitochondrial dysfunction and 
reactive oxygen species (ROS) production.  
 
1.3.2 Apoptosis  
Cellular apoptosis is the primary cell death pathway initiated following moderate HI 
(Northington et al., 2011) and is defined by cellular shrinkage, fragmentation into 
apoptotic bodies and rapid phagocytosis. Multiple apoptotic pathways have been 
demonstrated to be involved in HI, generally, apoptosis is ATP- and caspase-
dependent. Following ATP depletion, calcium influx and the activation of calcium-
dependent caspases, several pro-apoptotic proteins are released into the cytosol.  
 
1.3.3 Excitotoxicity  
Following prolonged HI, cellular homeostasis is disrupted and results in the failure of 
the cell (e.g. neurons, glia and glial precursor cells) to maintain ionic gradients, 
resulting in uncontrolled cellular depolarisation and release of glutamic acid into the 
synaptic cleft (Olney, Price, Samson, & Labruyere, 1986). High extracellular levels of 
glutamic acid cause cellular excitotoxicity, producing cytotoxic cellular influx of 
calcium ions. Increased intracellular levels of calcium activates calcium-dependent 
proteases, ROS production, cytotoxic oedema, mitochondrial dysfunction and the 
stimulation of pro-cell death pathways (Arai, Vanderklish, Kessler, Lee, & Lynch, 
1991; Castilho, Ward, & Nicholls, 1999; O’Hare et al., 2005; Stout, Raphael, 
Kanterewicz, Klann, & Reynolds, 1998; Zhang, Dawson, Dawson, & Snyder, 1994).  
 
8 
 
1.3.4 Oxidative stress 
As the developing brain is comprised of high levels of unsaturated fatty acids which 
are susceptible to lipid peroxidation, metals catalysing free radical reactions and low 
concentrations of antioxidants, the developing brain is highly susceptible to oxidative 
stress (Ikonomidou & Kaindl, 2011). Following HI, resident microglia produce excess 
inflammatory cytokines (IL-1β, TNF-α, etc.), glutamic acid, nitric oxide and ROS 
(Kaur, Rathnasamy, & Ling, 2013; Lai et al., 2017). Rapid increases in these levels of 
cytokines within cerebral tissue induces apoptosis, inhibits neurogenesis and 
contributes to immune cell migration to the site of HI injury.  
 
1.3.5 Mitochondrial dysfunction 
In cells affected by HI, several processes result in the activation of pro-apoptotic Bcl-
2 proteins (e.g. Bid, Bax, etc.), resulting in mitochondrial membrane permeability 
transition (MPT) (Bernardi et al., 2006; Wang et al., 2009). In addition, oxidative stress 
caused by ROS plays a critical role in mitochondrial dysfunction including ischaemic 
starvation, reperfusion-induced hyper activation and delayed neuronal death 
(Sanderson, Reynolds, Kumar, Przyklenk, & Hüttemann, 2013), prompting MPT and 
mitochondrial release of cytochrome-c. Cytosolic cytochrome-c, along with 
deoxyadenosine triphosphate, interact with apoptotic protease activating factor-1 
(Apaf-1) to form the apoptosome, contributing to pro-apoptotic cell death via the 
activation of pro-caspase-9 (Thornton et al., 2012). Further alterations to 
mitochondria, such as mitochondrial outer membrane permeabalisation, results in the 
release of other pro-apoptotic factors, including apoptosis-inducing factor, 
endonuclease-G and second mitochondria-derived activator of caspases 
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(smac)/DIABLO (Blomgren & Hagberg, 2006; Zhu et al., 2007), all of which mediate 
chromatin fragmentation and increase the activation of pro-apoptotic caspases, leading 
to cell death.   
 
1.3.6 Inflammation 
Following HI, resident microglia become activated in the cerebral parenchyma and 
develop macrophage-like attributes (e.g. phagocytic properties, cytokine production, 
matrix metalloproteinase release and antigen presentation) (Iadecola & Anrather, 
2011). Specifically, the release of matrix metalloproteinases compromises blood brain 
barrier integrity, promoting the invasion of peripheral leukocytes into the cerebral 
parenchyma; exacerbating cerebral injury (Kaur, Sivakumar, Yip, & Ling, 2009). Like 
macrophages, astrocytes also become activated due to the release of pro-inflammatory 
cytokines, and ROS. Activated astrocytes subsequently release pro-inflammatory 
cytokines [interleukin (IL)-6, tumour necrosis factor (TNF)α, IL1α/β and interferon 
(INF)γ]; further exacerbating pro-cell death pathways (e.g. apoptosis) (Liu & 
Mccullough, 2013; Tuttolomondo, Di Raimondo, di Sciacca, Pinto, & Licata, 2008).  
 
1.4 CURRENT ACUTE CLINICAL NEUROPROTECTIVE 
TREATMENT 
Hypothermia 
The use of hypothermia for the clinical treatment of HIE is presented in Chapter 2. 
Briefly, moderate hypothermia (33.5°C for 72 h) applied within 6 hours of birth 
improves the survival and neurodevelopmental outcomes in infants suffering from 
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moderate and severe HIE. While hypothermia is considered standard care in the 
treatment of infants with HIE and is well tolerated in term infants (Azzopardi et al., 
2009; Gluckman et al., 2005; Jacobs et al., 2011; Shankaran et al., 2005), it does not 
provide complete protection. Of those term infants who have moderate or severe 
encephalopathy, therapeutic hypothermia was shown to decrease mortality from 40% 
to 28%, while in surviving infants, neurological morbidity was reduced from 31% to 
19% of infants receiving hypothermia (Jacobs et al., 2013). The use of hypothermia is 
widely associated with increased risks of adverse events such as bradycardia and 
thrombocytopenia (Jacobs et al., 2013); although it is widely accepted that the risk of 
adverse events is outweighed by the neuroprotective outcomes demonstrated by a 
significant reduction in mortality or major neurodevelopmental disability 18 months 
after HIE (Jacobs et al., 2013). 
 
Importantly, whilst hypothermia is safe in pre-term infants suffering necrotising 
enterocolitis (Hall et al., 2010), it has not been adequately evaluated for use in pre-
term infants suffering HIE. Information regarding the safety and efficacy of 
hypothermia to treat pre-term infants suffering HIE is lacking, although information 
may be available in the near future (NCT1793129). In one study, hypothermia in pre-
term infants was associated with higher mortality and increased clinical complications 
when compared to term infants, although the study did not include a normothermic 
pre-term control group (Rao et al., 2017). 
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1.5 OTHER CLINICAL NEUROPROTECTIVE APPROACHES 
UNDER CONSIDERATION 
The following outlines neuroprotective approaches to treat HIE, that are currently, or 
have been assessed in human clinical trials.  
 
1.5.1 Xenon  
The noble gas xenon is an approved anaesthetic drug (Stoppe et al., 2013) with 
organoprotective and neuroprotective properties when administered alone or in 
combination with hypothermia in pre-clinical models of HIE (Banks, Franks, & 
Dickinson, 2010; David et al., 2003; Faulkner et al., 2011; Hobbs et al., 2008; 
Thoresen, Hobbs, Wood, Chakkarapani, & Dingley, 2009). Whilst the mechanism of 
action of xenon neuroprotection has not been elucidated, xenon is known to prevent 
N-methyl-D-aspartic acid (NMDA) receptor over activation via competitive inhibition 
at the glycine site of the NMDA receptor (Dickinson et al., 2007). 
 
Two clinical studies have assessed the safety of xenon in term infants with HIE and 
treated with hypothermia (33.5°C for 72 h). In one study, treatment with xenon (50% 
for 18 h; inhaled) and hypothermia was demonstrated to be safe (Dingley et al., 2014; 
ISRCTN75602528). The second study also demonstrated that xenon (30% for 24 h; 
inhaled) and hypothermia treatment was safe (Azzopardi et al., 2016; NCT00934700 
and ISRCTN08886155), but concluded that adjunct xenon therapy is unlikely to 
improve the neuroprotective effect of hypothermia.   
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1.5.2 Topiramate  
Topiramate is an anti-epileptic drug approved for partial and generalised seizures in 
adults and children. It has neuroprotective properties in pre-clinical models of HIE 
when administered alone or in combination with hypothermia (Cowell, Xu, Galasso, 
& Silverstein, 2002). Topiramate has been demonstrated to confer neuroprotection 
through the reduction in sodium- and calcium-dependent action potentials 
(DeLorenzo, Sombati, & Coulter, 2000), enhancement of γ-aminobutyric acid-
mediated neuronal chloride influx (White, Brown, Woodhead, Skeen, & Wolf, 1997) 
and the inhibition of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and 
kainate type glutamic acid receptors (Koh & Jensen, 2001).  
One clinical study has assessed the safety of topiramate in term infants with HIE and 
treated with hypothermia (33.5°C for 72 h) (Filippi et al., 2010; NCT01241019). 
Topiramate administration (10mg/kg once daily for 3 days; orally) was demonstrated 
to be safe; although hypothermia did slow the rate of clearance of topiramate from the 
body. A second clinical study has been completed, but the results have not been 
published to date (NCT01765218).   
 
1.5.3 Pre-term therapeutic hypothermia 
One clinical study has assessed the safety of hypothermia (33.5°C for 72 h) in pre-
term neonates (34 – 35 weeks gestation) suffering HIE (Rao et al., 2017; 
NCT00620711). The study demonstrated that the use of hypothermia was feasible, but 
cautioned its use for future application due to the increased risk of mortality and side 
effects. Additional, clinical studies are currently recruiting patients for the 
investigation of safety and efficacy of hypothermia in pre-term infants 
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(NCT01793129; 33.5°C for 72 h; 33 – 35 weeks gestation; expected completion 
October 2022 and NCT02676063; 33.5°C for 72 h; ≥ 34 weeks gestation; expected 
completion February 2021). 
 
1.5.4 Antenatal magnesium sulfate (MgSO4) 
Magnesium is a non-competitive NMDA receptor antagonist and following HI-
mediated excitotoxicity, magnesium is thought to prevent excitotoxic neuronal 
calcium influx (Kang et al., 2011) as well as reduce pro-inflammatory cytokines IL-6 
and TNFα (Aryana, Rajaei, Bagheri, Karimi, & Dabbagh, 2014). For decades, MgSO4 
has been administered antenatally for the prevention of seizures in women with pre-
eclampsia and eclampsia. Through antenatal administration, foetuses are passively 
exposed to MgSO4; with fetal MgSO4 levels almost half of the maternal blood levels 
(Sherwin et al., 2014).   
 
Five clinical studies have assessed the safety and/or efficacy of MgSO4 in pre-term 
infants suffering HIE when administered to the mother in the antepartum period. Three 
studies demonstrated that MgSO4 administration 4g within 24 h of birth (Crowther et 
al., 2003; ACTRN12606000252516; Marret et al., 2006) or 4g bolus followed by 1 g/h 
for 24 h was safe, but did not appear to improve infant outcomes (The Magpie Trial 
Collective Group, 2002; ISRCTN86938761). One study (Rouse et al., 2008; 
NCT00014989), demonstrated MgSO4 (6g bolus followed by 2g/h maintenance for 12 
h) was safe and reduced the rates of cerebral palsy at 1 year of age. Another study 
(Mittendorf et al., 1997) was prematurely terminated due to high mortality rates in 
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infants born to mothers administrated MgSO4 (4 g bolus, then 2 – 3 g/h infusion). A 
clinical study is currently recruiting patients (ACTRN12611000491965; 4g MgSO4 
within 24 h of birth).  
 
1.5.5 Erythropoietin (EPO) and darbepoetin adjuvant to hypothermia  
EPO is commonly used clinically for its erythropoietic properties to treat anaemia. 
Recombinant human EPO has been examined as a potential neuroprotective agent both 
in vitro and animal studies of HIE. Current dose regimens to elicit erythropoiesis are 
administered subcutaneously at 400 IU/kg, three times a week, or intravenously at 200 
IU/kg, daily (Robertson et al., 2012). EPO is known to increase neural stem cell 
proliferation (Zhang et al., 2017) and encourage cerebrovascular remodelling (Keogh, 
Yu, & Wei, 2007). EPO has also been demonstrated to be neuroprotective in animal 
models of ischaemic stroke, traumatic brain injury, chronic hypoxia and HIE as well 
as improve neurodevelopmental outcomes in pre-term infants (discussed below). 
Despite EPO’s neuroprotective properties, an appropriate clinical therapeutic dose and 
confirmation of efficacy in HIE has not yet been ascertained. Assessment of EPO in 
rodent models of HIE has demonstrated that doses ranging from 1,000 to 5,000 IU/kg 
are neuroprotective (Gonzalez et al., 2009; Chung, Kong, Goldberg, Stowe, & Raman, 
2015; Fan, van Bel, van der Kooij, Heijnen, & Groenendaal, 2013). 
 
Clinical studies have assessed the safety of EPO and darbepoetin (a modified form of 
EPO), in term infants suffering HIE and treated with hypothermia (33.5°C for 72 h). 
These studies demonstrated that EPO or darbepoetin in combination with hypothermia 
was safe (Wu et al., 2012; NCT00719407; Baserga et al., 2015; NCT01471015). A 
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clinical study further assessing the efficacy of EPO with hypothermia in term infants 
is currently recruiting patients (NCT03079167; estimated completion December 
2020).  
 
1.6 CARPS AND NEUROPROTECTION 
As previously outlined, this project aims to extend the previous findings that initially 
identified that CARPs, including poly-arginine peptides, possess intrinsic 
neuroprotective properties. Neuroprotective CARPs typically range in size from 6 – 
30 amino acids and are cationic due to the presence of arginine, lysine and to a lesser 
extent histidine residues. CARPs have the capacity to cross the plasma membrane and 
enter cells, and for this reason they are also referred to as cell penetrating peptides 
(CPPs). CARPs can also cross the blood brain barrier and enter the brain. Due to their 
membrane traversing properties, CARPs (i.e. cationic CPPs) have been extensively 
used for the intracellular delivery of agents in experimental in vitro and animal studies 
(Meloni, Milani, et al., 2015), as well as for the delivery of agents into the brain. A 
review summarising the application of CARPs as a neuroprotective therapeutic 
treatment for HIE is presented in Chapter 2.  
 
1.7 AIMS OF THE THESIS 
The overall goal of this thesis is to examine the neuroprotective efficacy of CARPs, 
namely the poly-arginine peptide R18, in a rat model of HIE. In order to accomplish 
this goal, a P7 rat model of HIE was established and characterised. Using different 
treatment regimens (e.g. L- and D-enantiomer R18, different peptide doses and 
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administration time points post-HI) the HIE model was subsequently used to examine 
the efficacy of R18 to reduce brain injury and improve functional outcomes.  
 
Specific aims of the project are:  
Aim 1: To establish and characterise a more reliable and reproducible P7 rat model of 
HIE.   
Hypothesis: Occlusion of the common and external carotid arteries (as opposed to 
occlusion of the common carotid artery only), followed by transient hypoxia will 
generate a more consistent brain lesion.   
 
Aim 2: To examine the dose response neuroprotective efficacy of R18 (L- and D-
enantiomers; R18 and R18D, respectively) using the newly established P7 rat model 
of HI (as described in Aim 1).   
Hypothesis: R18 peptides are neuroprotective following HIE.  
 
Aim 3: To examine the therapeutic time window and dose responsiveness of R18 (as 
identified in Aim 2) using the P7 rat model of HIE.   
Hypothesis: R18 will be effective when administered several hours after the 
commencement of hypoxia.  
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Abstract: Perinatal hypoxic-ischemic encephalopathy (HIE) is the leading cause of mortality and
morbidity in neonates, with survivors suffering significant neurological sequelae including cerebral
palsy, epilepsy, intellectual disability and autism spectrum disorders. While hypothermia is used
clinically to reduce neurological injury following HIE, it is only used for term infants (>36 weeks
gestation) in tertiary hospitals and improves outcomes in only 30% of patients. For these reasons,
a more effective and easily administrable pharmacological therapeutic agent, that can be used
in combination with hypothermia or alone when hypothermia cannot be applied, is urgently
needed to treat pre-term (≤36 weeks gestation) and term infants suffering HIE. Several recent
studies have demonstrated that cationic arginine-rich peptides (CARPs), which include many
cell-penetrating peptides [CPPs; e.g., transactivator of transcription (TAT) and poly-arginine-9 (R9;
9-mer of arginine)], possess intrinsic neuroprotective properties. For example, we have demonstrated
that poly-arginine-18 (R18; 18-mer of arginine) and its D-enantiomer (R18D) are neuroprotective
in vitro following neuronal excitotoxicity, and in vivo following perinatal hypoxia-ischemia (HI).
In this paper, we review studies that have used CARPs and other peptides, including putative
neuroprotective peptides fused to TAT, in animal models of perinatal HIE. We critically evaluate the
evidence that supports our hypothesis that CARP neuroprotection is mediated by peptide arginine
content and positive charge and that CARPs represent a novel potential therapeutic for HIE.
Keywords: hypoxic-ischemic encephalopathy; hypoxia-ischemia; birth asphyxia; neuroprotection;
cationic arginine-rich peptides; animal models
1. Introduction
Perinatal hypoxic-ischemic encephalopathy (HIE; also referred to as birth asphyxia) remains
the leading cause of neonatal mortality and morbidity, with an incidence in developed nations
of 2–6 and 7 in every 1000 live term (>36 weeks gestation) and pre-term (≤36 weeks gestation)
births, respectively [1,2]. The incidence is even higher in developing countries, with rates of up to
30 per 1000 live full-term births [3,4]. Of the individuals affected by HIE, 15–20% will die in the
Brain Sci. 2018, 8, 147; doi:10.3390/brainsci8080147 www.mdpi.com/journal/brainsci
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postnatal period, and an additional 25% will develop severe and permanent neurological sequela.
Each year, HIE accounts for up to 1.2 million deaths [5] and some form of central nervous system
(CNS) dysfunction in an estimated 1.15 million neonates [6] such as cerebral palsy, epilepsy, global
developmental delay, intellectual disability, behavioral disorders and autism spectrum disorders [7–11].
While hypothermia is used as a therapeutic intervention to minimize brain injury in neonates suffering
HIE, it only provides beneficial outcomes in approximately 30% of patients and has several limitations
(reviewed below). Therefore, an effective and easily administrable pharmacological therapeutic agent
to improve patient outcomes when used as an adjunct to hypothermia, on its own or when hypothermia
cannot be applied is urgently needed.
In recent years, there has been an increased application of putative neuroprotective peptides
designed to target cyto-damaging or cyto-protective pathways to reduce injury in acute brain disorders
such as HIE. One reason for this interest is the discovery of cell-penetrating peptides (CPPs), allowing
for the delivery of neuroprotective peptides and other molecular cargos (e.g., proteins, nucleic acids and
nanoparticles) across the blood brain barrier (BBB) and into cells within the CNS. Most studies assessing
neuroprotective peptides in animal models of HIE use the cationic arginine-rich CPP, transactivator
of transcription (TAT47–57 YGRKKRRQRRR), as the ‘carrier’ molecule. However, several years ago,
our and other laboratories demonstrated that the TAT peptide has modest intrinsic neuroprotective
properties in its own right [12–17]. We subsequently demonstrated that other cationic arginine-rich
peptides [CARPs; e.g., penetratin, protamine, sodium calcium exchanger inhibitory peptide (XIP),
poly-arginine peptides (e.g., R9, R12 and R18; R indicates amino acid arginine and number indicates
mer)], possess potent neuroprotective properties in both in vitro and animal models of cerebral
ischemia and/or hypoxia [12,18–29], and demonstrated that the arginine content and peptide positive
charge are critical determinants of neuroprotection [19,27,28].
Based on the recent application of cationic CPPs for the delivery of putative neuroprotective
peptides in animal models of HIE and the recent discovery of the intrinsic neuroprotective properties
of CARPs, the objectives of this review are: (i) catalogue studies that have used peptides as
neuroprotective agents in HIE, especially those employing a CPP delivery system; and (ii) to evaluate
the potential neuroprotective effects of both CPP and cargo molecules in terms of their arginine content
and cationic charge, as well as the content of other potentially neuroprotective amino acids such
as tryptophan [29]. We will propose that the neuroprotective properties of most, if not all putative
neuroprotective peptides fused to cationic CPPs are likely to be mediated in a large part by the actions
of the carrier CPP (e.g., TAT) rather than the cargo molecule itself, with potency being further enhanced
according to the amino acid content of the cargo (e.g., number of arginine residues) [19]. In addition,
we will also review the evidence that CARPs have multiple cellular modes of action that underlie their
neuroprotective properties.
First, we provide a brief overview of the major underlying pathophysiological mechanisms
associated with HIE and the application of hypothermia as an acute therapy for the disorder.
2. Pathophysiology of Perinatal Hypoxia-Ischemic Brain Injury
2.1. Initiation of the Pathophysiological Cascade in HIE
The etiology of HIE is associated with a variety of maternal, placental and fetal conditions; all of
which have variable clinical manifestations. These conditions include, but are not limited to, chronic
maternal hypoxia (e.g., chronic utero-placental hypoxia, cardiopulmonary arrest, acute hypotension,
pulmonary embolism or vascular disease), pre-eclampsia, nuchal cord, umbilical cord knotting,
umbilical cord prolapse, shoulder dystocia and premature placental detachment [30]. Perinatal hypoxia
is initiated following an impairment of oxygenated cerebral blood flow (CBF) to the fetus, triggering
responses at both the systemic and cellular levels. The fetal brain is particularly sensitive to a HI
environment, as there is a requirement of a constant supply of energy in the form of ATP, and when
interrupted, excitotoxicity occurs through the uncontrolled release of excitatory neurotransmitters
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such as glutamate; marking the beginning of the ischemic cascade. The acute and downstream
consequences of the ischemic cascade are damaging to neurons and other cells (e.g., glial progenitor
cells and astrocytes) at the cytoplasmic and mitochondrial levels, as well as causing disruption to the
BBB and the activation of inflammatory responses.
2.2. Excitotoxicity
The metabolic rate of the fetal brain is largely determined by the stage of gestational
development [30]. To meet metabolic demands, developing neural tissue metabolizes lactate, ketone
bodies and glucose. When compared to the developed brain, the fetal brain is more adaptable with
respect to energy utilization, thereby increasing its capacity to tolerate hypoxia-ischemia (HI) [31].
However, in the event of a critical depletion of ATP due to prolonged HI, the fetal brain eventually
becomes susceptible to injury.
Following prolonged HI, cellular homeostasis is disrupted due to the depletion of ATP and
failure to maintain ionic gradients, and as a result, neurons depolarize and release glutamate into the
synaptic cleft [32]. High extracellular levels of glutamate cause excitotoxicity in neurons and other cells,
namely glial progenitor cells, that express glutamate receptors (NMDA; N-methyl-D-asparate, AMPA;
α-amino-3-hydroxy-5-methy-4-isoxazolepropionic acid, kainic acid and metabotropic glutamate
receptors), producing a cytotoxic cellular influx of calcium ions [33]. The increased levels of
intracellular calcium in neurons and glial progenitor cells in turn results in the activation of
calcium-dependent proteases, lipases and deoxyribonuclease (DNase), reactive oxygen species (ROS)
production, oxidative stress, cytotoxic edema, mitochondrial dysfunction and the stimulation of
pro-cell death pathways [34–38].
2.3. Oxidative Stress
Oxidative stress plays an important role in the pathophysiology of HIE, as the developing brain
comprises high levels of unsaturated fatty acids susceptible to lipid peroxidation, metals catalyzing free
radical reactions and low concentrations of antioxidants [39]. The resulting heightened sensitivity to
oxidative stress and ROS production following HI causes significant damage to lipids (lipid oxidation),
nucleic acids (DNA degeneration) and proteins (protein oxidation). Sources of ROS following HI
include, the mitochondrial electron transport chain (ETC), NADPH oxidases (NOX), xanthine oxidase
(XO), arachidonic acid (12/15 lipoxygenase), and nitric oxide synthase (NOS). In particular, NOS has
been targeted in HIE, with strategies to ablate or inhibit NOS activity invariably being neuroprotective
in animal models of HIE [40].
2.4. Mitochondrial Dysfunction
Mitochondria have diverse functions, including ATP generation, intracellular calcium regulation,
ROS production, biosynthesis of amino acids, lipids and nucleotides and pro-cell death signaling.
The role of mitochondria in HIE has been extensively reviewed [41–43]. Here we focus on the role of
mitochondria in potentiating secondary pathophysiological cascades contributing to HI. Mitochondria
contribute to secondary brain injury following HI via the regulation of cell death pathways, namely
apoptosis. Cellular apoptosis following HI is activated via both intrinsic (e.g., in response to
mitochondrial dysfunction and damaged DNA) and extrinsic [e.g., in response to cell death receptors
such as Fas and tissue necrosis factor-α (TNF-α)] pathways and involve the release of pro-cell death
proteins from mitochondria.
In cells affected by HI, several processes such as excitotoxicity, ROS production, activation of
p53, DNA damage and altered mitochondrial function can influence the activity of pro-apoptotic
Bcl-2 proteins (e.g., Bid and Bax), resulting in Bax-dependent mitochondrial membrane permeability
transition (MPT) [44,45]. In addition, excessive mitochondrial ROS generation, due to leakage
from the ETC, can oxidize the inner mitochondrial membrane phospholipid, cardiolipin, promoting
mitochondrial membrane permeability transition pore (MPTP) opening and subsequent release of
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cytochrome-c. Cytosolic cytochrome-c, along with deoxyadenosine triphosphate (dATP), interact with
apoptotic protease activating factor-1 (Apaf-1) to form the apoptosome, which cleaves and activates
pro-caspase-9 [46]. Activated caspase-9 in turn activates caspase-3, which is a major proteolytic enzyme
responsible for the ultimate dismantling of cells during apoptotic cell death.
Further alterations to mitochondria, such as mitochondrial outer membrane permeabilization
(MOMP), results in the release other pro-apoptotic factors into the cytosol, including apoptosis-inducing
factor (AIF), endonuclease G (Endo-G), and Smac/DIABLO [47,48]. Translocation of AIF and Endo-G
to the nucleus mediates chromatin fragmentation and Smac/DIABLO interacts with inhibitors of
apoptosis to reduce their actions on activated caspases.
TNF cell death receptor signaling mainly stimulates the extrinsic pathway by activating caspase-8,
which activates other caspases, including caspase-3. While beyond the scope of this review, it is also
important to note that other cell death pathways associated with necrosis, necroptosis, ferroptosis and
autophagy may also be activated in response to HI. These pathways can be activated in response to
one or more cellular disturbances such as calcium influx, mitochondrial dysfunction, cellular energy
depletion, ROS production, TNF receptors cell signaling and other cellular cell signaling pathways
(e.g., adenosine monophosphate-activated protein kinase).
2.5. Inflammation
The inflammatory response following HIE has been extensively reviewed by [49,50] and is
therefore briefly discussed. In the immature brain following HI, an innate immune response occurs
within minutes of the injury [51]. Initially, microglia become activated within the cerebral parenchyma,
followed by a systemic inflammatory response, mediated by the infiltration of circulating monocytes,
neutrophils and T-cells into the brain. Activated microglia develop macrophage-like attributes, such as
phagocytic properties, cytokine production, antigen presentation and matrix metalloproteinase (MMP)
release. The release and activation of MMPs by microglia can compromise BBB integrity, further
promoting the invasion of peripheral leukocytes into the cerebral parenchyma; exacerbating ensuing
cerebral injury. A hallmark of HIE is the aggregation of amoeboid microglia within the periventricular
white matter, resulting in the production of inflammatory cytokines (TNF-α and IL1-β), NO and other
ROS [52]; collectively potentiating the toxic effects of the ischemic cascade in neurons, glial progenitor
cells and the cerebral vasculature.
While astrocytes attempt to provide neuroprotective support to neurons and glia via the release
of glutathione, superoxide dismutase (SOD), extra-synaptic uptake of glutamate and the maintenance
of ion channel gradients, these protective mechanisms can be quickly overrun. As with microglia,
astrocytes become hyper-activated due to the effects of pro-inflammatory cytokines, ROS, and dying
neurons and glia. Activated astrocytes also release pro-inflammatory cytokines (IL-6, TNF-α, IL-1α/β
and INF-γ), further exacerbating HI-induced cell death pathways (e.g., apoptosis). In addition,
astrocytes secrete chemokines that attracts systemic immune cells to infiltrate affected tissue, further
aggravating tissue injury.
3. Current Clinical Treatments: Hypothermia
Hypothermia is considered one of the most effective neuroprotective treatment interventions in
both experimental and clinical settings. While the exact beneficial effects of hypothermia are yet to be
elucidated in HIE, it is known to suppress many of the neuro-damaging events associated with HI
including excitotoxicity, apoptosis, inflammation, oxidative stress and BBB disruption [53].
In HIE, moderate hypothermia (33.5 ◦C for 72 h), applied within 6 h of birth, improves the
survival and neurodevelopmental outcomes in infants suffering from moderate and severe HIE.
While hypothermia is now considered standard care in the treatment of HIE and is well tolerated in
term infants [54–57], it does not provide complete protection. Of the infants who have moderate or
severe encephalopathy, therapeutic hypothermia was shown to decrease mortality from 40% to 28%,
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while in surviving infants neurological morbidity was reduced from 31% to 19% of infants receiving
therapeutic hypothermia [58].
Importantly, while hypothermia is safe in pre-term infants with necrotising enterocolitis [59],
it has not been adequately evaluated for use in pre-term infants suffering HIE. Information regarding
the safety and efficacy of hypothermia to treat pre-term infants suffering HIE is lacking, although
information may be available in the near future (NCT1793129). In one study, hypothermia in pre-term
infants was associated with higher mortality and increased clinical complications when compared
to term infants [60], although the study did not include a normothermic pre-term control group.
The inadequate application of hypothermia in the pre-term neonate highlights the need for the
development of safer therapeutic interventions in these patients following HI.
In addition, the induction of hypothermia requires specialized equipment, intensive care
monitoring and trained staff, limiting its use to centers that have the facilities and medical personnel
to undertake the procedure. This develops uncertainty regarding the timing, safety and efficacy
of initiating hypothermia in infants before transfer to a centre equipped to deliver hypothermia.
For example, the transfer of infants suffering HIE to a medical centre to provide hypothermia can
exceed 6 h from the time of birth and that attempts of passive cooling during transport can result
in excessive cooling [61]. In light of this, there is an urgent need for the application of an acute
neuroprotective therapy for infants who suffer HIE when hypothermia cannot be applied immediately,
or is not available. In addition, as the incidences of mortality and morbidity are still relatively
high following hypothermia, there is a requirement for additional therapeutic agents, adjuvant to
hypothermia, to further improve outcomes in infants suffering HIE.
4. Neuroprotective Peptides and Their Therapeutic Application in HIE
4.1. Peptide Therapeutics
Peptides represent an important and increasingly popular class of therapeutic agent. To date, over
60 general peptide drugs have been approved in the United States, Europe, and Japan, approximately
140 are in active clinical development and more than 500 peptides are being examined in preclinical
therapeutic studies [62]. Peptides have several beneficial properties over traditional drugs such as high
biological and structural diversity, less toxicity and accumulation in tissue and reduced propensity
to cause drug-drug interactions. The main disadvantage of most peptides is their inability to cross
the BBB and enter cells, which is an important issue if the peptide has an intracellular target and/or
is targeting a CNS disorder. However, as outlined above, the delivery of peptides into the CNS and
into cells can be achieved by using CPPs. For this reason, CPPs have been widely utilized as a carrier
molecule for the delivery of neuroactive compounds into the CNS, including putative neuroprotective
peptides. Below we review experimental studies that have used neuroprotective peptides in HIE
models, including putative neuroprotective peptides fused to a CPP. First, we summarize findings
from our own and other laboratories highlighting the intrinsic neuroprotective properties of CARPs.
4.2. CARPs Are Intrinsically Neuroprotective
An early study by Ferrer-Montiel et al. [63], demonstrated that cationic arginine-rich hexapeptides
(i.e. containing 2–6 arginine residues; net charge +3–+7; e.g., RRRRRR-NH2) were neuroprotective
in an in vitro hippocampal neuronal NMDA excitotoxic model. These findings were in line with
subsequent studies in our and other laboratories, demonstrating that the CPP TAT (YGRKKRRQRRR;
net charge +8) possesses intrinsic neuroprotective properties following in vitro glutamic acid
excitotoxicity and oxygen glucose deprivation (OGD), as well as in vivo following excitotoxicity and
cerebral ischemia in rats [13–16,64,65]. We subsequently demonstrated that in an in vitro cortical
neuronal excitotoxic model, the CPPs poly-arginine-9 (RRRRRRRRR-NH2; net charge +10) and
penetratin (RQIKIWFQNRRMKWKK-NH2; net charge +8) were even more potent than TAT [12].
The high potency of R9 led us to explore other poly-arginine peptides (e.g., R1, R3, R6–R15, R18, R22),
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as well as several other CARPs, including protamine in the in vitro excitotoxic and OGD neuronal
injury models [27–29]. These studies confirmed that CARPs are highly neuroprotective, with efficacy
increasing with arginine content and peptide positive charge; peaking at R15 to R18 for poly-arginine
peptides [27,29] [Note arginine and lysine (K) are the only positively charged amino acids, while
histidine has a low positive charge].
Our laboratory has also demonstrated that CARPs and in particular the poly-arginine
peptide R18 are neuroprotective in in vivo experimental brain ischemic and/or hypoxic injury
models [18,20–22,24,26,27,29], and that CARPs can reduce neuronal cell surface glutamate receptor
levels and excitotoxic calcium influx [19,22,23,25,27,28]. As highlighted previously [19], based on
our findings, we have proposed that the neuroprotective properties of most, if not all, putative
neuroprotective peptides fused to cationic CPPs (e.g., TAT, R9 and penetratin), as well as other CARPs,
are determined by the arginine content and positive charge of the peptide, with potency also influenced
by other amino acid residues (e.g., lysine, tryptophan and phenylalanine) [19,29]. Importantly,
an arginine and cationic charge mediated neuroprotective mechanism of action of CARPs, including
CPP-fused to putative neuroprotective peptides (e.g., TAT-NR2B9c and TAT-NR2Bct), is supported in
studies by Marshall et al. [65] and more recently McQueen et al. [66]. Based on studies from our own
and other laboratories, we believe that the mechanism of action of putative neuroprotective peptides
fused to a CPP need to be critically re-evaluated. In light of the potentially confounding effects of CPPs
and/or peptide arginine content and positive charge, we will review studies using neuroprotective
peptides in HIE models. First, we provide a summary of the known and potential neuroprotective
actions of CARPs.
4.3. Cationic Arginine-Rich Cell-Penetrating Peptide Neuroprotective Mechanisms of Actions
While the exact mechanisms of the neuroprotective effects are still being explored, we and
others have demonstrated that CARPs have multiple, potentially simultaneous mechanisms of action.
CARPs and putative neuroprotective peptides fused to cationic arginine-rich CPPs (i.e., TAT or R9;
e.g., JNKI-1-TATD, TAT-NR2B9c/NA-1, TAT-CBD3/R9-CBD3-A6K and TAT-3.2-III-IV) can mitigate
excitotoxic or potassium evoked neuronal intracellular calcium influx [19,27,67–69]. One mechanism
whereby CARPs have the capacity to reduce intracellular calcium influx is the reduction of neuronal
cell surface ion channels and receptors; thereby reducing excitotoxic calcium influx. To this end,
CARPs have been demonstrated to reduce the cell surface expression or function of neuronal
NMDA receptors [23,63,70–73], voltage gated calcium channels (CaV2.2 and CaV3.3) [68,70,74,75],
a voltage gated sodium channel (NaV1.7) [76] and the sodium calcium exchanger 3 (NCX3) [70].
Given their effects on different receptors, and the positive charge of CARPs, they may also be
antagonizing ion channel receptor function directly and/or by affecting calcium or sodium ion influx
via an electrostatic mechanism.
In addition to neuronal cell surface receptor interactions, CARPs may also exert pleiotropic
neuroprotective effects by targeting mitochondria and maintaining mitochondrial integrity by reducing
calcium influx into the organelle [65,77–83]. CARPs have the capacity to inhibit proteolytic enzymes
including the proteasome [84,85], as well as pro-protein convertases [86–88] that activate MMPs [89].
Inhibition of the proteasome is known to be beneficial following cerebral ischemia [90–92]; a mechanism
that could be mediated by increased activity of hypoxia-inducible factor 1-α (HIF1α) and decreased
activity of nuclear factor κ-light-chain-enhancer of B cells (NFκB). Similarly, MMP activation in the
brain is known to be detrimental following cerebral ischemia and inhibiting MMP activation is
neuroprotective (see review Cunningham et al. [93]).
Furthermore, there is also evidence that CARPs activate pro-survival signaling pathways [67,94],
modulate immune responses [95–97] and act as anti-oxidant molecules in their own right due to their
guanidine group in arginine residues [65,83,98–101].
Interestingly, the neuroprotective potency of CARPs appears to correlate with the same
characteristic that improve the ability of cationic CPPs to target and transverse cellular membranes [19,29].
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This suggests that CARP-mediated neuroprotection is associated with cellular membrane interactions
(e.g., plasma and mitochondrial), anionic structures (phospholipids/cardiolipin, heparan sulfate
proteoglycans, chondroitin sulfate proteoglycans, sialic acid resides, anionic regions of surface
receptors) and/or increased levels of cellular uptake, which enable the peptides to interact with
membrane (e.g., ion channel receptors) and intracellular targets (e.g., proteins, ROS and mitochondria).
4.4. Studies Using CARPs in Animal Models of HIE
All descriptive details of the studies discussed below are presented in chronological order of
publication (Table 1).
4.4.1. TAT-NEMO Binding Domain (NBD)
NEMO binding domain (NBD) is an 11-amino acid peptide (NBD: TALDWSWLQTE735–745; net
charge −2) derived from the Nuclear Factor-κβ (NF-κβ) Essential Modulator (NEMO)/IKK-γ-Binding
Domain. The NBD peptide was designed to inhibit the activation of NFκB, a transcription factor
involved in many stress responses. For example, NBD was originally developed to suppress
inflammatory responses (e.g., IL-6, iNOS, MMP-9 and COX-2) and the regulation of apoptotic
Bcl proteins (e.g., Bcl-2 and Bcl-x) following cytokine stimulation in several disorders including
inflammatory bowel disease, arthritis, type I diabetes, multiple sclerosis and Parkinson’s disease [102].
Activation of NF-κB requires upstream kinase complex formation (IκB-kinase; IKK) composed of the
IKKα, IKKβ and NEMO proteins. For NF-κB activation, NEMO interacts with a carboxyl terminal
sequence within both IKK-α and IKK-β, known as the NBD. The NBD peptide inhibits NF-κB activation
by blocking NEMO/IKK complex formation [103].
The first study examining the neuroprotective efficacy of the NBD peptide in a model of
HIE (P12 rat) administered the peptide [(14,820 nmol/kg: intraperitoneally (IP)] immediately,
6 and 12 h after hypoxia and did not demonstrate any neuroprotection; instead NBD appeared
to increase brain injury [104]. To improve delivery to the brain, the NBD peptide was fused
to TAT (TAT-NBD: YGRKKRRQRRR-TALDWSWLQTE; net charge +6) and assessed in a P7 rat
model of HIE [105], where administration (6917 nmol/kg: IP) immediately and 3 h, or as a single
injection at 0, 3 or 6 h, after hypoxia was neuroprotective up to 6 weeks post-HI. When TAT-NBD
was administered immediately and 3 h after hypoxia it prevented up-regulation of p53 and
activation of caspase-3 24 h post-HI. TAT-NBD treatment also prevented the activation of IKK in
the brain 3 h post-HI. Despite TAT-NBD inhibiting IKK and NF-κB activation, it had no effect on
HI-induced increases in cytokines (e.g., IL-1β, TNF-α, IL-4, IL-10 and IL-1-RA). The study also
assessed a TAT-NBD control peptide, where two tryptophan residues were substituted for two
alanine residues (YGRKKKRRQRRR-TALDASALQTE; net charge +6) and was shown not to be
neuroprotective. Further assessment of TAT-NBD (6817 nmol/kg: IP) involving administration
immediately and 3 h, immediately, 3, 6 and 12 h, immediately, 6 and 12 h, as well as 18 and 21 h
after hypoxia [106], revealed long-term neuroprotection only in animals treated immediately and 3 h
post-HI. Concomitantly, TAT-NBD treatment immediately and 3 h after hypoxia significantly reduced
HI-mediated cytokine levels, whereas immediate, 3, 6 and 12-h treatment did not reduce cytokines.
In a subsequent study, TAT-NBD treatment (6818 nmol/kg: IP) immediately and 3 h after hypoxia
demonstrated significant improvements in behavioral outcomes up to 14 weeks post-HI [107].
Since intrauterine infections can be associated with HIE, TAT-NBD was assessed in a
lipopolysaccharide (LPS)-sensitized (IP injection) HIE model in the P7 rat [108]. Animals were
administered with TAT-NBD (477 nmol/kg) intranasally (IN) 10 min after hypoxia, using three HI
injury conditions; HI only, 4-h LPS-pre-treatment + HI or 72-h LPS-pre-treatment + HI. Treatment with
TAT-NBD significantly reduced brain injury only in the LPS-sensitized HI models, when assessed 7
days post-HI. While it was surprising that TAT-NBD did not reduce brain injury following HI only,
its neuroprotective actions in LPS-sensitized HI models may be due to the ability of the cationic
TAT-NBD peptide to electrostatically bind and neutralize anionic LPS molecules or by reducing the
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effects of inflammatory cytokines. Neutralizing LPS would have the effect of suppressing the molecules
capacity to evoke an immune response and inflammatory response. In support of this mechanism,
previous studies using in vitro cell and in vivo tissue injury models have demonstrated that CARPs
(e.g., HBD-2, HNP-1 and indolicidin) can bind to LPS and reduce its inflammatory effects [109].
Furthermore, it is possible that the IN delivery of TAT-NBD was enough to reduce the detrimental
effects of LPS, but not ischemic injury associated with HI.
4.4.2. TAT-mGluR1
mGluR1 is a 14-amino acid peptide (mGluR1: VIKPLTKSYQGSGK929–942; net charge +3),
corresponding to an intracellular region of the metabotropic glutamate receptor-1α (mGluR1α) protein
that is cleaved by calpain in neurons following excitotoxicity [110]. It is proposed that TAT-mGluR1
(YGRKKRRQRRR-VIKPLTKSYQGSGK, net charge +11) blocks the ability of calpain to cleave
mGluR1α and thus maintain the receptors ability to stimulate the neuroprotective phosphoinositide
3-kinase/protein kinase B (PI3K-Akt) signaling pathway and protect neurons from the toxic effects
of excitotoxic calcium influx [110]. In a neuronal model of kainic acid mediated excitotoxicity,
TAT-mGluR1 prevented mGluR1α truncation and reduced neuronal cell death [110]. In a P7 rat
model of HIE [111] TAT-mGluR1 (58,590 nmol/kg; IP) administered 1 h before hypoxia significantly
reduced cerebral infarction at 24 h post-HI.
4.4.3. c-Jun N-Terminal Kinase (JNK) Inhibitors
JNKI-1 is a 20-amino acid peptide (also referred to as JBD: RPKRPTTLNLFPQVPRSQDT157–176;
net charge +3), derived from the signaling adaptor protein c-Jun N-terminal kinase protein-1
(JNKI-1) [112]. JNKs are a member of the mitogen-activated protein kinases (MAPK) family,
encoded by the Jnk1, Jnk2 and Jnk3 genes, with high expression levels in neurons, especially
after pathological injury (e.g., excitotoxicity, stroke, epilepsy and HI) [113]. The JNKI-1 peptide
can inhibit JNK interaction with JNK-interacting protein-1 (JIP-1), blocking JNK phosphorylation
and activation, thereby inhibiting downstream pro-death cellular signaling pathways [112].
JNK has emerged as a central mediator of excitotoxic damage in the developing [114,115] and
developed CNS [116,117]. The JNKI-1 peptide derivatives bound to TAT, such as TAT-JNKI-1L
(YGRKKRRQRRR-PP-RPKRPTTLNLFPQVPRSQDT-NH2, net charge +12) and its retro inverso
D-enantiomer JNKI-1-TATD (tdqsrpvqpflnlttprkpr-pp-rrrqrrkkrgy-NH2; net charge +12, lower
case indicates D-isoform amino acids) have demonstrated in vitro and/or in vivo neuroprotective
properties. Studies using the JNKI-1 peptide alone (D-JNKI-1) or when fused to TAT (TAT-JNKI-1L
and JNKI-1-TATD) have been assessed in neonatal HIE models.
The initial study examining the efficacy of D-JNKI-1 (tdqsrpvqpflnlttprkpr-NH2; net charge +4) in
a P7 rat model of HIE when administered (76 nmol/kg: IP) 30 min before and 3, 5, 8, 12 and 20 h after
hypoxia did not reveal any reduction in cerebral infarction at 24 h [115], although there was evidence
for reduced calpain, caspase-3 and autophagic activation.
A subsequent study demonstrated that the TAT-fused peptide JNKI-1-TATL administered
(2446 nmol/kg; IP) immediately and 3 h or 3 h after hypoxia, significantly reduced cerebral infarction
at 48 h, while administration 6 h after hypoxia was ineffective [118]. When administered immediately
and 3 h after hypoxia, functional benefits were observed 14 weeks post-HI. Despite improvements in
cerebral infarct and functional outcomes, JNKI-1-TATL failed to prevent caspase-8-mediated cleavage
of Bid, which was unexpected, as activated JNK is known to induce caspase-8 cleavage of Bid and
promote mitochondrial pro-apoptotic cell death pathways; this suggests JNKI-1-TATL-mediated
neuroprotection was occurring via mechanism independent of JNK suppression.
In a second study, the D-isoform peptide JNKI-1-TATD (2616 nmol/kg: IP) significantly reduced
cerebral infarct volume when administered immediately, 3 or 6 h after hypoxia, but not when
administered immediately and 3 h after hypoxia [119]. JNKI-1-TATD treatment also provided long-term
functional improvements. It was also demonstrated that treatment with JNKI-1-TATD reduced
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mitochondrial levels of phosphorylated JNK, preserved mitochondrial integrity, and up-regulated
anti-apoptotic proteins 24 h post-HI. The study also assessed a mitochondrial JNK scaffold
inhibiting peptide, SabKIM1 (gfeslsvpspldlsgprvva-pp-rrrqrrkkrg; net charge +7) and a scrambled
control (lpsvfgdvgapsrlpevsls-pp-rrrqrrkkrg; net charge +7); Sab (SH3 domain-binding protein 5) is
a mitochondrial scaffold protein required for JNK kinase activity. Administration of SabKIM1 (2700 and
5555 nmol/kg: IP) immediately after hypoxia was neuroprotective, whereas the scrambled peptide
(2700 nmol/kg: IP) was ineffective.
In our laboratory, administration of JNKI-1-TATD (1000 nmol/kg; IP) immediately after hypoxia
resulted in a positive trend in reduced total infarct volume (15% reduction) although it did not
improve behavioral outcomes 48 h post-HI [22]. It was also demonstrated that in cultured cortical
neurons JNKI-1-TATD dose-dependently reduced glutamic acid mediated excitotoxic intracellular
calcium influx.
While it was surprising that the SabKIM1 scrambled control peptide did not display any
neuroprotection, it is possible that the amino acid sequence of the cargo peptide may have
influenced neuroprotective potency. Importantly, we and others have confirmed that TAT-fused
scrambled peptides such as TAT-p53DMs and TAT-NR2cts [29,66] still retain neuroprotective
properties, again pointing to an active role of the TAT carrier and peptide arginine content mediated
neuroprotective action.
4.4.4. TAT-BH4
BH4 is a 25-amino acid peptide derived from the Bcl-x(L) protein BH4 homology domain region
(RTGYDNREIVMKYIHYKLSQRGYEW6–30, net charge +2.1). The BH4 domain is required by Bcl-x(L)
to block cytochrome-c release from mitochondria and prevent MPTP opening [120], as well as inhibiting
endoplasmic reticulum (ER) calcium release into the cytosol by binding to a regulatory domain of
the inositol triphosphate-3 (IP3) receptor [121]; highlighting potential mechanisms whereby the BH4
peptide could exert a neuroprotective action after HI.
The TAT-BH4 (YGRKKRRQRRR-RTGYDNREIVMKYIHYKLSQRGYEW, net charge +10.1) peptide
was demonstrated to reduce cerebral tissue damage and caspase-3 activation when administered
intracerebroventricularlly (ICV; 5 µL/20 ng) 30 min before hypoxia in a P7 rat model of HI [122].
Interestingly, exposure of cultured adult neural stem cells to TAT-BH4 promoted axonal remodeling,
suggesting the peptide exerts other effects that may be beneficial in improving recovery following HI.
4.4.5. Osteopontin (OPN) and TAT-Fused OPN Peptide (TAT-OPN)
Osteopontin (OPN) is a secreted acidic glycoprotein containing an arginine-glycine-aspartate
(RGD) motif and possesses multiple cellular functions including chemotactic and cytokine-like actions.
The OPN protein is expressed in various tissues including bone, placenta, pancreas and the CNS [123].
Following cerebral ischemia, OPN deficient mice demonstrate increased neurodegeneration [124] and
when administered ICV, the protein is neuroprotective in several adult rodent cerebral ischemia and
hemorrhagic stroke models [125–128].
Mechanisms thought to be associated with OPN-mediated neuroprotection include binding
to the cell surface αvβ3 integrin receptor to stimulate pro-survival signaling (i.e., PI3K/Akt
pathway), anti-inflammatory effects [126,129–131], inhibition of inducible NOS [132,133] STAT1
ubiquitination/degradation and by reducing MMP-9 and NF-κβ activation. Despite OPN’s
demonstrated neuroprotective effects, in one study OPN deficient mice demonstrated no change
in susceptibility to ischemic brain injury [126].
The first study to examine the neuroprotective efficacy of OPN in HIE used full length recombinant
OPN protein (rOPN) in a P7 rat model of HI [134]. Animals treated with rOPN (0.03 or 0.1 µg per animal:
ICV) 60 min after hypoxia, displayed a reduction in infarct volume at 48 h and significant improvements
in behavioral outcomes at 7 weeks post-HI. In contrast, treatment with rOPN (0.05 µg/animal: ICV
or 1.2 µg/animal: IN) or thrombin cleaved rOPN (1.2 µg/animal: IN) was not neuroprotective in
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a P5 mouse model of HI [135]. To improve cerebral delivery of OPN, a shorter peptide containing the
RGD motif (IVPTVDVPNGRGDSLAYGLR134–153; net charge 0) was developed. However, the shorter
peptide was not neuroprotective when administered ICV (0.2 µg/animal) or IN (30 µg/animal) before
hypoxia in P5 mice [135]. In a subsequent study the OPN134–153 peptide was fused to TAT (TAT-OPN;
YGRKKRRQRRR-IVPTVDVPNGRGDSLAYGLR, net charge +8) and assessed in a P9 mouse model of
HI [136] using several peptide treatment regimens consisting of multiple dosing using IN, IP or ICV
administration (see Table 1 for details). No treatment regimen reduced infarct volume or improved
functional assessments up to 35 days post-HI. Taken together, current evidence indicates that at the
dosing schedules examined for the TAT-OPN peptide, it is not neuroprotective in HIE rodent models.
4.4.6. P5-TAT
P5 is a 24-amino acid peptide derived from the C-terminal region of the p35 protein
(KEAFWDRCLSVINLMSSKMLQINA254–277, net charge +0.9). Following cleavage of p35 by calpain,
a cleavage fragment known as p25 can bind to cyclin-dependent kinase 5 (Cdk5) and alter its
cellular location and stimulate its activity [137], which is known to be associated with neuronal
cell death [138–140]. Administration (3,660, 7,320 and 9,761 nmol/kg: IP) of a modified P5 peptide
(TFP5: KEAFWDRCLSVINLMSSKMLQINAYARAARRAARR; net charge +5.9) can improve outcomes
in Parkinson’s disease, Alzheimer’s disease, and adult ischemic stroke models in rodents [140–142].
A dose-response assessment (0.23, 2.30, 5.76 and 11.5 nmol/kg; IP) of P5-TAT
(KEAFWDRCLSVINLMSSKMLQINA-YGRKKRRQRRR, net charge +8.9) when administered 30 min
before hypoxia in P7 rats demonstrated that all doses, except 0.23 nmol/kg, significantly reduced
cerebral infarct volume at 48 h [143]. In addition, P5-TAT, when administered (11.5 nmol/kg; IP) 24 h
after hypoxia, significantly improved behavioral outcomes up to 3 weeks post-HI. However, P5-TAT
treatment following HI did not have any effect on the levels of Cdk5 activators, p35, p25 or p29, despite
suppressing cleavage of caspase-3.
4.4.7. D-TAT-GESV
GESV is a 4-amino acid peptide (GESV, net charge −1) derived from the carboxyterminal PDZ
motif (PDZ-G(D/E)XV; net charge −1) of nNOS. Proteins containing PDZ domains play a key role in
anchoring receptor proteins in the membrane to intracellular cytoskeletal structures (e.g., actin and
microtubules) and cytosolic proteins. Following NMDA receptor stimulation, nitric oxide synthase-1
adaptor protein (NOS1AP) via its PDZ binding domain, binds nNOS and recruits the protein to the
cell membrane where it generates nitric oxide (NO). The D-TAT-GESV peptide (ygrkkrrqrrr-GESV,
net charge +7) inhibits NOS1AP/nNOS binding, and is believed to confer neuroprotection by reducing
NO production and activation of the p38 MAPK stress pathway [144]. In a P7 rat model of HIE,
D-TAT-GESV (100 ng: ICV), administered before hypoxia reduced cerebral infarction at 7 days
post-HI [145]. In comparison, the control peptide D-TAT-GASA (100 ng: ICV) was ineffective [145],
which is not surprising since alanine residues can reduce CARP neuroprotective efficacy [19].
4.4.8. TAT-NR2B9c/NA-1
The development of NR2B9c as a neuroprotective agent has recently been discussed in detail [146].
Briefly, NR2B9c is a 9 amino acid peptide (KLSSIESDV1479–1487) derived from the intracellular terminal
carboxyl region of the NMDA receptor NR2B subunit protein, a site that binds the adaptor protein
postsynaptic density-95 (PSD-95). PSD-95 couples nNOS to the NR2B subunit and following NMDA
receptor activation stimulates NO generation. The NR2B9c peptide was developed on the basis that it
blocks NR2B subunit and PSD-95 binding and thereby inhibiting NO production following NMDA
receptor stimulation.
TAT-NR2B9c (YGRKKRRQRRR-KLSSIESDV; net charge +7) administered (19,850 nmol/kg; IP)
either 110 min or 20 min before hypoxia in mice reduced brain injury at 24 h post-HI [147]. In addition,
TAT-NR2B9c treatment significantly improved behavioral outcomes up to 7 days after HI. Interestingly,
a 3000 nmol/kg dose (IP), administered 20 min before hypoxia was ineffective.
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4.4.9. Poly-Arginine-18 (R18 and R18D)
R18 (RRRRRRRRRRRRRRRRRR; net charge +18) and its D-enantiomer (rrrrrrrrrrrrrrrrrr; net
charge +18) is an 18-amino acid peptide and has been demonstrated to have potent neuroprotective
properties in various in vitro and in vivo stroke related injury models [18,24,26,29]. Moreover, we
have recently demonstrated for the first time that R18 and R18D (30, 100, 300 and 1000 nmol/kg; IP),
administered immediately after hypoxia, reduced cerebral infarct volume and improved behavioral
outcomes at 48 h post-HI [22]. In an additional study, administration of R18D 30 (10, 30, 300
and 1000 nmol/kg; IP) and 60 min (30 nmol/kg; IP) after hypoxia, reduced cerebral infarct volume
and improved behavioral outcomes at 48 h post-HI [21].
4.5. Other Peptides Examined in Animal Models of HIE
Several other peptides, not fused to a CPP, have also been examined in animal models of HIE.
All descriptive details of the studies discussed below are presented in chronological order of publication
and in Table 1.
4.5.1. COG133
COG133 is a 20-amino acid peptide (TEELRVRLASHLRKLRKRLL133–152, net charge +5.1) derived
from the apolipoprotein E (apoE) protein. COG133 has been demonstrated to be neuroprotective
in several acute brain injury models and demonstrated to possess anti-oxidant, anti-excitotoxic and
anti-inflammatory properties [148–152]. Exactly how the COG133 peptide imparts its anti-oxidant,
anti-excitotoxic and anti-inflammatory properties is not known, but the positive charge of the peptide
has been considered as a critical factor [19,148]. When examined in a P7 rat model of HIE, COG133
administration (40, 200, 300, 400 and 2000 nmol/kg: ICV) immediately before hypoxia displayed
a neuroprotective dose-response effect [151].
4.5.2. Connexin 43 (Cx43) Derived Peptides
Astrocytic gap junction hemichannels play an essential role in the regulation of electrolytes
and metabolites between the cytosol and extracellular space. Under physiological conditions,
hemichannels are usually in a closed state. Specifically, connexin 43 (Cx43) hemichannel opening occurs
following hypoxia, ischemia and OGD [153–156], resulting in a disruption to cellular homeostasis and
an exacerbation of excitotoxicity [157]. The non-specific blocking of gap junction hemichannels with
octanol and carbenoxolone demonstrates neuroprotective effects in in vitro models of hippocampal
hypoxic-hypoglycemic injury [158,159]. To overcome the non-specific blocking of gap junction
hemichannels, small mimetic peptides that bind to the extracellular loop of Cx43 hemichannels,
blocking hemichannel opening have been developed [160].
Several studies have assessed the administration of a Cx43 mimetic peptide (Peptide 5:
VDKFLSRPTEKT, net charge +1) in fetal sheep models of HIE. Administration of Peptide 5 continuously
for either 1 (50,000 nmol/kg/h; ICV) or 25 h (50,000 nmol/kg over 1 h and then over 24 h; ICV),
beginning 90 min after hypoxia, improved electroencephalographic (EEG) recovery, reduced seizure
activity and improved the return of sleep state cycling. In addition, the 25-h infusion of Peptide 5
improved oligodendrocyte survival at 7 days post-HI [161]. Another study demonstrated Peptide 5
administration immediately after hypoxia (50,000 nmol/kg over 1 h and then over 24 h; ICV) improved
neuronal and oligodendrocyte cell survival, whereas peptide administration beginning during hypoxia
(50,000 nmol/kg for 1 h and then for 24 h; ICV) was not neuroprotective [162]. In contrast, a continuous
high dose infusion of Peptide 5 (50,000 nmol/kg/h over 25 h: ICV) immediately after hypoxia did not
improve neurological outcome and contributed to cerebral edema in the fetal sheep 7 days post-HI [163].
In a pre-term (103 days gestation) fetal sheep model of HI, Peptide 5 administration (50,000 nmol/kg
for 1 h and then for 24 h; ICV) commencing 90 min after hypoxia improved EEG recovery, reduced
neuronal death and increased oligodendrocyte cell survival 7 days post-HI [164]. A study using
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term fetal sheep assessed Peptide 5 and hypothermia (32 ± 1 ◦C; 72 h), as individual treatments and
when combined. Peptide 5 administration 3 h after hypoxia (50,000 nmol/kg for 1 h and then for
24 h; ICV) and hypothermia treatments alone, improved EEG power, neuronal and oligodendrocyte
cell survival at 7 days post-HI. However, combined Peptide 5 and hypothermia treatment did not
result in any additional improvement in EEG power or histological outcomes [165]. This suggests that
neuroprotective targets, other than hemichannels, may be more appropriate to improve the therapeutic
effects of hypothermia for HIE.
Other Cx43 mimetic peptides (Gap 26: VCYDKSFPISHVR; net charge +1 and Gap 27: SRPTEKTIFII;
net charge +1) have demonstrated neuroprotective efficacy in a P7 rat model of HIE [166]. Gap 26 (0.64,
3.22, 6.44, 16.1 and 32.2 nmol/kg; IP) and Gap 27 (16.1 nmol/kg; IP) administered 1 h before hypoxia,
reduced infarct volume at 48 h post-HI; however, the two lower doses of Gap 26 were ineffective.
In addition, multiple administrations of Gap 26 (32.2 nmol/kg: IP) every day for 7 days, beginning
24 h after hypoxia reduced brain injury and improved neurological function, up to 3 weeks post-HI.
Since Cx43 mimetic peptides Peptide 5, Gap26 and Gap 27 have only one arginine residue and low
cationic charge, it would seem unlikely the peptides are operating via a CARP mechanism of action.
4.5.3. Apelin-36
Apelin is an endogenous ligand of the apelin receptor, a G protein-coupled receptor,
which is widely expressed throughout the body, including neurons and oligodendrocytes [167].
The human APELIN gene encodes a 77 amino acid pre-protein, that is cleaved into at least three
biologically active fragments, Apelin-13(65–77), Apelin-17(61–77) and Apelin-36(42–77). The active apelin
fragments are widely expressed in the body including the CNS [168]. Apelin peptides have been
demonstrated to reduce neuronal excitotoxicity and activate extracellular signal-regulated kinase
1/2 ERK-1/2 and PI3K/Akt cell survival pathways in cultured neurons [169–171]. Apelin-36
(LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF42–77; net charge +10.1) has been assessed
in a P7 rat model of HIE [172] with administration (1000 ng: IP) 1 h before hypoxia reduced infarct
volume at 48 h post-HI, and improving neurological function up to 14 days post-HI.
4.5.4. Innate Defense Regulator (IDR) Peptide IDR-1018
Innate defense regulator (IDR) peptides are endogenous cationic host defense peptides [173,174].
IDRs modulate inflammatory responses by increasing the recruitment of immune cells to sites
of infection and inflammation; increasing wound-healing properties. It is believed that IDRs
reduce cerebral injury following HI by reducing the impact of damaging inflammatory responses.
IDR-1018 (VRLIVAVRIWRR-NH2; net charge +5) is a synthetic host defense peptide examined in
an LPS-sensitized model of HIE in P9 mice [175]. IDR-1018 administered (5208 nmol/kg: IP) 4 h
before hypoxia reduced brain injury-related gene pathways that include p53 activation and calcium
signaling. In addition, IDR-1018 administered (5208 nmol/kg: IP) 3 h after hypoxia, reduced infarct
and inflammatory mediators (e.g., TNF-α, IL-1β, IL-4, IL-6, IL-10, IL-17, keratinocyte chemoattractant,
INF-γ and granulocyte-macrophage colony stimulating factor) 8 days post-HI.
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5. Do All CARPs Including TAT-Fused Peptides Share a Common Neuroprotective Mechanism
of Action?
Based on previous studies in our and other laboratories, examining the neuroprotective properties
of various CARPs, we view it highly likely that the neuroprotection demonstrated by the CARPs
described above (i.e., TAT-NBD, TAT-mGluR1, JNKI-1-TATL, JNKI-1-TATD, SabKIM1, TAT-BH4, P5-TAT,
D-TAT-GESV, TAT-NR2B9c, R18, R18D, COG133, Apelin-36 and IDR-1018) is largely mediated by
peptide arginine content and positive charge [19,27,29,65,66]. There are several lines of evidence
that support this hypothesis, which we provide below. In addition, we previously provided
an explanation why we believe a CARP-mediated neuroprotective mechanism of action is operating
for the TAT-NR2B9c and JNKI-1-TATD peptides, rather than the mechanism of action in which they
were originally developed [27].
It has been demonstrated that CARPs inhibit neuronal excitotoxic calcium [19,22,23,25,27,28] and
potassium [64,75] influx and in doing so inhibit many of the pathophysiological processes downstream
from the ischemic excitotoxic cascade (e.g., calpain activation, mitochondrial dysfunction and ROS
production, calcium induced cell signaling and lipase and DNase activation). Therefore, given that the
vast majority of the proposed mechanisms of action of developed TAT-fused and other neuroprotective
CARPs are molecular targets downstream from excitotoxicity (e.g., NF-κB, JNK and Cdk5), it is not
surprising that they are effective and appear to be inhibiting their intended targets.
Interestingly, in addition to the inhibition of excitotoxic cationic ion influx, CARPs also have
the capacity to modulate other cellular processes that are neuroprotective following HI such as
proteolytic enzyme activation (e.g., proteasome and MMPs), ERK-1/2 and Akt phosphorylation and
the modulation of immune responses. For example, in the case of TAT-NBD, which was developed to
block NF-κB activation, the ability of CARPs to inhibit the proteasome [84,85,176,177] would have the
effect of preventing NF-κB activation by preventing proteasomal degradation of the NF-κB inhibitor
protein i-κB.
In the case of Apelin-36, other CARPs, such as protamine and R9 (ALX40-4C) can also bind to the
apelin receptor [178,179]. Therefore, it is possible that CARPs, in addition to Apelin-36, may also be
able to stimulate pro-cell survival ERK-1/2 and Akt pathways [180]. Although it should be mentioned
that not surprisingly, Apelin-36 can also reduce excitotoxic calcium influx [169–171]. In the case of
CARP-mediated immune modulation, mR18L (Ac-GFRRFLGSWARIYRAFVG-NH2; net charge +4)
is known to reduce LPS-induced systemic infection [181], dRK6 (RRKRRR; net charge +6) inhibits
TNFα and IL-6 production by monocytes [182] and hBD3-3 (GKCSTRGRKCCRRKK; net charge +8)
downregulates NF-κB induced inflammation [183]. Thus, CARPs have the potential to suppress many
of the toxic inflammatory responses associated with HIE.
Future studies examining the efficacy of putative neuroprotective peptides fused to TAT would
benefit with respect to confirming neuroprotective mechanisms of action by fusing the peptide to
a non-cationic CPP (e.g., MTS; AAVALLPAVLLALLP) and/or replacing any negatively charged
aspartate (D) and glutamate (E) residues within the peptide sequence with arginine residues; we
predict these two manipulations will decrease and increase neuroprotective efficacy, respectively. It is
also advisable to confirm if the TAT-fused peptide has the capacity to reduce excitotoxic calcium influx.
6. Conclusions
There is now a large body of data from various sources demonstrating that CARPs comprise a class
of peptide with significant neuroprotective potential for development as an adjuvant to hypothermia,
or when hypothermia cannot be applied, for the treatment of HIE. While further studies are required
to elucidate neuroprotective mechanisms, available evidence indicates that CARP neuroprotection
is determined by the peptide’s arginine content and cationic charge and more specifically by the
guanidine head group in the arginine residues. Interestingly, CARP neuroprotective potency appears
to correlate with the same characteristics that improves the ability of the cationic CPPs to target and
traverse cellular membranes [19,29]. Taken together it is clear that CARPs possess many properties
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enabling them to target both intracellular and extracellular damaging and protective pathways that
are likely to be beneficial following HIE, not to mention their ability to cross the BBB and enter cells.
In conclusion, CARPs, including poly-arginine peptides, offer an exciting therapeutic approach for
HIE with the potential to reduce the severity of brain injury via potentially several neuroprotective
mechanisms of action.
7. Future Directions
There are several further considerations to be addressed before translation of CARPs as
a therapeutic for HIE in the clinic. It will be important to firstly identify a CARP that has high
efficacy and the greatest potential to be effective in HIE, in both pre-term and term infants. In addition,
preclinical studies will need to examine CARP treatment in combination with hypothermia to ensure
safety, and to identify any synergistic effects in terms of improving patient outcomes. It is also
important that beneficial results obtained in rodent models of HI, especially with combining CARPs and
hypothermia, are confirmed in a large animal model (e.g., piglet or lamb), allowing for assessment in
a gyrencephalic brain with greater comparability to the human and that the efficacy of IV administration
should be established prior to clinical trials.
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Chapter 3 
General Materials and Methods 
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3.1 MATERIALS AND METHODS 
In addition to information provided in Chapters 4 - 6, many of the materials and methods used 
in this thesis are provided in this chapter.  
 
3.2 PEPTIDES USED IN THIS THESIS 
The peptides used for in vitro and animal studies are summarised in Table 3.1. All peptides 
were purified using high performance liquid chromatography and were subjected to hydrolysis 
and amino acid liquid chromatography analysis to obtain a precise measurement of peptide 
content (Mimotopes, Melbourne, Australia). For animal studies, all peptides were prepared in 
0.9% sodium chloride for injection (Pfizer, Perth, Australia), aliquoted into a 50 µl volume 
within 300 µl syringes and stored at -20°C until use.  
 
Table 3.1 Summary of the peptides used in this thesis  
Peptide Sequence* 
Arginine 
residues 
Charge 
at pH 7 
R18 H-RRRRRRRRRRRRRRRRRR-OH 18 +18 
R18D H-rrrrrrrrrrrrrrrrrr-OH 18 +18 
JNKI-1-TATD H-tdqsrpvqpflnlttprkprpp-rrrqrrkkrg-NH2 9 +12 
*T = threonine, D = aspartic acid, Q = glutamine, S = serine, R = arginine, P = proline, V = 
valine, F = phenylalanine, L = leucine, N = asparagine, K = lysine. Lowercase letters signifies 
D-enantiomer amino acid.  
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3.3 P7 RAT MODELS OF HYPOXIC-ISCHAEMIC ENCEPHALOPATHY 
3.3.1 Animal ethics approval 
All animal surgical procedures and behavioural studies were approved by the University of 
Western Australia’s Animal Ethics Committee (RA/3/100/1329 and RA/3/100/1569), in 
accordance with the Policies and Guidelines of the National Health and Medical Research 
Council, Australia. In the design of these studies, every effort was made to minimise the 
amount of animal suffering and follow Animal Research: Reporting of In Vivo Experiments 
(ARRIVE) guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010), where 
appropriate. All animal surgical procedures and behavioural studies were conducted in an 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC) accredited animal research facility.  
 
3.3.2 Animals numbers used in experimentation 
Pregnant nulliparous Sprague-Dawley rats (dam; Animal Resource Centre, Murdoch, 
Australia) were used for experiments presented in this thesis. For determining a pup’s age, day 
of birth was considered P0. At P2, all litters were counted and where appropriate were culled 
to 10 – 12 pups per dam; this is to facilitate uniform growth of the pups without littermate 
competition for feeding. Animals with a weight range of 14.5 ± 1.5 grams were used for studies, 
with animals falling outside this weight range on day P7 excluded. In addition, while animals 
were sexed, both male and female pups were used in studies, in a random and blinded fashion. 
Prior to any surgical procedure, the dam and pups were housed in ventilated cages (Techniplast, 
Paola, Malta) which were placed in an animal holding room maintained at 25 ± 1°C. 
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3.3.3 Behavioural assessments 
For all behavioural assessments, each animal was given three attempts to complete each 
behavioural assessment per day, with 5 minutes between each attempt and assessment. All of 
the assessments used in this thesis are considered highly reproducible throughout the murine 
pre-weaning period (< P30) and are strain- and sex-independent (Heyser, 2004). In between all 
behavioural assessments, all animals were placed on a heating pad (37°C) to prevent 
hypothermia. Forty-eight hours after hypoxia-ischaemia (HI) pups’ responses in all 3 
behavioural assessments were recorded 3 times.  
 
3.3.3.1 Righting reflex 
For the righting reflex, pups were placed on a flat surface covered with a tightly stretched close-
knit fabric, to ensure adequate friction. Pups were placed in a supine position and the time 
recorded for them to rotate to a prone position recorded (in seconds).  
 
The righting reflex required behavioural sensitisation (i.e. pre-training). For three consecutive 
days before surgery (P4 – 6; inclusive), pups were accustomed to the righting reflex with a 
mean target inclusion range of ≤ 2 seconds by the day of surgery (P7; behavioural baseline 
recording measurement). Any animal that did not meet the inclusion criteria was excluded from 
the study.  
 
3.3.3.2 Negative geotactic response 
For the negative geotactic response, animals were placed on a board covered with tightly 
stretched close-knit fabric, to ensure adequate friction. The board was positioned on a 45° slope 
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and at the start of assessment, pups were placed facing downslope. The time for the pups to 
rotate 150° up the 45° slope recorded (in seconds).  
 
The negative geotactic response required behavioural sensitisation. For three consecutive days 
before surgery (P4 – 6; inclusive), pups were accustomed to the negative geotactic response 
with a mean target inclusion range of ≤ 30 seconds by the day of surgery (P7; behavioural 
baseline recording measurement). Any animal that did not meet the inclusion criteria was 
excluded from the study.  
 
3.3.3.3 Wire-hang assessment  
The wire-hang assessment involved suspending pups by their forelimbs on a 2 mm diameter 
steel wire, suspended 20 cm above a soft foam surface and recording the time taken (in seconds) 
for the animal to fall to the foam surface.  
 
The wire-hang assessment did not require any behavioural sensitisation and pups’ performance 
was assessed on the day of surgery (P7; behavioural baseline recording measurement) and did 
not have any study inclusion criteria.  
 
3.3.4 Original Rice-Vannucci HI surgical procedure 
Anaesthesia was induced using a facemask with 5% isoflurane in 100% O2, and once the animal 
was anaesthetised, the isoflurane concentration was reduced and maintained at 1.5 ± 0.5%; the 
duration of anaesthesia from induction to beginning of recovery did not exceed 10 minutes. 
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Through a 1 cm mid-line ventral incision, the right common carotid artery (CCA) was exposed 
and carefully dissected from the vagus nerve, venous circulation and carotid body. The CCA 
was permanently ligated using a 6-0 silk suture. A diagrammatic description of this surgical 
procedure is presented in Chapter 3, Figure 1. The wound was closed using Vetbond (3M, 
Maplewood, USA) and the animals recovered on 100% O2 for 5 minutes. Sham-operated 
animals underwent the same operative procedure, except the exposed CCA was not ligated. 
 
Following surgical recovery, pups were returned to their dam for approximately 1 hour prior 
to hypoxia, which consisted of placing between 4 and 6 pups into an airtight container 
(approximate volume: 4 litres) and gassing the container with warm humidified gas (8% O2/92 
% N2; 3 litres/minute) for 2.5 hours. During the gassing procedure, the container was housed 
in an incubator maintained at 35°C. Following hypoxia, pups were removed from the container 
and immediately administered peptide or saline (IP bolus; 50 µL), then placed back with the 
dam. For delayed post-hypoxia treatment administration, following hypoxia, pups were 
immediately returned to their dam and at the appropriate time injected with peptide or saline. 
Sham-operated animals remained with the dam at all times after the surgical procedure.  
 
3.3.5 Modified Rice-Vannucci HI surgical procedure 
For the modified Rice-Vannucci model, the surgical procedure was the same as described 
above for the original Rice-Vannucci model, except both the CCA and external carotid artery 
(ECA) were permanently occluded using a 6-0 silk suture. A diagrammatic description of this 
surgical procedure is presented in Chapter 3, Figure 1.  
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3.3.6 Post-surgical analgesia, animal body temperature monitoring and housing  
All animals were administered pethidine analgesia (5 mg/kg; intraperitoneally) immediately 
before the cessation of anaesthesia. Animal surface body temperature was monitored 
periodically throughout the surgical and hypoxia procedures and immediately post-hypoxia 
using an infrared thermometer. To avoid animals becoming hypothermic during the surgical 
procedure and when separated from the dam during behavioural assessments, animals were 
placed on a heating pad maintained at 37°C. During the surgical procedure, if the animal’s 
body temperature decreased (< 36.5°C) a heating fan would be used to maintain a surface body 
temperature of 37°C. In addition, from the conclusion of surgical anaesthesia to the 
experimental endpoint, all animals (pups and dam) are housed at 27 ± 1°C in a Ventilated 
Warming Cabinet (Techniplast, Paola, Malta).  
 
3.4 EX VIVO ASSESSMENT OF BRAIN INJURY 
3.4.1 Tissue sectioning and triphenyl tetrazolium chloride (TTC) staining  
Forty-eight hours after HI, animals were euthanised by lethal intraperitoneal injection of 
pentobarbitone (50 mg/kg; intraperitoneally). Infarct volume measurement was performed 
using coronal brain slices stained with TTC. The brain was carefully removed from the skull 
and placed in 0.9% sodium chloride and cooled for 15 minutes at -80°C before being placed in 
an adult mouse brain matrix (Note: the adult mouse brain matrix is a suitable size for a P9 rat 
brain). Razor blades were inserted into the matrix to generate 2 mm coronal slices. The brain 
slices were incubated for 20 minutes at 37°C in a 3% TTC (w/v; in 0.9% sodium chloride) to 
stain viable non-infarcted tissue, then fixed by placing in 4% formalin for at least 24 hours.  
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3.4.2 Measurement of infarct volume from TTC stained coronal slices 
Digital images of coronal brain slices (not including cerebellum) were acquired with a colour 
scanner and analysed using ImageJ software (National Institute of Health, Maryland, United 
States of America) to calculate an infarct volume. The calculation accounts for changes in 
hemisphere size due to oedema and is presented below and in Chapter 3:  
 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑓𝑎𝑟𝑐𝑡 𝑣𝑜𝑙𝑢𝑚𝑒 = (
𝐶𝑜𝑛𝑡𝑟𝑎𝑙𝑎𝑡𝑒𝑟𝑎𝑙 ℎ𝑒𝑚𝑖𝑠𝑝ℎ𝑒𝑟𝑒 𝑣𝑜𝑙𝑢𝑚𝑒
𝐼𝑝𝑠𝑖𝑙𝑎𝑡𝑒𝑟𝑎𝑙 ℎ𝑒𝑚𝑖𝑠𝑝ℎ𝑒𝑟𝑒 𝑣𝑜𝑙𝑢𝑚𝑒
) (𝐼𝑛𝑓𝑎𝑟𝑐𝑡 𝑣𝑜𝑙𝑢𝑚𝑒) 
 
Once the infarct area for all sections was defined, the total infarct volume was presented as a 
percentage of total brain volume.  
 
3.5 STATISTICAL ANALYSIS 
Data from mean total infarct volume measurements were evaluated by analysis of variance 
(ANOVA) followed by Fisher’s post hoc analysis. Data for behavioural assessments were 
analysed as described in Chapters 4 - 6.  
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h i g h l i g h t s
• An improved surgical procedure to reduce infarct volume variability.
• Procedure involves ligation of the common and external carotid arteries (CCA/ECA).
• The method abolishes communicational blood flow through internal carotid artery.
• CCA/ECA occlusion plus hypoxia improves infarct volume standard deviation.
• CCA/ECA occlusion plus hypoxia improves functional assessment reliability.
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a b s t r a c t
Background: The Rice-Vannucci model of hypoxic-ischaemic encephalopathy (HIE) has been associated
with a high degree of variability with respect to the development of cerebral infarction and infarct lesion
volume. For this reason,we examined the occurrence of communicational blood flowwithin the common
carotid (CCA), internal (ICA), and external (ECA) carotid arteries following CCA occlusion as a source of
variability in the model.
New method: We propose a novel modification to the Rice-Vannucci model, whereby both the CCA and
ECA are permanently ligated; mitigating communicational blood flow.
Results: Using magnetic resonance angiography, phase-contrast velocity encoding, and pulsed arterial
spin labelling, the modified Rice-Vannucci model (CCA/ECA occlusion) was demonstrated to mitigate
communicational blood flow, whilst significantly reducing ipsilateral hemispherical cerebral blood flow
(CBF). Comparatively, the original Rice-Vannucci model (CCA occlusion) demonstrated anterograde and
retrograde blood flowwithin the ICA and CCA, respectively, with a non-significant reduction in ipsilateral
CBF. Furthermore, CCA/ECA occlusion plus hypoxia (8% O2/92% N2; 2.5h) resulted in 100% of animals pre-
senting with an infarct (vs 87%), significantly larger infarct volume at 48h (18.5% versus 10.0%; p<0.01),
reduced standard deviation (±10% versus ±15%), and significantly worsened functional outcomes when
compared to CCA occlusion plus hypoxia.
Comparison with existing method: We compared a modified Rice-Vannucci model (CCA/ECA occlu-
sion±hypoxia) to the commonly used Rice-Vannucci model (CCA occlusion±hypoxia).
Conclusion: This study demonstrates that CCA/ECA occlusion in the Rice-Vannucci model of HIE reduces
infarct volume variability by limiting communicational blood flow.
© 2017 Elsevier B.V. All rights reserved.
∗ Corresponding author at: Perron Institute forNeurological and Translational Sci-
ence, QEIIMedical Centre, 8 Verdun St, Nedlands,WesternAustralia, 6009, Australia.
E-mail address: adam.edwards1@my.nd.edu.au (A.B. Edwards).
1. Introduction
Perinatal hypoxic-ischaemic encephalopathy (HIE) occurs at a
rate of 1–3 per 1000 live births, with the resulting brain injury
http://dx.doi.org/10.1016/j.jneumeth.2017.06.016
0165-0270/© 2017 Elsevier B.V. All rights reserved.
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causing death or neurological sequelae such as cerebral palsy,
epilepsy, cognitive/behavioural disorders, and mental retardation
(Graham et al., 2008; Kurinczuk et al., 2010; Vannucci and Perlman,
1997). Currently, while neonatal hypothermia can improve out-
comes in the term infant (≥37 weeks gestation), there is an urgent
need for the development of a safe and effective pharmacologi-
cal neuroprotective and/or neuroregenerative agent that can be
easily applied following HIE. The development of any new ther-
apies for HIE requires a reliable and reproducible animal model
that can be used for the assessment of potential neuroprotective or
neuroregenerative agents, as well as pathophysiological cascades.
The  HIE model in the 7-day-old (P7) rat first described by Rice
et al. (1981), commonly referred to as the Rice-Vannucci model, is
by far the most commonly used model for perinatal neuroprotec-
tion, neuroregenerative, and pathophysiological studies (Rice et al.,
1981; Ditelberg et al., 1996; Sheldon et al., 1996; McQuillen et al.,
2003). Reliable and reproducible injury development is imperative
for any ischaemic brain injury model, including HIE. In this regard
the Rice-Vannucci model is widely reported to be associated with
variable outcomes in terms of infarct presence, infarct volume size,
and by extension, functional outcomes (Rice et al., 1981; Ota et al.,
1997; Palmer et al., 1990, 1993; Silverstein et al., 2016; Hagberg
et al., 1994; Ashwal et al., 2007; Okusa et al., 2014).
Whilst a number of potential sources of variability within the
Rice-Vannucci model have been reported (Table 1), one additional
source of variability in both neonatal and adult ischaemic brain
injury models can be attributed to cerebral collateral circulation
via the circle of Willis and cerebral anastomoses. Cerebral collateral
circulation can stabilise cerebral blood flow following vessel occlu-
sion and/or haemodynamic compromise. For example, following
common carotid artery (CCA) occlusion, compensatory blood flow
is redistributed to the affected brain region through the circle of
Willis. Similarly, in the Rice-Vannucci model, while permanent CCA
occlusion is thought to impede blood flow through the internal
carotid artery (ICA) and the external carotid artery (ECA) branches,
retrograde perfusion is reported to occur from the ECA to the ICA,
thereby reperfusing cerebral tissue supplied by the ICA (Bates et al.,
2003). This retrograde perfusion occurs through two routes: firstly,
via facial, orbital, and meningeal branches, originating from the ECA
providing retrograde collateral connections between the ECA and
the ICA (Fig. 1) (Cuccione et al., 2016); and secondly, via collateral
blood flow through the ECA by anastomotic branches with the supe-
rior and inferior thyroidal, or occipital arteries (Fig. 1) (Nikanfar
et al., 2004).
Against this background and in light of the variability seen in
infarct development associated with the Rice-Vannucci model, the
aim of this study was to investigate the presence of retrograde
and anterograde blood flow through the CCA and ICA respectively,
following CCA occlusion and CCA/ECA occlusion in P7 Sprague-
Dawley rats. To investigate collateral circulation we  performed
magnetic resonance imaging (MRI) experiments to examine CBF
following the standard Rice-Vannucci CCA occlusion. To improve
infarct development reproducibility in the Rice-Vannucci model we
modified the procedure by occluding the CCA in addition to the ECA
(hereafter referred to as CCA/ECA occlusion; Fig. 1).
2.  Materials and methods
All  experimental procedures in this study adhered to the guide-
lines approved and specified by the Animal Ethics Committee of
the University of Western Australia, in accordance with the Poli-
cies and Guidelines of the National Health and Medical Research
Council, Australia.
2.1. Rice-Vannucci and modified HIE surgical models
Unsexed, P7 Sprague-Dawley rat pups (Animal Resource Cen-
tre, Murdoch, Australia) with a body weight of 13–16 g were used.
Litters were culled to a maximum of 10 pups per litter to facil-
itate uniform growth without littermate competition. Rat pups
were anaesthetised using isoflurane (5% induction, 1–2% main-
tenance) in 100% oxygen, while on a heating pad (37 ◦C); the
duration of anaesthesia from induction to beginning of recovery
did not exceed 10 min. Through a 1 cm mid-line ventral incision,
the right common, internal, and external carotid arteries were
exposed and isolated from the vagus nerve, venous circulation,
and carotid body. For the Rice-Vannucci CCA occlusion model, the
right CCA was  permanently ligated using 6–0 silk sutures, while for
the CCA/ECA occlusion model, the right CCA and ECA were per-
manently ligated using 6-0 silk sutures. The wound was  closed
using Vetbond (3 M,  Maplewood, USA) and the animals allowed to
recover on 100% oxygen for 5 min  on a heating pad. Animals were
provided with analgaesia (pethidine, 5 mg/kg; intraperitoneally)
immediately before cessation of anaesthesia. Sham-operated ani-
mals underwent the same operative procedure except the exposed
carotid arteries were not ligated.
Rat pups were returned to their dam for 1 h before the com-
mencement of hypoxia. Hypoxia consisted of placing up to 5 pups in
an airtight container (approximate volume: 4 L) and exposing them
to humidified and warmed hypoxic gas (8% O2/92% N2; 3 L/min) for
2.5 h. The container was placed inside an incubator with an ambi-
ent air temperature of 35 ◦C, ensuring a core body temperature of
36–37 ◦C, periodically monitored using an infrared thermometer.
To avoid any bias in outcomes of animals undergoing the differ-
ent surgical procedures for HIE, each batch of animals exposed to
hypoxia consisted of 2–3 animals with CCA occlusion and 2–3 ani-
mals with CCA/ECA occlusion. Additionally, operator was blinded
to surgical procedure groups for infarct volume analysis and func-
tional assessment.
Following hypoxia-ischaemia, animals were placed on a heat-
ing pad (37 ◦C) for 5 min  in a normoxic environment before being
placed back with the dam. To avoid hypothermia, rat cages were
housed at 26–28 ◦C during the study.
2.2.  Infarct volume assessment
Forty-eight  hours after hypoxia-ischaemia, animals were
euthanased by pentobarbital overdose (50 mg/kg; intraperi-
toneally) and infarct volume determined by preparing
2 mm  thick coronal brain slices, and incubating in 3% 2,3,5-
triphenyltetrazolium chloride (TTC; Sigma Aldrich, St. Louis,
USA) at 37 ◦C for 20 min, followed by fixation in 4% formalin at
room temperature overnight. Digital images of coronal sections
were acquired using a colour scanner and analysed, using ImageJ
software (3rd edition, NIH, Bethesda, USA). Total infarct volume
was determined by measuring areas of infarcted tissue on both
sides of the 2 mm sections. Infarct measurements were corrected
for oedema using the formula:
Corrected
infarct
volume
=
⎛
⎜⎜⎜⎜⎜⎜⎝
Contralateral
hemisphere
volume
Ipsilateral
hemisphere
volume
⎞
⎟⎟⎟⎟⎟⎟⎠
(
Infarct
volume
)
Where ipsilateral hemisphere indicates hemisphere with observ-
able infarct and contralateral hemisphere indicates hemisphere
with no observable infarct. Final infarct data is expressed as
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Table  1
Proposed sources of infarct variability within Rice-Vannucci HIE model.
Proposed
variability
Animal Model HI parameters Results Refs.
Strain C57BL/6, 129SVJ,
BALB/c,  CD1, and
FVB
LPS – HIE 8% O2/92% N2; 30 min  Varied ischaemic lesion development.
Small infarct (129SVJ & C57BL/6),
moderate infarct (BALB/c), and severe
infarct (CD1 & FVB).
Rocha-Ferreira
et  al. (2015)
Litter  size Sprague-Dawley;
P7, P8, and P9
HIE 8% O2/92% N2; 135 min  Varied ischaemic lesion development.
Non-culled litters reported uneven
distribution of infarct lesions (absent,
mild, moderate, and severe infarct).
Culled litters reported severe and
moderate infarcts. Weight of pups had
no influence on ischaemic lesion.
Oakden  et al.
(2002)
Resuscitation  Wistar; P10 HIE 8% O2/92% N2; 75 min  Resuscitation of pups in 100% oxygen
did not affect short term
neuropathological outcomes.
Wood  et al. (2016a)
Isoflurane Sprague-Dawley;
P7 and P10
HIE 8% O2/92% N2; 150 min  Exposure time of <9 min  to isoflurane
improves development of ischaemic
lesion, whilst isoflurane exposure time
of >9 min reduces ischaemic injury.
Chen et al. (2011)
Blood sugar Wistar; P7 HIE 8% O2/92% N2; 60 min.
Bilateral CCA occlusion
Increased blood glucose levels after HI
reduces ischaemic injury
Hattori and
Wasterlain, (1990)
Hypothermia Wistar; P7 HIE 8% O2/92% N2; 100 min  Lower temperature (30–33.5 ◦C) after
HI reduced ischaemic injury
Wood  et al. (2016b)
Maternal diet Wistar; P7 HIE 8% O2/92% N2; 90 min  Maternal diet does not affect
development of ischaemic lesion.
Maternal diet pre- and postnatally
influenced functional recovery after
hypoxia-ischaemia.
Barks et al. (2017)
All hypoxic-ischaemic (HI) parameters indicate unilateral occlusion of the CCA, unless otherwise stated. O2 = oxygen, N2 = nitrogen, and min  = minutes, Refs = references.
percentage infarct volume compared to whole brain (minus cere-
bellum).
2.3. Functional testing
To  determine if the development of brain infarct was associ-
ated with reduced sensorimotor function, three neurological tests
(righting reflex, negative geotactic response, and rope-hang) were
performed at 48 h after hypoxia-ischaemia. For three consecutive
days before surgery (P4 – 6; inclusive), pups were accustomed to
behavioural assessments with a target inclusion range of ≤2 s for
the righting reflex and ≤30 s for the negative geotactic response.
Any animal that did not record responses within these parame-
ters at P7 (day of surgery) were excluded from the experiment. All
of these reflexes are highly reproducible throughout the murine
pre-weaning period (<P30) and are strain- and gender-independent
(Heyser, 2004). Each animal was given three attempts to complete
each sensorimotor task, with 5 min  between each attempt. Testing
of all reflexes was performed on a board covered with a tightly-
stretched close knit-fabric, to ensure adequate friction.
The  righting reflex involved placing pups in a supine position,
and measuring the time (in sec) required to flip to the prone posi-
tion. The negative geotactic response involved placing pups facing
down-slope, on a 45◦ angled surface, and measuring the time
required (in sec) for the animal to turn 150◦ upslope. Rope-hang
was performed by suspending pups by their forelimbs on a 2 mm
diameter steel wire suspended 20 cm above a foam surface, and
recording the time taken (in sec) for the animal to fall to the foam
surface.
2.4. Magnetic resonance imaging
Animals were placed into three groups for imaging studies:
(i) sham-operated, (ii) CCA occlusion, and (iii) CCA/ECA occlusion.
Animals assigned to MRI  were not exposed to hypoxic conditions
(carotid vessel occlusion only). Imaging occurred on the day of
surgery (P7). Each animal was anaesthetised with isoflurane (5%
induction,  0.5–1.5% maintenance) in 100% oxygen; the duration of
anaesthesia from induction to euthanasia did not exceed 60 min.
MRI scans were performed with a Bruker BioSpec 94/30 US/R
magnet (B0 = 9.4 T), Avance III HD console, BGA-6SHP gradients,
ParaVision 6.0.1 software, 35 mm inner diameter H-1 quadrature
transmit-receive volume coil, and mouse cradle. To determine the
position of the brain in the magnet, a FLASH based scout scan
was performed over a field-of-view (FOV) = 50 mm × 50 mm,  with
repetition time (TR) = 200 msec, echo time (TE) = 3.8 msec, and
five interlaced 1.5 mm slices with a 1.0 mm  gap, in three orthog-
onal directions. A 2D multi-slice multi-echo sequence was  used to
obtain a series of T2-weighted images in the sagittal plane, with
a FOV = 36 mm × 27 mm,  in-plane pixel size = 150 m × 150 m,
from 700 m thick interlaced slices, with TR = 2400 msec, echo
spacing (ESP) = 8 msec, at TE = 12 msec and 60 msec, and
fat suppression. Time-of-flight (TOF) angiography (Reese et al.,
1999; Beckmann, 2000) was completed using a 3D FLASH scan
with coronal orientation, FOV = 24 mm × 22 mm × 18 mm,  voxel
size = 80 m × 80 m × 150 m,  TR = 12 msec, TE = 2 msec, flip
angle () = 20◦, and fat suppression. Velocity mapping was  com-
pleted with phase-contrast angiography (Dumoulin and Turski,
2000) using the FLOWMAP sequence, with coronal slices posi-
tioned to cover the CCA, ICA, and ECA, with FOV = 20 mm × 20 mm,
in-plane pixel size = 80 m × 80 m,  from 10 interleaved 700 m
thick slices with a gap of 250 m,  and a velocity encoding range
of +/−35 cm/sec. Lastly, a pulsed arterial spin labelling (PASL)
(Detre et al., 1992) perfusion scan was completed with a fluid
attenuation inversion recovery (FAIR) (Kim, 1995), single-shot,
spin-echo echo-planar imaging (SE-EPI) sequence. Prior to the
EPI scan B0 field shimming was completed using the Bruker
MAPSHIM routine according to standard procedures. The PASL
scan was  completed for a single 1 mm coronal slice positioned
over the cerebral territory of the middle cerebral artery (Sup-
plementary Fig. 1), with FOV = 22 mm × 22 mm,  in-plane pixel
size = 200 m × 200 m,  with fixed recovery time = 12 s, TE = 12.5
msec,  = 90◦, a set of eight inversion times (Xie et al., 2008) (30, 350,
700, 1050, 1400, 1750, 2100, and 2450 msec), and fat suppression.
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Fig. 1. Diagrammatic representation of communicational and anastomotic blood flow for CCA occlusion and CCA/ECA occlusive surgical procedures (image not to scale).
Green arrows (in colour image) indicate path of communicational blood flow. Blue arrows (in colour image) indicate path of anastomotic blood flow. Black arrows indicate
path  of net blood flow (combined communicational and anastomotic flow; * indicates blood flow within ICA). a. = artery. Continuation of the ECA includes facial, orbital, and
meningeal arteries. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Further imaging parameters are provided in the Supplementary
Information.
During MRI  procedures the temperature and respiration of the
animal was monitored using a Model 1030 Monitoring System
(Small Animal Instruments Inc, New York, USA) and animal tem-
perature was maintained using a heating blanket connected to a
recirculating water bath (ThermoFisher, Massachusetts, USA).
2.5.  Processing of FAIR-EPI data
Analysis and evaluation of the regional CBF was completed
within ParaVision 6.0.1 using the manufacturer provided macro
‘ASL Perfusion Processing’ that calculates perfusion based on the
T1 difference method according to (Herscovitch and Raichle, 1985;
Kober et al., 2004):
rCBF = 
(
T1nonsel
T1blood
)  (
1
T1sel
− 1
T1nonsel
)
where  is the blood partition coefficient assumed to be 0.89 mL  g−1
for mice (Leithner et al., 2010), T1nonsel and T1sel are the longitu-
dinal relaxation times of blood calculated from the images with
non-selective or slab-selective inversions, and T1blood = 2.4 s at a
magnetic field strength of 9.4 T (Dobre et al., 2007). The rCBF val-
ues  are expressed in mL  of blood per 100 g of tissue per minute,
and mean values and standard deviations for specific regions were
evaluated using manually defined regions-of-interest using T1-
weighted images as an anatomical guide (Supplementary Fig. 2).
2.6. Statistical analysis
Mean  percentage infarct volume measurement and data from
functional tests were evaluated by non-paired t-test. Values of
p < 0.05 were considered statistically significant. CBF data were
evaluated within groups using paired t-test. Value of p < 0.05 were
considered statistically significant. Additionally, functional assess-
ment and CBF data were evaluated between groups using a pairwise
comparison analysis of variance (ANOVA) followed by Bonferroni
post hoc analysis. Values of p < 0.05 were considered as signifi-
cant.
3. Results
3.1. Time-of-flight magnetic resonance angiography (TOF-MRA)
Time-of-flight magnetic resonance angiography was  performed
in animals 3–6 h following surgery for CCA occlusion, CCA/ECA
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Fig. 2. Maximum intensity projections of time-of-flight magnetic resonance angiography depicting arterial flow from caudal to rostral direction in sham, CCA occlusion, or
CCA/ECA  occlusion animals. Arrow represents the presence of the common carotid artery.
occlusion, or sham procedures (animals were not exposed to
hypoxia) to qualitatively visualise blood flow within vessels of
the neck and caudal brain. Representative images are presented in
Fig. 2. Despite the aforementioned significant differences between
the two surgical artery occlusion models, animals undergoing
CCA occlusion or CCA/ECA occlusion procedures demonstrated the
absence of a magnetic resonance signal in the right CCA; confirming
successful surgical occlusion of the CCA or CCA/ECA when com-
pared to the sham group.
3.2.  Phase-contrast velocity encoding
Phase-contrast velocity encoding was performed in animals
3–6 h following surgery for CCA occlusion, CCA/ECA occlusion, or
sham procedures (animals were not exposed to hypoxia) to quan-
titatively measure blood flow velocities (cm/sec) within the CCA,
ICA, and ECA. In sham animals, the flow of blood within the CCA
occurs in an anterograde direction (from caudal to rostral) and
continues into the ICA and ECA. In animals receiving either CCA
or CCA/ECA occlusion, cessation of anterograde flow should occur
due to artery occlusion. Data and representative images are pre-
sented in Fig. 3b and c . Despite the occlusion of the right CCA,
one animal that underwent the CCA occlusion procedure demon-
strated blood flow velocities within the right CCA (Fig. 3b and c),
and right ICA (Fig. 3b). In comparison, all animals that underwent
the CCA/ECA occlusion procedure reported no blood flow within
the CCA (Fig. 3c).
The  aforementioned animal within the CCA occlusion group
recorded a retrograde blood flow (−6.363 ± 2.54 cm/sec; Fig. 3b
and c) within the right CCA and anterograde blood flow
(4.543 ± 0 cm/sec; Fig. 3c) within the right ICA. Between CCA
occlusion, CCA/ECA occlusion, and sham animal groups, no sta-
tistical difference was observed in the distribution of blood flow
velocities within the non-occluded left CCA (19.87 ± 9.45 cm/sec,
22.8 ± 9.09 cm/sec, and 20.52 ± 9.49 cm/sec respectively; Fig. 3c).
Additionally, there was no significant difference between
right and left CCA velocities within the sham animal group
(Fig. 3c).
Variability in mean velocities in the left CCA (non-occluded) fol-
lowing CCA occlusion, CCA/ECA occlusion, and sham procedures,
whilst uniform across all groups, is likely to reflect the angle of
the  velocity encoding slice and/or depth of anaesthesia of the ani-
mals.
3.3. Pulsed arterial spin labelling (PASL)
Pulsed arterial spin labelling was  performed in animals 3–6 h
following surgery for CCA occlusion, CCA/ECA occlusion, or sham
procedures (animals were not exposed to hypoxia) to quantita-
tively measure the cerebral blood flow (CBF) (ml/100 g/min) within
a coronal slice at the level of the middle cerebral artery (determined
using TOF-MRA). Representative images and data are presented in
Fig. 4a and b. The occlusion of the right CCA or CCA/ECA resulted in
reduced CBF in the ipsilateral (right) hemisphere when compared
to the non-occluded (left) hemisphere (12.7 mL/100 g/min; p = 0.02
and 21.6 mL/100 g/min; p = 0.002, respectively; Fig. 4a and b).
The CCA/ECA occlusion demonstrated a significant reduction in
right hemispherical CBF when compared to the sham (p = 0.03).
Comparatively, the CCA occlusion did not demonstrate a signifi-
cant reduction in right hemispherical CBF when compared to the
sham. Additionally, there was  no significant difference in left CBF
between groups. When comparing total CBF (combined left and
right hemispheres) there is a trend that depicts a reduction in CBF
between surgical occlusion groups when compared to the sham
group (Fig. 4b).
3.4.  Infarct volume measurements after HIE
Data on infarct volume for animals undergoing CCA occlusion or
CCA/ECA occlusion combined with hypoxia are presented in Fig. 5a
and b. These results demonstrate that the CCA/ECA occlusion HIE
model, when compared to the CCA occlusion HIE model, results in
100% of animals presenting with an observable infarct (versus 87%),
a significantly larger infarct volume (18.5% versus 10.0%; p < 0.01)
and a reduced standard deviation (± 10% versus ± 15%).
Data on infarct volume for animals undergoing CCA or CCA/ECA
occlusion alone, and CCA/ECA occlusion plus hypoxia (2.5 h) are
presented in Fig. 6a and b. These results demonstrate that vessel
occlusion in combination with hypoxia (HIE) is required to gener-
ate an observable cerebral infarct. Animals with CCA/ECA occlusion
plus hypoxia produced a significant infarct volume compared with
animals undergoing CCA or CCA/ECA occlusion only (13.9% versus
0% and 0% respectively; p < 0.01).
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Fig. 3. Velocity analysis of blood through the pre- and post-bifurcated left and right CCA. (a) Grayscale time-of-flight angiography demonstrating coronal slice positioning
of  phase-contrast velocity encoding FLOWMAP sequence. Coronal slice positioning of CCA, ICA, and ECA mean vessel velocities (b) representative coronal section using 2D
phase-contrast velocity encoding of the CCA. (c) Individual blood velocities through the left and right CCA represented as mean ± SD. †  Denotes animal with observable
reversal of blood within the CCA. # Denotes animal with observable blood flow within the ICA. Black arrow indicates left CCA, white arrow indicates venous jugular flow,
and yellow arrow indicates left ICA. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 4. Cerebral blood flow (CBF) (mL/100 g/min) measured by PASL. Coronal CBF
maps obtained at the level of the middle cerebral artery (bregma 1.32). (a) Repre-
sentative  CBF maps in CCA occlusion, CCA/ECA occlusion, and sham animals. (b)
Individual CBF values of left and right hemispheres; CBF values are mean ± SD.
*p < 0.05 and ***p < 0.01.
3.5. Functional outcomes after HIE
Data on functional outcomes for animals undergoing CCA or
CCA/ECA occlusion combined with hypoxia are presented in Fig. 5c.
Animals undergoing the CCA or CCA/ECA occlusion HIE model
procedure displayed a significant level of reduced sensorimotor
function as assessed with the rope-hang test (p < 0.01 and p < 0.001
respectively; Fig. 5c) compared to sham animals. In addition,
animals subjected to the CCA or CCA/ECA occlusion HIE model
displayed reduced sensorimotor coordination in the negative geo-
tactic response, and increased reaction times for righting reflex
(p < 0.05 and p < 0.001, respectively; Fig. 5c) when compared to
sham. Animals subjected to the CCA/ECA occlusion HIE model dis-
played a significant increase in negative geotactic response time
(p < 0.05; Fig. 5c) when compared to sham. Conversely, animals sub-
jected to the CCA occlusion HIE model did not display a significant
increase in negative geotactic response when compared to sham
(Fig. 5c).
In  addition, functional parameters for animals undergoing CCA
or CCA/ECA occlusion alone, and CCA/ECA occlusion plus hypoxia
are presented in Fig. 6c. Animals undergoing CCA or CCA/ECA
occlusion only did not display any significant deviation in func-
tional outcomes compared to sham animals. In contrast, animals
subjected to CCA/ECA occlusion plus hypoxia displayed reduced
rope-hang times (p < 0.02; Fig. 6c) and trends for negative responses
in righting reflex and negative geotactic response when compared
to sham animals.
4. Discussion
The Rice-Vannucci HIE model, which is arguably the most com-
monly used pre-clinical model to replicate perinatal HIE, has long
been recognised as being affected by high variability with respect
to cerebral infarct volume, with infarcts often graded as absent,
mild, moderate, or severe (Ota et al., 1997; Okusa et al., 2014;
Cuccione et al., 2016; Liu et al., 2009; Noh et al., 2006). In the
present study, we have demonstrated that the permanent occlusion
of the CCA and ECA and exposure to hypoxia in P7 rats induces a
more reproducible and larger cerebral infarct compared to rats sub-
jected to CCA occlusion and hypoxia (i.e. the original Rice-Vannucci
model). In addition, histological outcomes in the CCA/ECA occlusion
and hypoxia HIE model corroborated functional outcomes. Further-
more, we  have confirmed that CCA occlusion or CCA/ECA occlusion
alone does not elicit an observable cerebral infarct.
While many explanations have been proposed to account for
the inconsistencies associated with the Rice-Vannucci procedure
(Table 1), we were able to confirm, using MRI  studies, that col-
lateral blood supply to the affected hemisphere is a significant
source of variability in the model. For example, using MRA phase-
contrast velocity encoding, retrograde blood flow within the CCA
and anterograde blood flow within the ICA were demonstrated to
exist following CCA occlusion in some cases. The source of ret-
rograde CCA and anterograde ICA flow is from collateral and/or
anastomotic flow from the ECA. In support of this, MRI  studies
using the CCA/ECA occlusion procedure demonstrated a more reli-
able disruption in cerebral haemodynamics, through the absence
of blood flow within the right CCA, ECA, and ICA.
To date, the collateral and/or anastomotic blood flow within
the immature rodent has not been robustly characterised. There
are significant similarities between human and murine extracra-
nial and cerebral vessel anatomy (Cuccione et al., 2016; Yamasaki,
1990), which are used to determine the source of collateral and/or
anastomotic blood flow within the Rice-Vannucci model (Fig. 1).
Specifically, following CCA occlusion, the patency of the ipsilat-
eral hemisphere can be maintained through extracranial collateral
vessels, supplying blood flow into the ECA in a retrograde man-
ner, maintaining the anterograde flow within the ICA (Nikanfar
et al., 2004; Kaspera et al., 2005; Bajkó et al., 2013). In humans,
extracranial collateral blood flow originates from the ipsilateral
thyrocervical trunk (via subclavian artery), vertebral artery, occip-
ital artery, from the contralateral ECA (via facial occipital, and
maxilla branches), and from occipital artery anastomosis to the ver-
tebral artery (Bajkó et al., 2013; Tsai et al., 2005; Parthenis et al.,
2008; Levine and Welch, 1989; Alexander et al., 2014; Suwanwela
and Suwanwela, 1998). The commonly demonstrated collateral
flow supplied by the leptomeningeal artery is not observed in the
rat (Coyle and Jokelainen, 1982). In various animal models, the pres-
ence of collateral blood flow preserving the patency of the ICA has
been reported. For example, in swine, occlusion of the CCA and ECA
depletes anterograde blood flow within the ICA (Bates et al., 2003).
Additionally, the presence of collateral blood supply preserving the
patency of the ICA in P7 rodents has been reported following mid-
dle cerebral artery occlusion (Bonnin et al., 2011) and CCA occlusion
(Choy et al., 2006).
With  regards to the surgical approach taken in this study, the
findings indicate that the occlusion of the ICA alone would have
similar effects to occlusion of the CCA and ECA. Notwithstanding,
the ICA is anatomically placed under the sternocleidomastoid mus-
cle, which would require the muscle to be manipulated surgically
to gain access to the ICA. Such surgical manipulation would predis-
pose the sternocleidomastoid muscle to injury, potentially affecting
the performance of the animal in motor functional tests and the
ability to feed. Therefore, in our studies, occlusion of the CCA and
ECA was chosen over occlusion of the ICA alone, which reduces
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Fig. 5. Infarct volume analysis, representative images of coronal brain slices, and behavioural assessment 48 h after hypoxic-ischaemic insult. (a) Infarct volume analysis,
represented as a percentage (%) infarct volume in relation to whole brain volume as determined 48 h after hypoxic-ischaemic insult. Values are mean ± SD. (b) Representative
images of TTC stained coronal brain slices. (c) Functional assessments using rope-hang, righting reflex, and negative geotactic response tests 48 h after hypoxic-ischaemic
insult. All animals received a combination of surgical occlusion and hypoxia. Rope-hang, time (sec = s) for animal to hold onto a rope. Righting reflex, Time (sec) for animal to
rotate  from supine to prone position. Negative geotactic response, time (sec) for animal to rotate 150◦ up a 45◦ slope. †  Denotes animal that was assigned the largest infarct
due to hemisphere liquefaction, which did not permit coronal brain slicing and infarct volume analysis. Time values are mean ± SD. *p < 0.05, **p < 0.02, and ***p < 0.01.
surgical time while depleting the anterograde or retrograde flow
within the ICA.
To  our knowledge, this is the first report that defines CBF using
PASL following extracranial vessel occlusion in immature rats. The
use of PASL is a non-invasive technique for the assessment of CBF
in various rat stroke models (Baskerville et al., 2012). In line with
previous studies (Buckley et al., 2015), using PASL we  demonstrated
that there is a bilateral reduction in CBF following CCA or CCA/ECA
occlusion compared to sham surgical animals. Additionally, CCA or
CCA/ECA occlusion results in a significant reduction in blood flow
in the affected right hemisphere when compared to the unaffected
left hemisphere. Furthermore, the CCA/ECA occlusion procedure
resulted in a statistically significant (p = 0.03) reduction in CBF in
the affected hemisphere when compared to the CBF of the sham.
The  primary aim of this study was to confirm the superior-
ity of the CCA/ECA occlusion HIE model through the mitigation
of ICA patency, which was conclusively demonstrated by a sig-
nificant reduction of CBF in the ipsilateral hemisphere. Despite
the significant reduction in CBF of the CCA/ECA occlusion proce-
dure, establishment of an ischaemic infarct lesion is unlikely, as
CBF must fall below 18 mL/100 g/min to elicit ischaemia (Bouma
and Muizelaar, 1995). In agreement with this, and in line with a
previous study (Buckley et al., 2015), we have demonstrated that
CCA/ECA occlusion in combination with hypoxia is required to elicit
a cerebral infarct.
A  limitation of this study is anaesthetisation using isoflu-
rane, which can reduce mean arterial pressure and heart rate
below  conscious baselines at concentrations greater than 1.5%
(Constantinides et al., 2011). With this in mind, animals assigned
to PASL groups were not exposed to concentrations of isoflurane
above 1.5%. Furthermore, mean arterial pressure is known to be
independent of changes in CBF in sham animals (Manole et al.,
2009). In addition, whilst the 48-h endpoint used in the present
study is commonly used in neuroprotective, neuroregenerative and
pathophysiological investigations, we  acknowledge that additional
characterization of the CCA/ECA occlusion HIE model at extended
end points is required if the model is to be used for long-term
studies.
5. Conclusion
The modification to the Rice-Vannucci surgical procedure
through the ligation of the CCA and ECA is shown to improve model
reproducibility in terms of mitigation of cerebral and communi-
cational blood flow and improving reliability in infarct presence,
infarct size, and behavioural outcomes.
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Supplementary Table 1. All RF pulses were automatically calculated within ParaVision 6.0.1 based on the Shinnar-Le Roux (SLR) algorithm. 
Sequence Orientation NA TR 
(ms) 
TE 
(ms) 
Flip () ESP 
(ms) 
RARE 
factor 
BW (Hz) FOV 
(mm  mm) 
MTXacq 
(R  PE) 
PF MTXreco
(R  PE) 
PIX 
( m  m) 
NS THK 
( m) 
Gap 
( m) 
Time 
(ms) 
2D FLASH tri-plane 2 60 3.0 30 - - 75000 50  50 250  167 0.67 PE 250  250 200  200 5 1000 1000 0:20 
2D MSME sagittal 1 2400 12, 60 90 8 - 75000 36  27 240  112 0.62 PE 240  180 150  150 20 700 50 4:28 
3D TOF 
FLASH 
coronal* 1 12 2 20 - - 89285.7 24  22 x 18 208  206  133 0.69 R 300  276  120 80  80  150 - - - 5:29 
2D 
FLOWMAP 
coronal* 12 100 4 20 - - 59523.8 20  20 188  250 0.75 R 250  250 80  80 10 700 250 10:00 
2D FAIR-SE-
EPI 
coronal* 1 12000 12.5 90 - - 340909.1 22  22 110  69 0.63 PE 110  110 200  200 1 1000 - 3:32 
2D RARE coronal* 4 3900 36 90 12 8 59523.8 24  20 320  176 0.66 PE 320  266 75  75 34 500 20 5:43 
2D RARE sagittal 4 3900 36 90 12 8 59523.8 24  20 320  176 0.66 PE 320  266 75  75 27 500 20 5:43 
2D RARE axial* 4 3900 36 90 12 8 59523.8 24  20 320  176 0.66 PE 320  266 75  75 20 500 20 5:43 
*relative to rat brain anatomy, NA = number of averages, TR = repeat time, TE = echo time, ESP = echo spacing, ETL = RARE echo train
length, BW = receiver bandwidth, FOV = field-of-view, MTXacq = image acquisition matrix size, PF = partial Fourier acquisition in phase-
encode (PE) or read (R) direction, MTXreco = image reconstruction matrix size, PIX = in-plane pixel size, NS = number of slices, THK = slice
thickness, Gap = inter-slice gap.
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Supplementary Figure 1. Grayscale 2D, T2-weighted RARE slices in the (a) sagittal 
and (b) coronal plane demonstrating the 1 mm ASL slice positioning in Figure 4 (red 
bar; to scale). White bar = 1 cm. 
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Supplementary Figure 2. Grayscale T1-weighted slice in the coronal plane. Region 
of interest (ROI) indicated for ASL values represented in Figure 3. 
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Poly-arginine R18 and R18D (D-enantiomer)
peptides reduce infarct volume and
improves behavioural outcomes following
perinatal hypoxic-ischaemic
encephalopathy in the P7 rat
Adam B. Edwards1,2,3, Jane L. Cross1,3,4, Ryan S. Anderton1,2,4, Neville W. Knuckey1,3,4 and Bruno P. Meloni1,3,4*
Abstract
We examined the neuroprotective efficacy of the poly-arginine peptide R18 and its D-enantiomer R18D in a
perinatal hypoxic-ischaemic (HI) model in P7 Sprague-Dawley rats. R18 and R18D peptides were administered
intraperitoneally at doses of 30, 100, 300 or 1000 nmol/kg immediately after HI (8% O2/92%N2 for 2.5 h). The
previously characterised neuroprotective JNKI-1-TATD peptide at a dose of 1000 nmol/kg was used as a control. Infarct
volume and behavioural outcomes were measured 48 h after HI. For the R18 and R18D doses examined, total infarct
volume was reduced by 25.93% to 43.80% (P = 0.038 to < 0.001). By comparison, the JNKI-1-TATD reduced lesion volume
by 25.27% (P = 0.073). Moreover, R18 and R18D treatment resulted in significant improvements in behavioural outcomes,
while with JNKI-1-TATD there was a trend towards improvement. As an insight into the likely mechanism underlying the
effects of R18, R18D and JNKI-1-TATD, the peptides were added to cortical neuronal cultures exposed to glutamic acid
excitotoxicity, resulting in up to 89, 100 and 71% neuroprotection, respectively, and a dose dependent
inhibition of neuronal calcium influx. The study further confirms the neuroprotective properties of poly-
arginine peptides, and suggests a potential therapeutic role for R18 and R18D in the treatment of HIE.
Keywords: Hypoxic-ischaemic encephalopathy, Hypoxia-ischaemia, Neuroprotection, Poly-arginine peptides,
R18, Cationic arginine-rich peptides (CARPs)
Introduction
In the human neonate, hypoxic-ischaemic encephalop-
athy (HIE) remains the leading cause of neonatal mortal-
ity and morbidity, with a reported incidence of 1–3 per
1000 live term births [1], [2]. Neurological sequelae asso-
ciated with HIE include cerebral palsy, epilepsy, mental
retardation and learning disabilities [3]. Clinically, treat-
ment to reduce brain injury for HIE is extremely limited,
consisting of moderate hypothermia (32–34 °C), main-
tained for up to 72 h. While hypothermia appears to be
well tolerated, its safety has only been assessed in full-
term infants (37–40 weeks gestation), hence no
treatments are available for preterm neonates with HIE
born before 37 weeks gestation. In addition, while
hypothermia has been shown to improve outcomes in
clinical trials, 31–55% of infants do not benefit from the
therapy and suffer severe neurological sequelae [4]. Fur-
thermore, hypothermia can only be used in hospital set-
tings that have the necessary equipment and trained
staff to induce and monitor hypothermia following HIE,
and thus is not available in non-tertiary hospitals or hos-
pitals located in remote locations and in many develop-
ing countries.
Due to the need for additional neuroprotective strat-
egies for HIE, research has focused on the development
of a pharmacological neuroprotective agent that can be
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administered alone and/or in combination with current
hypothermia treatment to improve neonatal outcomes in
HIE. An added advantage of a pharmacological neuro-
protective agent is the possibility it can be used in re-
mote locations, is effective in preterm infants, and/or
can improve neuroprotective outcomes for hypothermia.
We and others have recently demonstrated that cationic
arginine-rich and poly-arginine peptides (hereafter re-
ferred to as CARPs) have potent neuroprotective proper-
ties in in vitro excitotoxicity neuronal injury models [5–
13], as well as in animal stroke models [10, 11, 14–16].
In particular, we have demonstrated that the poly-
arginine peptide, R18, is highly neuroprotective in per-
manent and transient middle cerebral artery occlusion
(MCAO) stroke models [11, 14–16].
While the exact mechanisms of the neuroprotective ef-
fects are still being explored, we and others have demon-
strated that CARPs, including “putative” neuroprotective
peptides fused to cationic arginine-rich cell penetrating
peptides (i.e. TAT or R9; e.g. JNKI-1-TATD, TAT-
NR2B9c/NA-1, TAT-CBD3/R9-CBD3-A6K and TAT-
3.2-III-IV) have the ability to mitigate excitotoxic or po-
tassium evoked neuronal intracellular calcium influx [7,
8, 17–19], and in doing so, likely suppress damaging
down-stream signaling and cell death pathways. Beyond
this, we have demonstrated that the poly-arginine R12
and TAT-NR2B9c/NA-1 peptides reduce neuronal cell
surface expression of the glutamate receptor subunit
NR2B [20]. The ability of CARPs to reduce neuronal cell
surface levels of NR2B (due to internalization during
endocytic uptake) is at least one mechanism whereby
the peptides reduce the damaging effects of glutamate-
induced calcium influx and excitotoxicity. Additionally,
other “putative” neuroprotective peptides bound to TAT
or R9 have been shown to reduce neuronal surface ex-
pression or activity of NMDA receptors [5, 21–23], as
well as voltage gated calcium channels CaV2.2 [21, 24,
25] and CaV3.3 [18], and the sodium calcium exchanger
3 (NCX3) [21]. Given their effects on different receptors,
presently, it cannot be ruled out that CARPs, due to
their cationic charge, are also antagonizing ion channel
receptor function directly and/or affecting calcium ion
influx via an electrostatic mechanism [7, 9].
In addition to CARPs reducing the effects of excito-
toxicity, based on other properties of this class of pep-
tide, they may exert more pleiotropic neuroprotective
effects by targeting mitochondria and maintaining mito-
chondrial integrity [6, 26–32], thereby reducing reactive
oxygen species (ROS) production and release of pro-cell
death proteins such as cytochrome-c. Furthermore,
CARPs have the capacity to inhibit proteolytic enzymes
including the proteasome [33, 34], as well as proprotein
convertases [35–37] that activate matrix metalloprotein-
ases (MMPs) [38]. Inhibition of the proteasome is
known to be beneficial following cerebral ischaemia [39,
40], a mechanism that could be mediated by increased
activity of hypoxia-inducible factor 1-α (HIF1α) and de-
creased activity of nuclear factor κ-light-chain-enhancer
of B cells (NFκB). Similarly, due to the damaging effects
of MMPs on the neurovascular unit and blood brain bar-
rier, any down-regulation of their proteolytic activity is
likely to be beneficial following brain HI. In addition,
there is also evidence that CARPs can activate pro-
survival signaling pathways [17, 41] and modulate im-
mune responses [42–44], as well as act as anti-oxidant
molecules in their own right due to their guanidino
group containing arginine residues [32, 45–49].
Since HIE and stroke are thought to share many
pathophysiological processes (e.g. excitotoxicity and oxi-
dative stress) it is likely that R18 will also be effective in
reducing HI brain injury. To this end, several CARPs, in-
cluding “putative” neuroprotective peptides fused to
TAT such as JNKI-1-TATD [50], P5-TAT [51], TAT-
NDB [52], TAT-mGluR1 [53], TAT-NR2B9c/NA-1 [53],
IDR-1018 [54], and COG133 [55], have demonstrated ef-
ficacy in perinatal HI models. Importantly, CARPs like
the TAT peptide also have cell penetrating properties
and can cross the blood brain barrier and enter the brain
[56–58].
Therefore, given the demonstrated efficacy of the R18
poly-arginine peptide in a number of experimental
stroke studies [11, 14–16], the present study examined
the neuroprotective efficacy and dose responsiveness of
R18, as well as its D-amino acid enantiomer (R18D) in a
perinatal HI model in the P7 Sprague-Dawley rat, and
their effects on neuronal calcium influx in an in vitro
glutamic acid excitotoxicity model. In addition, as a con-
trol, the study also examined the effects of the cationic
arginine-rich JNKI-1-TATD peptide, which has previ-
ously been shown to be neuroprotective in various ro-
dent brain injury models, including perinatal HI [50, 59].
Methods
Animal ethics and study design
All experimental procedures in this study adhered to the
guidelines approved and specified by the Animal Ethics
Committee of the University of Western Australia (RA/
3/100/1329), in accordance with the Policies and Guide-
lines of the National Health and Medical Research
Council, Australia. Treatments were randomised and all
procedures (e.g. peptide administration, behavioural test-
ing and infarct volume analysis) were performed while
being blinded to treatments.
Peptides used in the study
Peptides used in the study are shown in Table 1. R18,
R18D and JNKI-1-TATD used were synthesised by
Mimotopes (Melbourne, Australia). Peptides were purified
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using high performance liquid chromatography to at least
98% purity, and were subject to peptide hydrolysis and
amino acid liquid chromatography analysis to obtain a
precise measure of peptide content.
For the in vitro and animal studies, peptides were pre-
pared as a 500 μM stock solution in water for irrigation
(Baxter, Australia), and in 0.9% sodium chloride for in-
jection (Pfizer, Australia), respectively. Reconstituted
peptides were stored at − 20 °C until use.
Surgical procedure for modified Rice-Vannucci model
We used a modified Rice-Vannucci HI model. This in-
volved occluding the right common, as well as the right
external carotid artery, a procedure that we have previ-
ously demonstrated to lead to the generation of a highly
reliable infarct [60]. Briefly, unsexed, Sprague-Dawley P7
rat pups (Animal Resource Centre, Murdoch, Australia;
P0 = day of birth) with a body weight of 13–16 g were
used. Litters were culled to a maximum of 12 pups per
litter to facilitate uniform growth without littermate
competition. Rat pups were anaesthetised using isoflur-
ane (5% induction, 1–2% maintenance) in 100% oxygen,
while on a heating pad (37 °C). Through a 1 cm mid-line
ventral incision, the right common, internal and external
carotid arteries were exposed and isolated from the
vagus nerve, venous circulation and carotid body. The
right common carotid and external carotid arteries were
permanently ligated using 6–0 silk sutures. The wound
was closed using Vetbond (3M, Maplewood, USA) and
the animals were recovered on 100% oxygen for 5 min
on a heating pad. The duration of anaesthesia from in-
duction to beginning of recovery was between 5 and
8 min. Animals were provided with analgaesia (pethid-
ine, 5 mg/kg; intraperitoneally) immediately before ces-
sation of anaesthesia. Sham-operated animals underwent
the same operative procedure, except the exposed ca-
rotid arteries were not ligated.
Rat pups were returned to their dam for 1 h before the
commencement of hypoxia which consisted of placing 4
to 6 pups in an airtight container (approximate volume:
4 L) and exposing them to humidified and warmed hyp-
oxic gas (8% O2/92% N2; 3 L/min) for 2.5 h. The con-
tainer was placed inside an incubator with an ambient
air temperature of 35 °C, ensuring a body temperature
of 36–37 °C, which was periodically monitored using an
infrared thermometer. Following hypoxia, animals were
placed on a heating pad for 5 min in a normoxic envir-
onment before being placed back with the dam. Sham-
operated animals remained with the dam at all times.
Peptide administration
Immediately after hypoxia, treatments were administered
intraperitoneally (50 μl bolus) and consisted of either the
vehicle (saline; 0.9% sodium chloride), or R18 or R18D
at four different doses (30, 100, 300 or 1000 nmol/kg) or
JNKI-1-TATD at a single dose (1000 nmol/kg).
Animals used and sample size
One hundred and thirty-three Sprague-Dawley P7 pups
housed under controlled conditions on a 12-h light-dark
cycle underwent surgery for HI or the sham procedure
(i.e. anesthesia, neck incision, wound closure and anal-
gesia). Twenty-seven animals were excluded from the
study; a list of animal exclusions is provided in Table 2.
The saline treatment group consisted of 19 animals and
the sham group 6 animals. All other treatment groups
consisted of between 7 and 11 animals (see Fig. 1a and
Table 3). Additional vehicle treated animals were in-
cluded in the study to ensure that each batch of animals
subjected to HI contained a vehicle control and to in-
crease the statistical power of the study.
Infarct volume assessment
Forty-eight hours after HI, animals were euthanised by
pentobarbital overdose (50 mg/kg; intraperitoneally). In-
farct volume was determined by preparing 2 mm thick
coronal brain slices, and incubating in 3% 2,3,5-triphe-
nyltetrazolium chloride (TTC; Sigma Aldrich, St. Louis,
USA) at 37 °C for 20 min, followed by fixation in 4% for-
malin at room temperature overnight. Digital images of
coronal slices were acquired using a colour scanner and
analysed, using ImageJ software (3rd edition, NIH, Be-
thesda, USA). Total infarct volume was determined by
measuring areas of infarcted tissue on both sides of the
2 mm slices. Infarct volume measurements were cor-
rected for a degree of hemisphere volume changes [60].
Final infarct data is expressed as percentage infarct vol-
ume compared to whole brain (minus cerebellum). For
analysis of infarct volumes in male and female animals,
Table 1 Peptides used in study
Peptide Sequencea Arginine/AA residues % Arginine
residues
Net charge
R18 H-RRRRRRRRRRRRRRRRRR-OH 18/18 100 + 18
R18D H-rrrrrrrrrrrrrrrrrr-OH 18/18 100 + 18
JNKD H-tdqsrpvqpflnlttprkprpp-rrrqrrkkrg-NH2 9/32 28 + 12
aAt the N-terminus, H indicates free amine. At the C-terminus, OH indicates free acid, and NH2 indicates amide. AA = amino acids. Lowercase single letter code
indicates D-isoform of the amino acid. JNKD = JNKI-1-TATD
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due to low numbers of each gender per group, data for
the different doses of R18 and R18D were combined.
Behavioural assessment
To determine if the development of cerebral infarct was
associated with reduced sensorimotor outcomes, three
neurological tests (righting reflex, negative geotactic re-
sponse and wire-hang) were performed at 48 h after HI,
as previously reported [60]. Briefly, for three consecutive
days before surgery (P4 to P6 inclusive), pups were ac-
customed to behavioural assessments with a target inclu-
sion range of ≤2 s for the righting reflex and ≤30 s for
the negative geotactic response. Any animal that did not
record responses within these parameters at P7 (day of
surgery) were excluded from the experiment. All of these
reflexes are highly reproducible throughout the murine
pre-weaning period (< P30) and are strain- and gender-
independent [61]. Each animal was given three attempts
to complete each sensorimotor task, with 5 min between
each attempt. Testing of all reflexes was performed on a
board covered with a tightly-stretched close knit-fabric,
to ensure adequate friction.
The righting reflex involved placing pups in a supine
position, and measuring the time required to rotate to
the prone position. The negative geotactic response in-
volved placing pups facing down-slope, on a 45° angled
surface, and measuring the time required for the animal
to turn 150° upslope. Wire-hang test was performed by
suspending pups by their forelimbs on a 2 mm diameter
steel wire suspended 20 cm above a foam surface, and
recording the time taken for the animal to fall to the
foam surface.
Cortical neuronal cultures
Establishment of rat primary cortical neuronal cultures
was performed as previously described [8, 10]. Briefly,
cortical tissue was obtained directly from E18-day old
embryos. Dissociated neurons were seeded into 96-well-
sized glass wells (7 mm diameter, Grace, Melbourne,
Australia), 96-well plastic plates (Nunc, Thermo Fisher
Scientific, Melbourne, Australia) in Neurobasal/2% B27
supplement (Life Technologies, Melbourne, Australia)
and maintained in a CO2 incubator (5% CO2, 95% air
balance, 98% humidity) at 37 °C until use on day in vitro
10 to 14. Under these conditions, cultures routinely con-
sist of > 97% neurons and 1–3% astrocytes.
Glutamic acid excitotoxicity
A dose response experiment was performed as previ-
ously described [8]. Briefly, peptides in a 50 μl volume in
Minimum Essential Medium (Life Technologies)/2% B27
supplement (MEM/B27) were added to culture wells for
10 min at 37 °C in the CO2 incubator before the
addition of 50 μl MEM/B27 containing glutamic acid (L-
glutamic acid; Sigma-Aldrich: 200 μM; final concentra-
tion 100 μM). Following a 5 min incubation at 37 °C in
the CO2 incubator (note: peptide concentration reduced
by half during this step), media was replaced with
100 μL MEM/B27 and cultures wells were incubated for
a further 24 h at 37 °C in the CO2 incubator. Untreated
controls with or without glutamic acid treatment under-
went the same incubation steps and media additions.
At different times after treatment (e.g. 0.5 to 4 h and
18–24 h), cultures were examined by light microscopy
for qualitative assessment of neuronal cell viability.
Neuronal viability was quantitatively measured by MTS
Table 2 Animals excluded in the study
Exclusion rationale Number of exclusions Peptide Dose Total number of exclusions
No detectable infarct 3 Saline – 15
1 R18 300
3 R18 100
2 R18 300
1 R18 1000
2 R18D 30
1 R18D 300
1 R18D 1000
1 JNKD 1000
Hyperthermiaa 1 R18 1000 1
Failure to complete behavioural
assessment
3 – – 3
Surgical haemorrhageb 5 – – 5
Premature deathc 3 – – 3
All peptide doses are in nmol/kg. aHyperthermia is a recorded body temperature > 37.5. bSurgical haemorrhage is defined as any animal which had an abnormal
bleed (arterial rupture) during the surgical parameter. cPremature deaths occurred during hypoxia. JNKD = JNKI-1-TATD
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(3-(4,5,dimethyliazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H–tetrazolium salt) assay
(Promega, Sydney, Australia). The MTS absorbance data
were converted to reflect proportional cell viability rela-
tive to both the untreated (no insult; 100% viability) and
treated (glutamic acid; 5% viability) controls. At least
four wells were used in assays, repeated a minimum of
three to four times independently.
Intracellular calcium kinetics
Intracellular calcium influx was monitored as previously
described [8]. Briefly, primary cortical neuronal cultures
a
b
c
Fig. 1 Percentage infarct volume; percentage infarct volume, representative images of coronal brain slices and percentage infarct volume in brain slices
for the different treatment groups as determined 48 h after HI. Treatments were administered intraperitoneally (saline or R18, R18D and JNKI-1-TATD;
doses in nmol/kg) immediately after hypoxia. a Percentage of infarct volume when compared to total brain volume. b Representative TTC coronal brain
slice 2, from saline and peptide treated animals. Minor adjustments to brightness and contrast has been made to improve digital images. c Infarct volume
analysis in 2 mm coronal brain slices (slices numbered 1–6 from rostral to caudal) from saline and peptide treated animals. Statistical significance is
expressed in the table. Values are mean ± SE; *P< 0.05, **P< 0.01 when compared to saline. JNKD = JNKI-1-TATD
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were loaded with the fluorescent calcium ion indicator
Fura-2 AM (5 μM; Sigma Aldrich) in 50 μL MEM/B27,
0.1% pluronic F-127 (Sigma Aldrich), for 20 min at 37 °
C in the CO2 incubator. Fura-2 AM solution was re-
moved from wells, replaced with 50 μL MEM/B27 con-
taining peptides (R18 and R18D; 0.2, 2 and 5 μM) or
NMDA and AMPA receptor blockers (MK801/CNQX;
5 μM/5 μM; Tocris Bioscience, Bristol, United Kingdom)
and incubated for 10 min at 37 °C in the CO2 incubator.
Control cultures received 50 μL of MEM/B27 only. After
the 10 min incubation period, media in wells was re-
placed with 50 μL of balanced salt solution (BSS: mM:
116 NaCl, 5.4 KCl, 1.8 CaCl2, 0.8 MgSO4, 1 NaH2PO4;
pH 7.2) and wells transferred to a spectrophotometer
(BMG Labtec, CLARIOstar, Mornington, Australia)
while maintaining temperature at 37 °C. Fifty microliters
of BSS containing glutamic acid (200 μM; 100 μM final
concentration) was added to wells, and every 5 s, start-
ing 30 s before and for 90 s after glutamic acid addition,
spectrophotometer measurements (excitation: 355 nm/
emission 495 nm) were recorded. Experiments were per-
formed in triplicate. Area under the curve (AUC) for cal-
cium kinetics data was calculated by trapezoidal
approximation of the AUC using fluorescent kinetic data
obtained after the addition of glutamic acid to wells.
Statistical analysis
The number of animals used in each experiment was
justified by statistical power calculation based on a pre-
vious study [60]. Group sizes have been calculated based
on a predicted treatment effect of 40%, at a power level
of 80–90% and an alpha level of 0.05. Mean percentage
infarct volume, behavioural measurements weight gain
and neuronal viability data were analysed by analysis of
variance (ANOVA), followed by post-hoc Fisher’s PLSD
test, with P < 0.05 values considered statistically signifi-
cant. All descriptive statistics are presented in Table 3
and Additional file 1: Table S1, Additional file 2: Table
S2 and Additional file 3: Table S3.
Results
Infarct volume measurements
Data on infarct volume and representative TTC stained
coronal brain slices are presented in Fig. 1a and b. When
compared to the saline vehicle control (hereafter re-
ferred to as saline), both R18 and R18D significantly re-
duced infarct volume at all doses examined (30, 100, 300
and 1000 nmol/kg) by between 25.27 and 43.80% (P =
0.045 and < 0.001, respectively; refer to Table 3 for de-
scriptive statistics). By comparison, the JNKI-1-TATD
peptide (1000 nmol/kg) reduced infarct volume by
25.27% (P = 0.073). No single R18, R18D or JNKI-1-
TATD dose was significantly more effective than any
other dose. To assess infarct development within 2 mm
coronal slices, rostral to caudal topographic analysis of
infarcts revealed that R18, R18D and JNKI-1-TATD at
all doses significantly reduced brain injury in one or
more coronal slices 1 to 6 (Fig. 1c; refer to Additional
file 1: Table S1 for descriptive statistics).
Behavioural outcomes, weight gain and gender analysis
Data on behavioural outcomes and weight gain is pre-
sented in Fig. 2a–h and descriptive statistics presented
in Additional file 2: Table S2. All data is transformed to
demonstrate the percentage improvement from baseline
for each treatment group, 48 h following HI. The sham
procedure is taken as equivalent to 100% improvement
and saline control to 0% improvement. The results of
the righting reflex test demonstrated that R18 (30 and
1000 nmol/kg) and R18D (300 and 1000 nmol/kg) sig-
nificantly improved the righting reflex time by between
53.95% and 79.88% (P = 0.008 and 0.007), respectively,
when compared to saline. In comparison, animals
treated with JNKI-1-TATD (1000 nmol/kg) showed no
Table 3 Cerebral infarct. Percentage of total cerebral volume
Treatment Dose N Mean of total infarct volume (%) SE
(%)
Reduction in total infarct volume (%) P
Saline – 19 18.24 1.393 – –
JNKD 1000 7 13.63 2.843 25.27 0.073
R18 30 10 11.34 1.401 37.82 0.002
100 10 11.93 1.924 34.59 0.004
300 8 11.78 1.921 35.42 0.007
1000 11 10.25 2.082 43.80 < 0.001
R18D 30 9 13.51 2.058 25.93 0.038
100 9 10.33 0.874 43.36 < 0.001
300 9 12.07 1.540 33.82 0.007
1000 8 11.83 0.957 35.14 0.007
N number of animals, SE standard error of mean, P calculated compared to saline vehicle control. All doses are in nmol/kg. Mean and SE expressed as percentage
of total cerebral volume. JNKD = JNKI-1-TATD. Percentage reduction is mean percentage reduction compared to saline. All values P < 0.05 are in bold
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statistically significant improvement, although there was
a trend towards improvement (43.87%; P = 0.063).
Analysis of the negative geotactic response test re-
vealed that R18 (1000 nmol/kg) and R18D (100 and
1000 nmol/kg) significantly improved the time taken for
animals to rotate 150° up the 45° slope when compared
to saline by between 54.44% and 69.17% (P = 0.049 and
0.036), respectively. All other doses improved the
a b
c d
e f
g h
Fig. 2 Behavioural measurements using righting reflex, negative geotactic response, wire-hang test and weight gain 48 h after HI. Treatments were ad-
ministered intraperitoneally (saline, R18, R18D or JNKI-1-TATD; doses in nmol/kg). The sham procedure group was assessed 48 h following sham-surgery.
a R18 righting reflex percentage improvement from 0 to 48 h. b R18D righting reflex percentage improvement from 0 to 48 h. c R18 negative geotactic
response percentage improvement from 0 to 48 h. d R18D negative geotactic response percentage improvement from 0 to 48 h. e R18 wire-hang per-
centage improvement from 0 to 48 h. f R18D wire-hang percentage improvement from 0 to 48 h. g R18 weight percentage improvement from 0 to
48 h. h R18D weight percentage improvement from 0 to 48 h. Values are mean ± SE. *P < 0.05 when compared to saline. JNKD = JNKI-1-TATD
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negative geotactic response time by between 10.40% and
59.87% (P = 0.738 and 0.057), respectively. In compari-
son, JNKI-1-TATD (1000 nmol/kg) resulted in no statis-
tically significant improvement, although there was a
trend towards improvement (42.18%; P = 0.187).
For the wire-hang test, only R18 at a dose of
1000 nmol/kg resulted in a statistically significant im-
provement in the time animals held onto the wire, in-
creasing hang-time by 64.29% (P = 0.033) when
compared to saline. All other doses improved the wire
hang time by between 0.59% and 37.26% (P = 0.997 and
0.227), respectively. By comparison, JNKI-1-TATD
(1000 nmol/kg) resulted in no statistically significant im-
provement in the wire-hang time (30.93%; P = 0.374).
Analysis of weight gain over 48 h revealed that R18
at a dose of 1000 nmol/kg was the only treatment to
significantly improve weight gain (44.59%; P = 0.009)
when compared to saline (see Additional file 3: Table
S3 for descriptive statistics), while all other doses of
R18 and R18D demonstrated an increase in weight by
between 16.83% and 34.49% (P = 0.327 and 0.065), re-
spectively. In comparison, JNKI-1-TATD (1000 nmol/
kg) treated animals demonstrated a gain in weight
(1.94%; P = 0.935). The only dose to demonstrate a
loss of weight was R18D at 1000 nmol/kg (−10.01%;
P = 0.659).
Analysis of R18 and R18D neuroprotective efficacy in
male and female animals revealed a significant reduction
in total infarct volume in both sexes when compared to
male and female saline treated animals (Additional file 4:
Figure S1; note: for analysis the different doses of R18
and R18D were combined). While intra-group compari-
sons demonstrated no significant differences in total in-
farct volumes between male and female animals treated
with R18, R18D or saline; there was a trend towards re-
duced infarcts in female animals treated with R18 and
R18D (Additional file 4: Figure S1).
In vitro neuroprotective efficacy and calcium kinetics
following glutamic acid excitotoxicity
To provide an insight into the potential mechanism
of action of R18 and R18D, in vitro neuroprotective
efficacy and excitotoxic neuronal calcium influx kinet-
ics were assessed. In line with previous findings from
our laboratory R18 and JNKI-1-TATD [7, 10, 11], as
well as R18D displayed dose-dependent neuroprotec-
tion following excitotoxicity (Fig. 3). For example,
R18 and R18D increased neuronal survival from 5%
for the glutamic acid control to 89% and 83% and
96% and 100% at 1 μM and 2 μM, respectively (Fig.
3). By comparison, JNKI-1-TATD increased neuronal
survival to 23 and 71% at 1 μM and 2 μM, respect-
ively. As we have previously observed, higher peptide
concentrations (i.e. 5 μM) can have a negative impact
on neuronal survival [8], this was particularly evident
for R18D, a fact which most likely reflects the higher
stability of D-isoform peptides in the closed neuronal
culture system [9].
Again, in line with our previous findings, R18 and
JNKI-1-TATD [7, 10, 11], as well as R18D, reduced glu-
tamic acid induced neuronal intracellular calcium influx
in a dose dependent manner (Fig. 4). In addition, the
calcium influx data for R18, R18D and JNKI-1-TATD
correlated with their neuroprotective effectiveness fol-
lowing glutamic acid excitotoxicity, with JNKI-1-TATD
displaying the least neuronal intracellular calcium influx
inhibitory effects.
Fig. 3 Glutamic acid excitotoxicity model; R18, R18D and JNKI-1-TATD dose response study. Peptides present in neuronal cultures 10 min before
and during 5 min glutamic acid exposure. Neuronal viability measured 24 h after glutamic acid exposure. Concentration of peptide in μmol/L.
MTS data were expressed as percentage neuronal viability with no insult (100% viability) and glutamic acid control (5% viability). Values are mean ± SE;
n = 4; *P < 0.05 when compared to no glutamic acid control. Cont = no treatment control. Glut = glutamic acid control. JNKD = JNKI-1-TATD
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Discussion
The present study extends our previous findings exam-
ining the neuroprotective effectiveness of CARPs in in
vitro and animal stroke injury models [7–11, 13–16]. In
doing so, the data provides compelling evidence for the
neuroprotective action of poly-arginine peptides R18
and R18D, as well as the JNKI-1-TATD peptide, which is
also a CARP, in a modified Rice-Vannucci model of HIE.
The modified Rice-Vannucci model used in this study
leads to the generation of a more reproducible infarct,
accompanied with a greater severity of brain injury [60].
The original and modified Rice-Vannucci models are
likely to mimic the clinical development of a pattern of
brain injury, whereby white matter and cerebral cortex,
supplied by the middle cerebral and posterior cerebral
arteries, are affected following prolonged birth asphyxia
[62]. Importantly, the neuroprotective actions of R18
and R18D, as measured in terms of infarct volume, was
a
b
Fig. 4 Intracellular calcium assessment using Fura-2 AM after glutamic acid exposure in primary neuronal cultures. a Fluorescent Fura-2 AM tracers;
fluorescent intensity (FI) of neuronal cultures 30 s before and after the addition (arrow) of glutamic acid (100 μM final concentration). Peptides (1, 2 and
5 μM) or glutamate receptor blockers (MK801/CNQX; 5 μM/5 μM) were added to neuronal cultures for 10 min and removed (time = 0) before glutamic
acid addition (time = 30 s). Values are mean ± SE; n = 3. b Trapezoidal area under the curve (AUC) approximation of calcium kinetic tracers. AUC is
determined at 35 s (point after glutamic acid addition. Values are mean ± SE; n = 3; *P< 0.05 when compared to glutamic acid control. Cont = no
treatment control. Glut = glutamic acid control. Blkrs = glutamate receptor blockers (MK801/CNQX; 5 μM/5 μM). JNKD = JNKI-1-TATD
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associated with improved behavioural outcomes at a
number of the peptide doses with respect to the righting
reflex, negative geotactic response and wire-hang tests,
while JNKI-1-TATD only demonstrated trends towards
improvement in the righting reflex and negative geotac-
tic response tests. In addition, unlike JNKI-1-TATD,
some doses of R18 and R18D improved weight gain fol-
lowing HI. This is another indicator for improved behav-
ioural outcomes as it is likely to reflect the animals’
increased motor capacity to search and feed from the
dam, as well as potential reduced weight loss due to in-
creases in respiratory demand, metabolic rate and cach-
exia [63]. Furthermore, treatment with R18 and R18D
was effective at reducing total infarct volume in both
male and female animals following HI.
It is noteworthy that, the R18 and R18D were highly
effective at reducing infarct volume at all doses exam-
ined without displaying a typical dose response effect.
The efficacy of both R18 and R18D over a wide dose
range (30–1000 nmol/kg) is highly significant, which ul-
timately could translate to the peptides being effective at
low doses when used clinically following HIE. The ef-
fectiveness of JNKI-1-TATD (also referred to as XG-102)
in a wide dose range with IP administration has also
been demonstrated previously following transient
MCAO in adult mice [64] and following permanent
MCAO in P14 rats [65].
In the present study, R18 and R18D appeared more ef-
fective than JNKI-1-TATD across all the in vivo (infarct
volume and behavioural outcomes) and in vitro (neuro-
protection and neuronal intracellular calcium influx in-
hibition) outcomes examined. The lower efficacy of
JNKI-1-TATD may reflect its lower arginine content (R
= 9) and cationic charge (+ 12) compared to R18 and
R18D (R = 18, charge = + 18). On this point, our previous
studies have confirmed that CARP neuroprotective effi-
cacy and neuronal excitotoxic influx inhibition increases
with increasing peptide arginine content and peptide
positive charge [8, 9]. It is also noteworthy that in the
present study, no obvious overall differences were un-
covered between the R18 peptide and its R18D
enantiomer.
As mentioned above, the only currently available treat-
ment known to improve neurological outcomes follow-
ing HIE is moderate hypothermia (32–34 °C for 72 h).
As such there is an urgent need for the development of
an effective pharmacological neuroprotective agent that
can be readily administered following HIE and that is
compatible and synergistic with hypothermia. Therefore,
it will be important in future studies to assess whether
R18 or R18D treatment is compatible with hypothermia,
and whether the combined therapies have an additional
effect in reducing brain injury and improving behav-
ioural outcomes. In addition, whilst a 48 h endpoint is
commonly used in initial neuroprotective and patho-
physiological investigations, it is important that the ef-
fectiveness of R18 and R18D at more extended time-
points should also be evaluated. We also recognise that
the IP route for peptide administration may not be
ideally suited to the clinical situation, and that an intra-
venous (IV) route would be preferable. Furthermore,
due to the potential differences in blood pharmacokinet-
ics following IP or IV administration of R18 and R18D,
at present it is not known how the different delivery
routes would impact on the neuroprotective efficacy of
the peptides. To this end, further assessment of R18 and
R18D when administered by the IV route could be more
appropriately carried out in a large animal model of HI
(i.e. piglet or lamb).
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Supplementary Table 1. Cerebral infarct. Percentage of topographical coronal slices. 
Treatment Slice N Mean 
(%) 
SE 
(%) 
Percentage 
reduction 
P 
Saline 
1 
19 
0.683 0.148 - - 
2 2.392 0.290 - - 
3 3.858 0.387 - - 
4 4.124 0.358 - - 
5 4.081 0.269 - - 
6 2.860 0.272 - - 
JNKD 1,000 
1 
7 
0.063 0.041 90.65 0.031 
2 1.152 0.345 51.83 0.008 
3 2.973 0.805 22.93 0.211 
4 3.529 0.620 14.42 0.376 
5 3.797 0.777 6.95 0.671 
6 2.170 0.536 24.12 0.200 
R18 30 
1 
10 
0.233 0.107 65.90 0.074 
2 1.327 0.301 44.52 0.010 
3 2.243 0.363 41.86 0.011 
4 3.034 0.522 26.43 0.069 
5 2.665 0.359 34.69 0.019 
6 1.732 0.182 39.44 0.030 
R18 100 
1 
10 
0.374 0.103 45.29 0.216 
2 1.488 0.369 37.79 0.227 
3 2.514 0.574 34.83 0.033 
4 2.747 0.374 33.38 0.022 
5 2.998 0.418 26.53 0.071 
6 1.852 0.309 35.24 0.051 
R18 300 
1 
8 
0.623 0.500 8.76 0.823 
2 1.015 0.349 57.56 0.002 
3 1.747 0.344 54.71 0.002 
4 2.729 0.460 33.82 0.032 
5 3.057 0.502 25.09 0.112 
6 2.606 0.535 8.88 0.644 
R18 1,000 
1 
11 
0.067 0.038 90.07 0.013 
2 0.409 0.131 82.90 <0.0001 
3 1.739 0.436 54.92 <0.001 
4 2.541 0.476 38.38 0.007 
5 3.217 0.621 21.17 0.135 
6 2.275 0.559 20.45 0.239 
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Supplementary Table 1 continued. Cerebral infarct. Percentage of topographical 
coronal slices. 
N, number of animals; SEM, standard error of mean; P, calculated compared to saline vehicle control. 
All doses are in nmol/kg.  Mean and SE expressed as percentage of total slice volume. JNKD = JNKI-
1-TATD. Percentage reduction expressed as percentage reduction from corresponding saline slice. All
values P < 0.05 are bold.
R18D 30 
1 
9 
0.383 0.142 43.86 0.122 
2 1.351 0.309 43.52 0.014 
3 3.237 0.604 16.09 0.334 
4 3.263 0.575 20.87 0.130 
5 2.950 0.458 27.71 0.028 
6 2.634 0.256 7.90 0.591 
R18D 100 
1 
9 
0.308 0.128 54.86 0.054 
2 1.135 0.260 52.55 0.003 
3 1.702 0.265 55.88 0.001 
4 2.597 0.230 37.02 0.008 
5 2.580 0.300 36.78 0.004 
6 2.008 0.151 29.79 0.046 
R18D 300 
1 
9 
0.347 0.106 49.12 0.084 
2 1.296 0.359 45.81 0.010 
3 2.182 0.418 43.44 0.011 
4 2.791 0.333 32.32 0.021 
5 3.092 0.378 24.23 0.533 
6 2.358 0.283 17.55 0.234 
R18D 1,000 
1 
8 
0.428 0.145 37.38 0.204 
2 1.425 0.217 40.42 0.028 
3 2.416 0.498 37.37 0.034 
4 2.757 0.424 33.14 0.023 
5 2.845 0.188 30.28 0.213 
6 1.964 0.404 31.32 0.044 
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Supplementary Table 2. Behavioural assessment. 
Behavioural 
assessment 
Treatment Dose N Mean* 
(%) 
SE 
(%) 
P 
Righting 
reflex 
Sham - 6 100 10.36 <0.001 
Righting 
reflex 
Saline - 19 0 13.41 - 
Righting 
reflex 
JNKD 1,000 7 43.87 27.69 0.063 
Righting 
reflex 
R18 
30 10 63.21 13.16 0.003 
100 10 40.20 7.70 0.054 
300 8 19.77 28.03 0.375 
1,000 11 53.95 14.22 0.008 
Righting 
reflex 
R18D 
30 9 -6.18 43.28 0.822 
100 9 45.33 19.81 0.104 
300 9 63.14 15.24 0.025 
1,000 8 79.88 11.97 0.007 
Geotactic 
test 
Sham - 6 100 9.30 0.004 
Geotactic 
test 
Saline - 19 0 26.59 - 
Geotactic 
test 
JNKD 1,000 7 42.18 19.85 0.187 
Geotactic 
test 
R18 
30 10 28.23 14.48 0.317 
100 10 32.95 14.46 0.243 
300 8 58.21 15.44 0.058 
1,000 11 54.44 12.11 0.049 
Geotactic 
test 
R18D 
30 9 10.40 24.84 0.738 
100 9 66.71 12.06 0.035 
300 9 59.87 15.96 0.057 
1,000 8 69.17 16.83 0.036 
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Supplementary Table 2 continued. Behavioural assessment. 
*Mean percentage improvement from baseline to 48 h after HI. N, number of animals; SE, standard
error of mean; P calculated compared to saline. All doses are in nmol/kg.  Mean and SE expressed as
percentage improvement in behavioural assessment from baseline to 48 h after HI. All values P < 0.05
are in bold.
Wire 
hang 
Sham - 6 100 39.27 <0.001 
Wire 
hang 
Saline - 19 0 4.91 - 
Wire 
hang 
JNKD 1,000 7 30.93 21.15 0.374 
Wire 
hang 
R18 
30 10 37.26 20.08 0.227 
100 10 11.99 5.579 0.695 
300 8 32.99 11.25 0.320 
1,000 11 64.29 49.70 0.033 
Wire 
hang 
R18D 
30 9 0.59 6.67 0.997 
100 9 13.9 4.80 0.410 
300 9 14.95 12.15 0.356 
1,000 8 16.36 12.7 0.330 
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Supplementary Table 3. Weight gain 48 hours after hypoxia-ischaemia. 
*Mean weight gain from P7 (day of injury) to P9 (48 hour endpoint). #Mean percentage weight gain
from baseline to 48 h after HI. N, number of animals; g, gram; SE, standard error of mean; P calculated
compared to saline. All doses are in nmol/kg. Mean and SE are expressed as gram improvement from
baseline to 48 h after HI. All values P < 0.05 are in bold.
Treatment Dose N 
Mean 
(g)* 
SE (g) 
Mean 
(%)# 
SE 
(%) 
P 
Sham - 6 4.6 0.841 100 23.95 <0.001 
Saline - 19 1.089 0.295 0 8.424 - 
JNKD 1,000 7 1.157 0.67 1.941 19.34 0.935 
R18 
30 10 1.68 0.64 16.83 18.32 0.327 
100 10 1.95 0.42 24.52 12.07 0.155 
300 8 2.30 0.46 34.49 13.20 0.065 
1,000 11 2.65 0.35 44.59 10.17 0.009 
R18D 
30 9 2.15 0.45 30.38 12.87 0.167 
100 9 1.75 0.39 18.98 11.22 0.386 
300 9 1.82 0.23 20.88 6.62 0.340 
1,000 8 0.73 1.42 -10.01 40.50 0.659 
104
Supplementary Figure 1. Comparison of percentage total infarct volume in male and 
female animals treated with R18, R18D or saline. Due to the small number of female 
and male animals within the different peptide treatment groups total infarct volume 
data for R18 and R18D doses have been pooled. Values are mean ± SE; ** P < 0.01 
and *** P < 0.001 when compared to corresponding male or female saline control. 
Note: due to small animal numbers the  JNKI-1-D peptide was not included in the 
analysis.  
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1  | INTRODUC TION
Hypoxic‐ischaemic encephalopathy (HIE) remains the leading cause 
of neonatal mortality and morbidity, affecting between 3 and 26 per 
1,000 live births in developed and developing countries, respec‐
tively (Douglas‐Escobar & Weiss, 2015; Logitharajah, Rutherford, 
& Cowan, 2009; Pierrat et al., 2005). The relatively high prevalence 
and devastating neurological sequelae of HIE is accompanied with a 
significant social and economic burden (Kruse et al., 2009). Clinically, 
moderate hypothermia (33.5°C for 72 hr) within 6 hr of birth is used 
to treat moderate or severe hypoxia‐ischaemia (HI), but is largely re‐
stricted for use in tertiary hospitals due to the need for specialised 
equipment and trained staff to monitor neonates during the proce‐
dure. Whilst hypothermia appears to be well tolerated in term infants 
Received: 29 April 2018  |  Revised: 24 July 2018  |  Accepted: 24 July 2018
DOI: 10.1002/jnr.24315
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Abstract
Hypoxic‐ischaemic encephalopathy (HIE) remains the leading cause of mortality and 
morbidity in neonates, with no available neuroprotective therapeutic agent. In the 
development of a therapeutic for HIE, we examined the neuroprotective efficacy of 
the poly‐arginine peptide R18D (arginine 18 mer synthesised with D‐arginine) in a 
perinatal model of hypoxia‐ischaemia (HI; common carotid and external carotid oc‐
clusion + 8%O2/92%N2 for 2.5 hr) in the P7 Sprague‐Dawley rat. R18D was adminis‐
tered intraperitoneally 30 min (doses 10, 30, 100, 300 and 1,000 nmol/kg), 60 min 
(doses 30 and 300 nmol/kg) or 120 min (doses 30 and 300 nmol/kg) after HI. Infarct 
volumes and behavioural outcomes were measured 48 hr after HI. When adminis‐
tered 30 min after HI, R18D at varying doses reduced infarct volume by 23.7% to 
35.6% (p = 0.009 to < 0.0001) and resulted in improvements in the negative geotac‐
tic response and wire‐hang times, at a dose of 30 nmol/kg. When administered 
60 min after HI, R18D at the 30 nmol/kg dose reduced total infarct volume by 34.2% 
(p = 0.002), whilst the 300 nmol/kg dose improved wire‐hang time. When adminis‐
tered 120 min after HI, R18D at the 30 and 300 nmol/kg doses had no significant 
impact on infarct volume, but the 300 nmol/kg dose improved the negative geotactic 
response. This study further confirms the neuroprotective properties of poly‐argi‐
nine peptides, demonstrating that R18D can reduce infarct volume and improve be‐
havioural outcomes after HI if administered up to 60 min after HI and improve 
behavioural outcomes up to 2 hr after HI.
K E Y W O R D S
hypoxia, hypoxia‐ischaemia, neonatal, neuroprotection
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(> 36 weeks gestation) (Azzopardi et al., 2009; Gluckman et al., 2005; 
Jacobs et al., 2011; Shankaran et al., 2005), most infants do not ben‐
efit from the intervention, and its use in preterm infants (≤ 36 weeks 
gestation) warrants caution due to a high risk of adverse effects (e.g., 
coagulopathy, hyperglycaemia, hypocalcemia, hyponatremia, hypov‐
olemia and immune suppression) and high mortality rate (Jenkins et 
al., 2013; Mosalli, 2012; Rao et al., 2016). Hence, there is an urgent 
need for the development of new and easily applicable neuroprotec‐
tive therapies that can be used in combination with hypothermia to 
further improve patient outcomes and/or minimise side‐effects as‐
sociated with hypothermia, or when hypothermia cannot be applied, 
as a stand‐alone therapy to reduce HI‐mediated brain injury.
Recently, we have highlighted the potential of cationic argi‐
nine‐rich peptides (CARPs), which possess inherent cell penetrating 
properties and can cross the blood brain barrier, as a new class of 
neuroprotective agent. This class of peptide includes poly‐arginine 
peptides (e.g., R9 and R18) and in terms of mechanism of action, 
most likely extends to most, if not all, putative neuroprotective pep‐
tides fused to cationic cell penetrating peptides (e.g., TAT‐NR2B9c, 
JNKI‐1‐TATD, TAT‐NR2Bct, TAT‐CBD3, R9‐CBD3, COG112) because 
of their arginine content and positive charge (Marshall et al., 2015; 
McQueen et al., 2017; Meloni, Brookes, et al., 2015; Meloni, Milani, 
et al., 2015). Importantly, we have demonstrated that the poly‐ar‐
ginine peptides R18 and its D‐enantiomer R18D, can reduce brain 
injury in P7 rats when administered immediately after HI (Edwards, 
Cross, Anderton, Knuckey, & Meloni, 2018). The positive findings 
with R18 and R18D in HI are in line with previous studies from our 
laboratory demonstrating efficacy of these peptides in adult rat 
models of stroke due to middle cerebral artery occlusion (MCAO) 
and traumatic brain injury (Chiu et al., 2017; Edwards et al., 2018; 
Milani, Clark, et al., 2016; Milani, Cross, et al., 2016; Milani, Knuckey, 
et al., 2016; Meloni et al., 2014, 2017).
Whilst the exact mechanisms whereby CARPs exert their neuro‐
protective effects are still being explored, there is increasing evidence 
that this class of peptides possess properties that can impart mul‐
tiple potential beneficial effects following acute brain injuries such 
HIE and stroke. For example, CARPs have the capacity to mitigate 
excitotoxicity (Edwards et al., 2018; Edwards, Anderton, Knuckey, & 
Meloni, 2016; Meloni et al., 2014; Meloni, Milani, et al., 2015), reduce 
intracellular and mitochondrial calcium influx (Edwards et al., 2016; 
2018; Marshall et al., 2015; Meloni, Milani, et al., 2015; Rigobello, 
Barzon, Marin, & Bindoli, 1995), reduce cell surface levels of ion 
channels (Brittain et al., 2011; Brustovetsky, Pellman, Yang, Khanna, 
& Brustovetsky, 2014; MacDougall, Anderton, Edwards, Knuckey, & 
Meloni, 2016; Sinai, Duffy, & Roder, 2010) and TNF receptors (Fotin‐
Mleczek et al., 2005), assist in maintaining mitochondrial integrity 
(Birk, Chao, Liu, Soong, & Szeto, 2015; Cerrato, Pirisinu, Vlachos, & 
Langel, 2015; Ferré et al., 2016; Marshall et al., 2015; Rigobello et 
al., 1995; Szelechowski et al., 2014; Szeto et al., 2011; Zhao et al., 
2004), inhibit the activity of the proteasome and matrix metallopro‐
teinases (Anbanandam, Albarado, Tirziu, Simons, & Veeraraghavan, 
2008; Cameron, Appel, Houghten, & Lindberg, 2000; Fugere, Appel, 
Houghten, Lindberg, & Day, 2007; Gaczynska, Osmulski, Gao, Post, 
& Simons, 2003; Kacprzak et al., 2004), reduce lipid peroxidation and 
oxidative stress and modulate immune responses and activate pro‐
survival signalling (Cook et al., 2011; Yang et al., 2014).
In a previous study in the P7 rat, we demonstrated that both 
R18 and R18D peptides reduced infarct volume and improved be‐
havioural outcomes when administrated intraperitoneally (IP) imme‐
diately after HI (Edwards et al., 2018). The objective of the present 
study was to examine the therapeutic time window when R18D 
could be administered IP in P7 rats and still have a significant impact 
on infarct volume and/or behavioural outcomes when measured 
48 hr after HI. In addition, in view of the increased resistance of pep‐
tides synthesised with D‐amino acids to proteolytic degradation and 
hence potentially higher potency, the R18D peptide was used for the 
therapeutic time window studies.
2  | MATERIAL S AND METHODS
2.1 | Peptides used in the study
The R18D peptide (H‐rrrrrrrrrrrrrrrrrr‐OH; charge +18; r = D‐arginine) 
was synthesised by Mimotopes (Melbourne, Australia). R18D was pu‐
rified using high performance liquid chromatography to at least 98% 
purity and subjected to hydrolysis and amino acid liquid chromatogra‐
phy analysis to obtain a precise measure of peptide content.
2.2 | Animal ethics and study design
All experimental procedures in this study adhered to the guide‐
lines approved by the Animal Ethics Committee of the University 
of Western Australia (RA/3/100/1329 and RA/3/100/1569), in ac‐
cordance with Policies and Guidelines of the National Health and 
Medical Research Council, Australia. Treatments were randomised 
and all procedures (e.g., peptide administration, behavioural assess‐
ments and measurement of infarct volumes) were performed whilst 
being blinded to treatments, with an experimental end‐point of 
48 hr post‐HI. A diagrammatic representation of the study design is 
presented in Figure 1.
Significance
Hypoxic‐ischaemic encephalopathy (HIE) remains the lead‐
ing cause or mortality and morbidity in neonates, with no 
known clinically appropriate therapeutic agent to treat the 
ensuing brain injury. This study demonstrates that the poly‐
arginine peptide R18D is neuroprotective in a P7 rodent 
model of HIE, following administration up to 60 min after 
hypoxia‐ischaemia (HI), with concomitant improvements in 
behavioural assessments. This study further confirms the 
neuroprotective properties of poly‐arginine peptides, offer‐
ing an exciting potential in the prevention of brain injury in 
infants following HI.
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2.3 | Surgical procedure for modified Rice‐
Vannucci model
The modified Rice‐Vannucci procedure was performed as previously 
described (Edwards et al., 2017, 2018). Briefly, unsexed, Sprague‐
Dawley P7 rat pups (Animal Resource Centre, Murdoch, Australia; 
P0 = day of birth; RRID: RGD_1566457) with a body weight of 
16 ± 1.5 grams were used. Litters were culled to a maximum of 12 
pups per litter to facilitate uniform growth without littermate com‐
petition. Rat pups were anaesthetised using isoflurane (5% induction, 
1%–2% maintenance) in 100% oxygen, whilst on a heating pad (37°C). 
Through a 1 cm mid‐line ventral incision, the right common, internal 
and external carotid arteries were exposed and isolated from the 
vagus nerve, venous circulation and carotid body. The right common 
carotid and external carotid arteries were permanently ligated using 
6‐0 silk sutures. Occlusion of the external carotid artery is a modifica‐
tion to the original Rice‐Vannucci model that we have shown to result 
in a more reproducible infarct, accompanied by a more severe degree 
of brain injury (Edwards et al, 2017). The wound was closed using 
Vetbond (3M, Maplewood, USA), and animals were recovered on 
100% oxygen for 5 min on a heating pad. The duration of anaesthesia 
from induction to beginning of recovery did not exceed 8 min. Sham‐
operated animals underwent the same operative procedure, except 
the exposed carotid arteries were not ligated; duration of anaesthesia 
from induction to recovery did not exceed 5 min.
Pups were returned to their dam for 1 hr before the commence‐
ment of hypoxia which consisted of placing 4–6 pups in an airtight 
container (approximate volume: 4 L) and exposing them to humid‐
ified and warmed hypoxic gas (8% O2/92% N2; 3 L/min) for 2.5 hr. 
The container was placed in an incubator with an ambient air tem‐
perature of 35°C, ensuring a body temperature of 36.5 ± 0.5°C, 
which was periodically monitored using an infrared thermometer. 
Following hypoxia, animals were placed on a heating pad for 5 min 
in a normoxic environment before being placed back with the dam. 
Sham‐operated animals remained with the dam at all times.
2.4 | Post‐surgical analgesia and monitoring
Immediately before the cessation of anaesthesia, pethidine was 
administered (5 mg/kg; IP). The surface body temperature of the 
animals was monitored using an infrared thermometer following the 
cessation of anaesthesia, before and after hypoxia and maintained 
between 36.5 and 37.5°C. To avoid hypothermia, rat cages were 
housed in a Ventilated Warming Cabinet (Techniplast; New South 
Wales, Australia) maintained at 26°C until the end of experiment. 
Animals that recorded a surface body temperature of >37.5°C within 
1 hr after hypoxia were excluded from the study (Supplementary 
Table 1).
2.5 | Peptide administration
R18D was administered at separate time points of 30, 60 or 120 min 
after the conclusion of hypoxia. Treatments were administered IP 
(50 µL bolus) and consisted of either saline vehicle (0.9% sodium 
chloride for injection) or R18D, at up to five different doses (10, 30, 
100, 300 or 1,000 nmol/kg).
2.6 | Animals used and sample size
One‐hundred and ninety‐five Sprague‐Dawley P7 pups (96 female 
and 99 male), housed with the dam under controlled conditions on 
a 12 hr light‐dark cycle, underwent surgery for HI or the sham pro‐
cedure (i.e., anaesthesia, neck incision, wound closure and analge‐
sia). Twenty nine animals were excluded from the study based on 
exclusion criteria provided in Supplementary Table 1. For the 30 min 
post‐HI time point, the saline group consisted of 15 animals and the 
R18D treatment groups consisted of between 9 and 12 animals (see 
Figure 2a). For the 60 min post‐HI time point, the saline group con‐
sisted of 16 animals and the R18D treatment groups consisted of 
between 10 and 11 animals (see Figure 3a). For the 120 min post‐HI 
time point, the saline group consisted of 14 animals and R18D treat‐
ment groups consisted of between 10 and 13 animals (see Figure 4a). 
Separate sham animals were used for all the time window studies. 
As sham animals were treated in an identical fashion, functional data 
from these animals were pooled (N = 25).
2.7 | Infarct volume assessment
Forty‐eight hours after HI, animals were euthanised by pentobar‐
bital overdose (50 mg/kg; IP). Infarct volume was determined by 
preparing 2 mm thick serial coronal brain slices, and incubating in 
3% 2,3,5‐triphenyltetrazolium chloride (TTC; Sigma Aldrich, St. 
Louis, USA) at 37°C for 20 min, followed by fixation in 4% formalin 
at room temperature overnight. Digital images of coronal slices were 
acquired using a colour scanner and analysed using ImageJ software 
(3rd edition, NIH, Bethesda, USA; RRID: SCR_003070). Total infarct 
volume was determined by measuring the area of infarcted tissue 
on both surfaces of the 2 mm slices. Due to the presence of cer‐
ebral oedema, infarct volume measurements were corrected for a 
degree of hemisphere volume changes (Edwards et al., 2017). Final 
infarct data was expressed as percentage infarct volume compared 
to whole brain volume (minus cerebellum).
2.8 | Behavioural assessments
To determine if R18D treatment improved sensorimotor outcomes, 
three behavioural tests (righting reflex, negative geotactic response 
and wire‐hang) were performed at 48 hr after HI, as previously re‐
ported (Edwards et al., 2017, 2018). Briefly, for three consecutive 
days before surgery (P4 to P6 inclusive), pups were accustomed to 
behavioural assessments with a target inclusion range of ≤ 2 s for 
the righting reflex and ≤ 30 s for the negative geotactic response. 
Each animal was given three attempts to complete each sensorimo‐
tor task, with 5 min between each attempt. One animal did not re‐
cord responses within these parameters at P7 (day of surgery) and 
was excluded from the study. All of these reflexes are reproducible 
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throughout the murine preweaning period (< P30) and are strain‐ 
and gender‐independent (Heyser, 2004).
The righting reflex involved placing pups in a supine position, 
and measuring the time required to rotate to the prone position. 
The negative geotactic response involved placing pups facing down‐
slope, on a 45° angled surface, and measuring the time required for 
the animal to turn 150° upslope. Testing of the righting reflex and 
negative geotactic response was performed on a board covered 
with a tightly‐stretched close knit‐fabric, to ensure adequate grip. 
Wire‐hang test was performed by suspending pups by their fore‐
limbs on a 2 mm diameter steel wire suspended 20 cm above a foam 
surface, and recording the time taken for the animal to fall to the 
foam surface.
2.9 | Statistical analysis
The number of animals used in each experiment was justified by sta‐
tistical power calculation based on a previous study (Edwards et al., 
F I G U R E  1   Schematic representation followed for R18D neuroprotective study in a perinatal rodent model of HIE. PND = postnatal day 
of age, CCA + ECAO = common carotid artery and external carotid artery occlusion, HI = hypoxia‐ischaemic, min = minutes, TTC = 2,3,5‐
triphenyltetrazolium chloride. [Color figure can be viewed at wileyonlinelibrary.com] 
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F I G U R E  2   Assessment of R18D when administered 30 min after the conclusion of hypoxia. Histological and behavioural assessments 
for saline, sham and R18D treatment groups determined 48 hr after HI. Treatments were administered IP (saline or R18D; doses in nmol/kg). 
Behavioural assessments are presented as fold change (baseline vs. 48 hr). (a) Percentage of infarct volume when compared to total brain 
volume. (b) Representative TTC coronal brain slices from saline and R18D treated animals. (c) Negative geotactic response. (d) Wire‐hang 
test. (e) Righting reflex. Values are mean ± SD. *p < 0.05 when compared to saline. [Color figure can be viewed at wileyonlinelibrary.com] 
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F I G U R E  3   Assessment of R18D when administered 60 min after the conclusion of hypoxia. Histological and behavioural assessments 
for saline, sham and R18D treatment groups determined 48 hr after HI. Treatments were administered IP (saline or R18D; doses in nmol/kg). 
Behavioural assessments are presented as fold change (baseline vs. 48 hr). (a) Percentage of infarct volume when compared to total brain 
volume. (b) Representative TTC coronal brain slices from saline and R18D treated animals. (c) Negative geotactic response. (d) Wire‐hang 
test. (e) Righting reflex. Values are mean ± SD. *p < 0.05 when compared to saline. †Brain assigned largest infarct due to liquefactive brain 
incompatible for sectioning. [Color figure can be viewed at wileyonlinelibrary.com] 
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2018). Group sizes have been calculated based on a predicted treat‐
ment effect of a 33% reduction in infarct volume, at a power level 
of 90% and an alpha level of 0.05. Mean percentage infarct volume 
and weight gain were analysed by analysis of variance (ANOVA), fol‐
lowed by post‐hoc Fisher’s PLSD test, with p < 0.05 values consid‐
ered statistically significant. For behavioural assessment analysis, 
data has been expressed as a fold change improvement as assessed 
48 hr after HI. All values have been transformed to express saline 
treated as a reference value of 1 and analysed using a one‐sam‐
ple t‐test, with p < 0.05 values considered statistically significant. 
Cohen’s d effect size was calculated for mean infarct differences. 
All statistical analysis was performed using Graphpad Prism (RRID: 
SCR_0020798).
3  | RESULTS
3.1 | Infarct volume measurements
Data on infarct volume and representative TTC stained coronal brain 
slices are presented in Figures 2‒4a,b. When administered 30 min 
after hypoxia (i.e., 3 hr after the commencement of HI) R18D at 
doses of 10, 30, 300 and 1,000 nmol/kg significantly reduced in‐
farct volume by between 23.7 [F(5, 61) = 0.70; n = 10; p < 0.01] and 
35.6% [F(5, 61) = 0.70; n = 12; p < 0.0001], whilst at the 100 nmol/
kg dose, infarct volume was also reduced by 16.2%, albeit not to a 
statistically significant extent [F(5, 61) = 0.70; n = 9; p = 0.07] (refer 
to Supplementary Table 2 for descriptive statistics). To confirm dose 
efficacy in the 30 min post‐hypoxia treatment group, Cohen’s d ef‐
fect size calculations determined the 30 and 300 nmol/kg doses pro‐
vided the largest treatment effects at the 30 min post‐hypoxia time 
point, therefore these doses were assessed at the 60 and 120 min 
post‐hypoxia time points.
When administered 60 min after hypoxia (3.5 hr after the com‐
mencement of HI) R18D at a dose of 30 nmol/kg significantly re‐
duced infarct volume by 34.2% [F(2, 36) = 2.89; n = 12; p < 0.01], 
whilste the 300 nmol/kg dose was ineffective. When administered 
120 min after hypoxia (4 hr after the commencement of HI) R18D 
at a dose of 30 nmol/kg decreased infarct volume by 8% [F(2, 35) 
= 0.09; n = 13; p 0.52], albeit not to a statistically significant level. 
The R18D 300 nmol/kg dose did not influence infarct volume with a 
12.8% increase in cerebral infarct [F(2, 35) = 0.09; n = 10; p = 0.26]. 
For all treatment groups, gender had no significant effect on infarct 
volume (data not shown).
3.2 | Behavioural outcomes following R18D 
administration
Data on behavioural outcomes is presented in Figures 2c–e, 3c–e, 
4c–e and Supplementary Tables 3–5. Data on weight gain is pre‐
sented in Supplementary Table 6. For all treatment groups, gen‐
der had no significant effect on behavioural outcomes (data not 
shown).
3.2.1 | 30 min post‐HI
R18D, at a dose of 30 nmol/kg, significantly improved the negative 
geotactic response (3.45‐fold; p < 0.01) and wire‐hang (3.11‐fold; 
p = 0.01). Similarly, R18D at doses of 100 and 1,000 nmol/kg sig‐
nificantly improved righting reflex (2.44 and 2.55‐fold; p < 0.01 and 
0.02, respectively). All other R18D treated groups did not improve 
performance in behavioural assessments (Figure 2).
3.2.2 | 60 min post‐HI
R18D, at a dose of 300 nmol/kg, significantly improved wire‐hang 
time (3.51‐fold; p = 0.03). All other R18D treated groups did not im‐
prove performance in behavioural assessments (Figure 3).
3.2.3 | 120 min post‐HI
R18D, at a dose of 300 nmol/kg, significantly improved the negative 
geotactic response (2.32‐fold; p < 0.01). All other R18D treated groups 
did not improve performance in behavioural assessments (Figure 4).
4  | DISCUSSION
The present study adds to our previous findings which demonstrate 
the neuroprotective effectiveness of R18 and R18D in a P7 rat 
model of perinatal HIE (Edwards et al., 2018), and other acute neu‐
ronal injury models (Chiu et al., 2017; Edwards et al., 2016; Meloni et 
al., 2017; Meloni, Brookes, et al., 2015; Meloni, Milani, et al., 2015; 
Milani et al., 2018; Milani, Clark, et al., 2016; Milani, Cross, et al., 
2016; Milani, Knuckey, et al., 2016). Importantly, the present study 
examined the neuroprotective efficacy of R18D when administered 
30, 60 or 120 min after HI. The 30 min post‐HI treatment time win‐
dow study examined the dose response effectiveness of R18D and 
revealed that at all doses (10, 30, 100, 300 and 1,000 nmol/kg) re‐
sulted in a reduction in infarct volume by between 16.2% and 35.6%. 
In addition, R18D treatment was associated with animals displaying 
significantly improved, or positive trends for improved, negative 
geotactic response, wire‐hang and righting reflex times.
The reduction in infarct volume and improved behavioural out‐
comes at the 30 min treatment time point are similar to our previous 
findings for R18D and R18 when administered immediately after HI 
at doses of 30, 100, 300 and 1,000 nmol/kg in the same experimen‐
tal HIE model and 48 hr endpoint (Edwards et al., 2017). In addition, 
as previously observed when R18D and R18 were administered im‐
mediately after HI (Edwards et al., 2017), treatment with R18D at 
30 min after HI at the doses used did not generate a typical dose 
response effect in terms of infarct volume reduction. These find‐
ings suggest that when administered early after HI, R18D is effec‐
tive over a wide dose range from 10 to 1,000 nmol/kg, however, 
we cannot exclude the possibility that there may be a typical dose 
response effect with doses outside of this range. Interestingly, the 
JNKI‐1‐TATD peptide (also referred to as XG‐102), which is also a 
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F I G U R E  4   Assessment of R18D when administered 120 min after the conclusion of hypoxia. Histological and behavioural assessments 
for saline, sham and R18D treatment groups determined 48 hr after HI. Treatments were administered IP (saline or R18D; doses in nmol/kg). 
Behavioural assessments are presented as fold change (baseline vs. 48 hr). (a) Percentage of infarct volume when compared to total brain 
volume. (b) Representative TTC coronal brain slices from saline and R18D treated animals. (c) Negative geotactic response. (d) Wire‐hang 
test. (e) Righting reflex. Values are mean ± SD. *p < 0.05 when compared to saline. [Color figure can be viewed at wileyonlinelibrary.com] 
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CARP (arginine residues = 9 and net charge +12), displayed a non‐
dose response reduction in infarct volume over a wide dose range 
(0.076 to 760 nmol/kg), when administered intravenously 6 hr after 
a 30 min duration of MCAO in mice (Wiegler, Bonny, Coquoz, & Hirt, 
2008).
When R18D was administered 60 min after HI, the 30 nmol/kg, 
but not the 300 nmol/kg dose significantly reduced infarct volume. 
Animals treated with the 30 nmol/kg dose, but not the 300 nmol/
kg dose, 120 min after HI, displayed a nonsignificant reduction in 
infarct volume, but animals treated with the higher peptide dose dis‐
played better negative geotactic response. At present, the reason 
for the lack of efficacy of R18D in reducing infarct volume at the 
300 nmol/kg dose when administered 60 min after HI is not known. 
One possible explanation is that over time after HI, vulnerable, but 
potentially salvageable brain tissue becomes more sensitive to the 
adverse effects of higher peptide concentrations. In support of this, 
we have observed that following in vitro glutamic acid neuronal exci‐
totoxicity, higher R18D concentrations (e.g., 5 µM) result in reduced 
neuroprotective efficacy (30% neuronal survival) compared to lower 
peptide concentrations (e.g., 2 µM; 100% neuronal survival). In addi‐
tion, any adverse effects of R18D would likely to be exacerbated by 
the increased stability of the peptide due its D‐arginine configura‐
tion. Notwithstanding the lack of efficacy of the 300 nmol/kg dose 
in reducing infarct volume, this dose did provide beneficial effects in 
terms of functional outcomes. This suggests that the R18D peptide 
may be having additional beneficial effects independent of reducing 
the infarct, possibly by improving synaptic function in noninfarcted 
areas, as observed with other CARPs (e.g., TAT‐NR2B9c) (Srejic, 
Hutchison, & Aarts, 2013).
4.1 | Limitations of study
Whilst we have confirmed the effectiveness of R18D when admin‐
istered after HI, there are several limitations associated with the 
study. Whilst the 48 hr endpoint was used to replicate our initial 
neuroprotection study, it is important that the efficacy of R18D also 
be evaluated at more extended time points after HI (e.g., 1–4 weeks). 
In addition, behavioural outcomes were quite variable when meas‐
ured at 48 hr after HI, and therefore may not have provided an ac‐
curate reflection of the beneficial effects of R18D treatment. It will 
therefore be important that in longer‐term studies, suitable behav‐
ioural tests with high sensitivity and low variability are used to de‐
tect potential treatment effects (e.g., gait analysis, rotarod, Barnes 
maze). Due to the current clinical application of therapeutic hypo‐
thermia to treat HIE, the assessment of CARP‐mediated neuropro‐
tection adjunctly to therapeutic hypothermia is required. We also 
acknowledge that an intravenous rather than intraperitoneal route 
of administration would be favoured in a clinical setting and would 
be more appropriately assessed in a larger animal model of HIE such 
as the piglet or lamb. Finally, a typical R18D dose response pattern 
in infarct volume reduction and behavioural outcomes was not ob‐
served in the study, and therefore it would be worthwhile examining 
a wider dose range of the peptide in future studies.
5  | CONCLUSION
Whilst hypothermia is currently the only available treatment known 
to improve neurological outcomes following HIE, the use of R18/
R18D peptides as neuroprotective therapies offers exciting poten‐
tial in the prevention of brain injury in infants following HI. This 
study demonstrates R18D efficacy when administered up to 60 min 
after HI in the rat, with concomitant improvements in behavioural 
assessments. Following on from these positive results, it will be im‐
portant for future preclinical studies to assess R18D or R18 in other 
pre‐term and term HIE models using larger animals (foetal sheep or 
piglet), and when combined with hypothermia.
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Supplementary Table 1. Animals excluded in the study. 
*Hyperthermia is a recorded body temperature >37.5 immediately after hypoxia. #Surgical
haemorrhage is defined as any animal which had an abnormal bleed (arterial rupture) during the
surgical procedure. †Premature deaths occurred during hypoxia.
Exclusion 
rationale 
Number of 
exclusions 
R18D peptide 
treatment time 
after HI (min) 
R18D peptide 
dose 
(nmol/kg) 
Total number of 
exclusions 
No detectable 
infarct 
6 30 30 
11 
1 60 30 
1 60 Saline 
1 120 30 
2 120 Saline 
Hyperthermia* 1 30 100 
7 4 60 30 
2 60 300 
Failure to 
complete 
behavioural 
assessment 
1 - - 1 
Surgical 
haemorrhage# 
4 - - 4 
Premature death† 3 - - 3 
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Supplementary Table 2. Cerebral infarct. Percentage of total cerebral volume 
N, number of animals; SE, standard error of mean; P, calculated compared to saline vehicle control. 
All doses are in nmol/kg. Mean and SE expressed as percentage of total cerebral volume. Percentage 
reduction is mean percentage reduction compared to saline. All values P < 0.05 are in bold. Cohen’s d 
is compared to the saline within each peptide administration group (30, 60 or 120 min). 
Peptide 
administration 
time after HI 
(min) 
Dose N Mean of 
total 
infarct 
volume 
(SD) (%) 
Reduction 
in cerebral 
infarct (%) 
P d 
30 Saline 15 16.7 (4.41) - - - 
10 11 12.4 (4.25) 25.4 <0.01 0.99 
30 12 10.7 (2.36) 35.6 <0.0001 1.70 
100 9 14.0 (3.27) 16.2 0.08 0.70 
300 10 11.3 (3.43) 32.0 <0.01 1.37 
1,000 10 12.7 (3.01) 23.7 <0.01 1.06 
60 Saline 17 16.2 (6.01) - - - 
30 12 10.5 (3.60) 34.2 <0.01 1.15 
300 10 16.9 (4.27) 0.06 0.73 0.13 
120 Saline 15 15.0 (5.20) - - - 
30 13 13.8 (4.35) 8.0 0.52 0.25 
300 10 17.2 (4.83) -14.6 0.26 0.44 
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Supplementary Table 3. Behavioural assessment; treatment 30 min post-HI. 
*Mean time difference to perform behavioural assessment from baseline to 48 h after
HI; negative integer indicates a reduction in time taken to perform task. N, number of
animals; SD, standard deviation; P calculated compared to hypothetical mean of 1.
All doses are in nmol/kg. All values P < 0.05 are bold.
Behavioural 
assessment 
Treatment Dose N Mean (SD)* 
(seconds) 
P when 
compared to 
hypothetical 
mean of 1 
Negative 
geotactic 
response 
Saline - 15 2.06 (6.04) 1 
R18D 
10 11 0.20 (3.81) 0.13 
30 12 -3.00 (4.45) <0.01 
100 9 -0.26 (3.50) 0.08 
300 10 -0.30 (6.30) 0.26 
1000 10 0.32 (3.71) 0.17 
Sham - 25 -4.20 (4.56) <0.0001 
Wire hang 
Saline - 15 -2.06 (6.04) 1 
R18 
10 11 -0.20 (3.81) 0.15 
30 12 2.24 (5.03) 0.01 
100 9 0.48 (3.82) 0.08 
300 10 0.41 (6.00) 0.19 
1000 10 -0.32 (3.71) 0.17 
Sham - 25 7.32 (4.50) <0.0001 
Righting 
reflex 
Saline - 15 0.20 (0.32) 1 
R18D 
10 11 0.07 (0.40) 0.34 
30 12 -0.04 (0.46) 0.09 
100 9 -0.11 (0.22) <0.01 
100 10 -0.06 (0.40) 0.06 
1000 10 -0.11 (0.37) 0.02 
Sham - 25 -0.10 (0.50) <0.01 
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Supplementary Table 4. Behavioural assessment; treatment 60 min post-HI. 
*Mean time difference to perform behavioural assessment from baseline to 48 h after
HI; negative integer indicates a reduction in time taken to perform task. N, number of
animals; SD, standard deviation; P calculated compared to hypothetical mean of 1.
All doses are in nmol/kg. All values P < 0.05 are bold.
Behavioural 
assessment 
Treatment Dose N Mean (SD)* 
(fold change) 
P when 
compared to 
hypothetical 
mean of 1 
Negative 
geotactic 
response 
Saline - 17 -2.23 (4.40) 1 
R18D 30 12 -2.48 (1.66) 0.61 
300 10 -1.50 (1.51) 0.15 
Sham - 25 -4.20 (4.56) 0.04 
Wire hang 
Saline - 17 1.76 (5.70) 1 
R18 30 12 2.20 (1.55) 0.34 
300 10 6.20 (5.53) 0.03 
Sham - 25 7.32 (4.50) <0.0001 
Righting 
reflex 
Saline - 17 0.13 (0.65) 1 
R18D 30 12 0.13 (0.67) 0.98 
300 10 -0.50 (0.43) 0.21 
Sham - 25 -0.10 (0.50) <0.01 
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Supplementary Table 5. Behavioural assessment; treatment 120 min post-HI 
*Mean time difference to perform behavioural assessment from baseline to 48 h after
HI; negative integer indicates a reduction in time taken to perform task. N, number of
animals; SD, standard deviation; P calculated compared to hypothetical mean of 1.
All doses are in nmol/kg. All values P < 0.05 are bold.
Behavioural 
assessment 
Treatment Dose N Mean (SD)* 
(fold change) 
P when 
compared to 
hypothetical 
mean of 1 
Negative 
geotactic 
response 
Saline - 15 4.27 (5.60) 1 
R18D 30 13 4.82 (5.20) 0.71 
300 10 -1.40 (4.74) <0.01 
Sham - 25 -4.20 (4.56) <0.0001 
Wire hang 
Saline - 15 1.60 (6.60) 1 
R18 30 13 1.31 (5.16) 0.85 
300 10 0.36 (6.40) 0.56 
Sham - 25 7.32 (4.50) <0.0001 
Righting 
reflex 
Saline - 15 0.30 (0.61) 1 
R18D 30 13 0.23 (0.45) 0.61 
300 10 0.20 (0.32) 0.30 
Sham - 25 -0.10 (0.50) <0.01 
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Supplementary Table 6. Weight gain from baseline to 48 h post HI. 
N, number of animals; SE, standard error of mean; P, calculated compared to saline 
vehicle control or sham animals. All doses are in nmol/kg. Mean, SD and SE 
expressed as grams. All values P < 0.05 are in bold. 
Peptide 
administration 
time after HI 
(min) 
Dose N Mean of total 
weight gain (SD) 
(g) 
P when 
compared to 
saline 
30 
Saline 15 -0.07 (1.94) - 
10 11 0.62 (1.88) 0.29 
30 12 1.02 (1.57) 0.09 
100 9 0.14 (1.60) 0.75 
300 10 1.01 (1.94) 0.09 
1,000 10 0.68 (2.24) 0.28 
60 
Saline 17 1.63 (1.32) - 
30 12 1.30 (2.20) 0.54 
300 10 1.37 (1.30) 0.64 
120 
Saline 15 1.21 (1.70) - 
30 13 1.77 (1.57) 0.26 
300 10 1.16 (1.83) 0.93 
Sham - 25 5.10 (0.80) <0.0001 
124 
 
 
 
 
 
 
Chapter 7 
General Discussion 
 
 
 
 
 
 
 
 
 
125 
 
7.1 INTRODUCTION 
 Perinatal HIE occurs when there is a reduction in fetal CBF and/or cerebral oxygen 
supply, resulting in neuronal and glial cell loss and brain injury. Currently, the most 
effective clinical therapy to minimise cerebral injury is moderate hypothermia (33.5°C 
for 72 hours); to be effective, hypothermia needs to be administered within 6 hours of 
HIE onset. In infants who suffer moderate or severe encephalopathy, hypothermia has 
been shown to decrease mortality from 40% to 28%, while in surviving infants, 
neurological morbidity (e.g. cerebral palsy, epilepsy, intellectual disability and autism 
spectrum disorders) is reduced from 31% to 19% (Jacobs et al., 2013).  
 
Despite the clinical benefits of hypothermia in HIE, its application can be associated 
with low risk levels of adverse effects such as haemorrhage, infection, impairment of 
oxygen retention and an increased risk of drug related side-effects (van den Broek, 
Groenendaal, Egberts, & Rademaker, 2010). Importantly, whilst hypothermia is safe 
in pre-term infants with necrotising enterocolitis (Hall et al., 2010), it has not been 
adequately evaluated for use in pre-term infants suffering HIE. Information regarding 
the safety and efficacy of hypothermia to treat pre-term infants suffering HIE is 
lacking. In one study, hypothermia in pre-term infants was associated with higher 
mortality and increased clinical complications when compared to term infants (Rao et 
al., 2016); and for these reasons it is not routinely used in these patients. In addition, 
the induction of hypothermia requires specialised equipment, intensive care 
monitoring and trained staff, which limits its use to centres that have the facilities and 
medical personnel to undertake the procedure. The transfer of infants to a centre 
equipped to deliver hypothermia, delays cooling induction, or if induced during 
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transfer, creates uncertainty regarding the safety and effectiveness of the cooling 
provided (Committee on Fetus and Newborn et al., 2014). In light of this, the 
application of a neuroprotective therapeutic agent to HIE patients (e.g. a 
neuroprotective cationic arginine-rich peptide) prior to transfer to a tertiary hospital 
may extend the therapeutic time window and effectiveness of hypothermia. In 
addition, as HIE infant mortality and morbidity are still relatively high following 
hypothermia treatment (discussed in Chapter 2), there is an urgent need for the 
development of additional therapeutic agents, which can be used in combination with 
hypothermia, to further improve outcomes in infants suffering HI. Furthermore, in 
situations when hypothermia is not available or contra-indicated, an alternative 
neuroprotective therapy would be highly advantageous. 
 
Recent studies in A/Prof Meloni’s laboratory have demonstrated that cationic arginine-
rich peptides (CARPs), such as R18, are highly neuroprotective agents both in in vitro 
neuronal and animal models of stroke (Edwards, Anderton, Knuckey, & Meloni, 2016; 
MacDougall, Anderton, Edwards, Knuckey, & Meloni, 2016; Meloni, Brookes, et al., 
2015; Meloni et al., 2017; Meloni, Milani, et al., 2015; Milani, Clark, et al., 2016; 
Milani et al., 2017; Milani, Knuckey, Anderton, Cross, & Meloni, 2016). As such, 
previous studies in A/Prof Meloni’s laboratory have provided the rationale for this 
thesis to investigate the application of CARPs as a potential neuroprotective therapy 
for HIE.  
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7.2 KEY FINDINGS ARISING FROM THIS THESIS 
7.2.1 Cerebral collateral circulation and infarct volume variability  
The application of the HIE model using the 7-day-old (P7) rat was first described by 
Rice et al. (1981), and is often referred to as the Rice-Vannucci model. This is the most 
commonly used animal model for perinatal HIE neuroprotective and 
neurodegenerative pre-clinical studies. The model involves the permanent occlusion 
of the common carotid artery (CCAO) followed by a transient period of hypoxia (e.g. 
8% O2/92% N2; for 2.5 h). Since its inception, the Rice-Vannucci model is widely 
reported to be associated with variable outcomes with respect to infarct presence, 
infarct volume size and by extension, functional outcomes (Ashwal, Tone, Tian, 
Chong, & Obenaus, 2007; Barks et al., 2017; Hagberg, Gilland, Diemer, & Andiné, 
1994; Okusa et al., 2014; Ota, Ikeda, Ikenoue, & Toshimori, 1997; Palmer, Towfighi, 
Roberts, & Heitjan, 1993; Palmer, Vannucci, & Towfighi, 1990; Rice et al., 1981). 
 
Whilst several sources of variability in the Rice-Vannucci model have been described 
(see Table 1, Chapter 4), an additional source of variability in both perinatal and adult 
ischaemic brain injury models can be attributed to the presence of cerebral collateral 
circulation via the circle of Willis and/or cerebral anastomoses; stabilising CBF 
following vessel occlusion and/or haemodynamic compromise. However, prior to this 
thesis the impact of collateral circulation as a source of variability in the Rice-
Vannucci model had not been investigated. 
 
128 
 
In an attempt to minimise the known variability associated with the Rice-Vannucci 
model of HIE, a modified Rice-Vannucci model was developed (Chapter 4). The 
surgical procedure involves the permanent ligation of both the right common carotid 
artery (CCA) and external carotid artery (ECA) followed by hypoxia (8% O2/92% N2; 
for 2.5 h). The modified Rice-Vannucci model demonstrated a more reproducible 
cerebral infarct (infarct presence and reduced standard deviation), a larger infarct 
lesion, and more severe behavioural deficits when compared to the original Rice-
Vannucci model.  
 
In addition, magnetic resonance angiography phase-contrast velocity encoding and 
pulsed arterial spin labelling analysis in animals subjected to the original Rice-
Vannucci model (right CCA occlusion only) demonstrated residual blood flow in the 
right internal carotid artery; an effect that would help preserve CBF to tissue affected 
by the CCA occlusion. In contrast, animals subjected to the modified Rice-Vannucci 
model (right ECA/CCA occlusion) demonstrated complete cessation of blood flow 
within the right internal, external and common carotid arteries, and a significant overall 
reduction in CBF to the right hemisphere. The source of cerebral collateral and 
anastomotic circulation is detailed diagrammatically in Figure 1, Chapter 4.  
 
As a consequence of the modification to the original Rice-Vannucci surgical 
procedure, the model now offers a more reliable and reproducible cerebral infarct and 
was used for all animal experimental studies in this thesis (Chapters 5 & 6). 
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7.2.2 Effectiveness of R18 and R18D in a perinatal HIE model 
One of the primary aims of this study was to identify a potential lead neuroprotective 
poly-arginine peptide and an effective peptide dose. Based on previous in vitro 
(Meloni, Brookes, et al., 2015) and adult animal studies in stroke related brain injury 
models (Milani, Clark, et al., 2016; Milani et al., 2017; Milani, Knuckey, et al., 2016), 
two peptides were selected; R18 (L-enantiomer) and R18D (D-enantiomer). The initial 
study examined the dose response effectiveness of R18 and R18D when administered 
immediately after HI in the modified Rice-Vannucci model. The CARP, JNKI-1-
TATD (also referred to as XG-102) at the 1000 nmol/kg dose (equivalent to the highest 
dose of R18 and R18D examined), was used as a positive control and benchmark 
(Nijboer et al., 2010).  
 
This thesis demonstrated that both R18 and R18D at all doses examined reduced 
cerebral infarct volume, and at several doses improved functional outcome measures, 
as well as improving weight gain in animals. In contrast, JNKI-1-TATD treatment 
resulted in a non-significant reduction in cerebral infarct volume and did not 
significantly improve any functional outcomes or weight gain. The efficacy of both 
R18 and R18D over a wide dose range (30 – 1000 nmol/kg) is highly significant and 
could ultimately translate to clinical efficacy at low doses, which would have the 
advantage of reducing the risk of side effects due to the peptide. Interestingly, a wide 
neuroprotective dose-response range has been observed previously for JKNI-1-TATD 
following intraperitoneal administration in adult mice (Wiegler, Bonny, Coquoz, & 
Hirt, 2008) and P14 rats (Vaslin, Naegele-Tollardo, Puyal, & Clarke, 2011) subjected 
to a middle cerebral artery occlusion. 
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However, the inferior efficacy observed with JNKI-1-TATD in HIE may reflect its 
lower arginine content (R = 9) and cationic charge (+12), compared to R18 and R18D 
(R = 18, net charge +18). In support of this, previous studies from our laboratory have 
confirmed that the neuroprotective efficacy of CARPs increases with increasing 
peptide arginine content and peptide positive charge (Edwards et al., 2016; Meloni, 
Brookes, et al., 2015). 
 
One of the key principals to developing a therapeutic intervention for HIE is the 
concept of a delayed secondary phase of brain injury. In infants suffering from a 
cerebral HI event, the development of secondary brain injury is associated with 
mitochondrial energy failure, cytotoxic oedema, cell death and the presence of clinical 
seizures. The secondary injury phase typically occurs 6 – 15 hours following HI onset, 
and thus provides a therapeutic window for intervention to reduce further brain injury. 
Therefore, a subsequent aim of this thesis was to determine if the R18 peptide was 
effective when administered at delayed time points following hypoxia in the modified 
Rice-Vannucci model. While R18 and R18D demonstrated similar efficacy when 
administered immediately after hypoxia, the R18D peptide was selected for the 
delayed administration studies in view of the known resistance of D-enantiomer 
peptides to enzymatic degradation (Weinstock, Francis, Redman, & Kay, 2012), which 
would potentially extend peptide half-life and tissue bioavailability. Furthermore, due 
to the acute and ongoing nature of brain injury following HI, delayed administration 
would expose the peptide to increasing levels of proteolytic enzymes activated in the 
extracellular matrix and released from dead and dying cells in the brain. Hence, the 
use of a D-enantiomer peptide (R18D), as opposed to a L-enantiomer peptide (R18) is 
potentially likely to be more effective in this situation. 
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The therapeutic window study revealed that R18D at all the doses examined 
significantly reduced cerebral infarct volume when administered 30 or 60 minutes after 
hypoxia (3 and 3.5 h after the commencement of HI, respectively), and at several doses 
improved functional outcomes. As with the dose response study, the efficacy of R18D 
over a wider dose range (10 – 1000 nmol/kg) when administered after HI was shown 
to be highly significant and demonstrated neuroprotective efficacy at even lower doses 
down to 10 nmol/kg.   
 
7.3 LIMITATIONS OF THIS THESIS 
While this thesis has confirmed the neuroprotective efficacy of R18 and R18D in a rat 
model of HI, and the potential application of the peptides as a novel therapeutic to treat 
HIE, there are several limitations associated with the study. A 48-hour endpoint was 
used in the HI studies (Chapters 5 and 6), however, to confirm that neuroprotection 
provided by R18 and R18D is maintained longer-term, extended time points after HI 
(e.g. 4 – 7 weeks) need to be assessed. In addition, the use of an extended study 
endpoint would allow for the assessment of R18 and R18D neuroprotective effects  
following cell death that occurs beyond 48 hour time point, as well as examine 
additional behavioural assessments (e.g. gait analysis, rotarod and Barnes maze) to 
provide a more comprehensive and sensitive measure of functional outcomes and 
therapeutic benefit.  
 
Whilst the R18D peptide was chosen for the delayed treatment studies due to its 
potentially greater resistance to proteolytic degradation, it remains to be determined if 
the R18 peptide is less, more or equally effective than R18D. The efficacy of delayed 
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administration of R18 will be important to determine, as the use of an L-enantiomer 
peptide may be more suitable for repetitive dosing due to less likelihood of the 
accumulation of the peptide in affected brain tissue, which at high concentrations may 
be toxic to already vulnerable neurons and glial cells. 
 
Histologically, the P7 rat brain corresponds with a late pre-term human (34 weeks 
gestation), while growth/proliferation, persistence of a periventricular germinal 
matrix, neurochemical and metabolic data, EEG pattern, synapse formation and 
patency of the blood brain barrier of the P7 rat correspond well with the full term 
human (37 weeks gestation) (Hagberg, Bona, Gilland, & Puka-Sundvall, 1997). 
Despite the physiological similarities, to confirm R18 and R18D neuroprotective 
efficacy in term humans, pre-clinical efficacy in P10 rodents would need to be 
assessed.  
 
The current clinical ‘gold standard’ to treat HIE is hypothermia. Consequently, in the 
event that a R18 peptide progresses to clinical trials, it would have to be assessed 
alongside or in combination with hypothermia. Therefore, it will be essential for pre-
clinical studies to determine if the addition of R18 has synergistic effects or can extend 
the therapeutic time window of hypothermia. Initial preclinical studies could be 
examined in the rodent HI model, and if positive, could then be extended to the fetal 
sheep or piglet HI models. To this end, previous studies have been performed 
examining adjunct therapies with hypothermia in rodent, sheep and piglet animal 
models of HI (Davidson et al., 2015; Faulkner et al., 2011; Liu, Dingley, Scull-Brown, 
& Thoresen, 2015).  
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It is acknowledged that an intravenous, rather than intraperitoneal, route of 
administration would be favoured in a clinical setting. Owing to the difficulty for 
intravenous administration of rodent pups due to their small size, assessment of the 
intravenous route for peptide delivery would be more appropriately assessed in a larger 
animal model of HIE, such as the piglet or lamb. It should also be noted that following 
intraperitoneal injection, the first circulatory pass of the peptide would be through the 
hepatic portal vein, which would likely reduce the concentration of the peptide 
available reaching the brain. An additional benefit of using a larger animal model is 
the assessment of R18 efficacy in an animal with a gyrencephalic brain, which more 
closely resembles the human brain.  
 
It is widely accepted that temperature maintenance in rodent neuroprotective studies 
is paramount. Despite surface temperatures of the animals routinely examined until the 
end of experiment and animals being house in a ventilated warming cabinet (26°C ± 
1°C) throughout the experimental period, it is possible animal temperatures can vary. 
Alternative telemetric rectal probes are inappropriate for long-term temperature 
monitoring in this model as the leads cannot be incorporated into the sealed hypoxic 
chamber and maternal grooming would result in the removal of the probes. Additional 
implantable wireless temperature probes are not appropriate for the current studies as 
this would require extended surgical times and isoflurane exposure to allow for 
intraperitoneal implantation.  
 
Finally, as a typical dose-response pattern of cerebral infarct volume reduction was 
not observed in this thesis, it would be worthwhile examining a wider dose range of 
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both R18 and R18D in future pre-clinical studies. The assessment and identification of 
an R18 peptide dose, lower than the lowest dose used this thesis may prove beneficial 
in terms of reducing potential side effects of the treatment.  
 
7.4 SUMMARY OF IMPORTANT FINDINGS OF STUDIES 
The findings presented in this thesis have for the first time confirmed the 
neuroprotective properties of the poly-arginine peptide R18 and its D-enantiomer 
R18D in a modified and more consistent rat model of perinatal HIE. Although 
additional studies are required to elucidate the full neuroprotective potential of the R18 
peptides as a neuroprotective therapy in this model of HIE, the present findings do 
suggest that CARPs are an exciting and promising new class of neuroprotective agents. 
Further evaluation of CARP neuroprotective mechanisms of actions are warranted, as 
well as the assessment of neuroprotective efficacy in other animal models of HIE.  
 
Although the present studies have provided clear evidence of neuroprotective efficacy 
of the R18 peptides in a rodent model of HIE, a number of crucial questions will need 
to be resolved before consideration is given to their evaluation in a human clinical trial. 
Firstly, their efficacy will next need to be demonstrated in a larger gyrencephalic 
animal model (e.g. the piglet or lamb), which have longer but clearly defined gestation 
times and whose brain and cerebrovascular anatomy is closer to that of the human. 
Furthermore, as therapeutic hypothermia is considered ‘standard care’ for infants 
suffering from HIE, it is paramount that R18 peptides are assessed as an adjunct to 
hypothermia in a larger animal model of HIE, to ensure safety and to identify any 
synergistic effects associated with hypothermia. Moreover, as there is currently no 
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available therapeutic agent to reduce the severity of brain injury in the pre-term infants 
with HIE, and as HIE in pre-term and term infants share pathophysiological 
similarities relating to the mechanism of action of R18, it is important that R18 
peptides are also assessed in pre-clinical animal models of pre-term HIE, both to 
ensure safety and the capacity to reduce brain injury and functional impairment.  
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